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Chapter 1
General Introduction
Part of this chapter is based on 
Genetic variation in thyroid hormone transporters
Wendy M. van der Deure, Robin P. Peeters and Theo J. Visser
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General Introduction 11
introDuction
Adequate levels of thyroid hormone are essential for normal development and growth, since 
thyroid hormone plays an important role in virtually all metabolic processes in the human 
body (1). This is clearly demonstrated in patients with thyroid hormone disorders. Hyperthy-
roidism leads to high circulating serum thyroid hormone levels. Patients complain of palpita-
tions, excessive sweating, weight loss and can display swelling of thyroid gland, known as 
goiter (2-4). In contrast, decreased serum thyroid hormone levels due to hypothyroidism can 
result in weight gain, depression, atherosclerosis and hypertension (2, 5, 6). 
Even subtle changes in serum thyroid parameters in patients with subclinical thyroid 
disease can have important consequences on thyroid hormone related end-points, such as 
atherosclerosis, heart rate, depression and osteoporosis (7-10). Therefore, it is likely that small 
variations in genes involved in thyroid hormone metabolism that result in altered thyroid 
hormone bioactivity can also have effects on clinical end-points. This thesis focuses on the 
effect of thyroid hormone pathway genes on serum thyroid hormone levels and clinical end-
points using a candidate gene approach. In addition, associations between serum thyroid 
parameters and clinical endpoints, such as osteoporosis and hypertension are studied.
tHyroiD HorMone syntHesis anD tHe HyPotHalaMus-Pituitary-
tHyroiD axis
The thyroid gland is situated in front of the thyroid cartilage in the neck. It contains two lobes 
joined by an isthmus and weighs only 20 grams in adults (11). It produces two hormones, 
i.e., thyroid hormone and calcitonin. The latter is secreted by the C-cells and is involved in 
the regulation of Ca2+-homeostasis together with parathyroid hormone secreted by the 
parathyroid glands (11). The production of thyroid hormone occurs in the follicular cells and 
involves several steps, which start with trapping of iodide from the blood and the synthesis 
of thyroglobulin. This is followed by the production of monoiodotyrosyl and diiodotyrosyl 
residues, which are coupled to form thyroid hormone. Finally, thyroid hormone is released 
into the circulation by proteolysis of thyroglobulin (12). Under normal conditions, the main 
product secreted by the thyroid gland is the prohormone thyroxine (T4). Besides T4, a small 
amount of the active hormone 3,3’,5-triiodothyronine (T3) is produced. 
The production of thyroid hormone by the thyroid gland is regulated by the hypothal-
amus-pituitary-thyroid (HPT) axis (11) (Fig. 1). Thyroid hormone is secreted in response to 
thyroid-stimulating hormone (TSH), which is synthesized in and released from the pituitary 
and mediates its effect via binding to the TSH receptor (TSHR). In turn, TSH production is 
stimulated by hypothalamic thyrotropin releasing hormone (TRH). The production of TRH 
and TSH can be downregulated by thyroid hormones, a process known as negative feedback 
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regulation. However, also other hypothalamic hormones and drugs, such as somatostatin and 
bromocriptine can lower TSH production. Besides the regulation by TSH, thyroid hormone 
synthesis depends on the availability of iodine. 
tHyroiD HorMone action anD MetabolisM
T3 exerts its effect by binding to nuclear thyroid hormone receptors (TR), thereby altering the 
transcription-rate of T3-responsive genes (13).  The THRA and THRB genes encode TRα and 
TRβ, respectively. Both receptors exist in several isoforms, which arise from alternative splic-
ing and the use of different transcription start sites (14-16). TRα1 appears at its highest levels 
in heart and brain, whereas TRβ1 is predominantly expressed in liver, kidney and thyroid (17). 
TRβ2 is important for regulation of the negative feedback of the HPT-axis (18). Since the TRs 
are located in the cell nucleus, the biological activity of thyroid hormone is mainly determined 
by the intracellular T3 concentration. This intracellular concentration is dependent on the 
circulating T3 concentration, transport of thyroid hormone across the cell membrane and the 
presence of iodothyronine deiodinases, which activate or inactivate thyroid hormone. Three 
deiodinases have been cloned and characterized as homologous selenoproteins, meaning 
that they have a selenocysteine in their catalytic center. This selenocysteine is encoded by a 
UGA codon (19). Since UGA is usually recognized as a STOP codon, a selenocysteine insertion 
Chapter 1, Figure 1 
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Figure 1: The hypothalamic-pituitary-thyroid axis.
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sequence (SECIS) element in the 3’untranslated region (3’UTR) of the deiodinase messenger 
RNA (mRNA) is necessary for selenocysteine incorporation at the site of a UGA codon. 
Deiodinases are capable of outer- and inner ring deiodination (ORD and IRD respectively). 
ORD is the removal of an iodide atom at the phenol (outer) ring, whereas by IRD an iodide is 
removed from the tyrosyl (inner) ring. ORD is regarded as an activating pathway, whereas IRD 
is an inactivating pathway (Fig. 2).
Type I deiodinase (D1), expressed in liver, kidney and thyroid, facilitates ORD as well as IRD 
(19). The preferred substrate for D1 is the inactive metabolite reverse T3 (rT3) (20), which is 
converted to 3,3’-diiodothyronine (3,3’-T2) by ORD. This makes D1 the primary site for clear-
ance of rT3. In addition, D1 is important for the production of plasma T3 from T4, although this 
conversion is much less efficient (21). D1 is under positive control of T3 and can be blocked 
by a drug commonly used in the treatment of hyperthyroidism, namely 6-propyl-2-thiouracil 
(PTU) (22).
Type II deiodinase (D2) is expressed in brain, pituitary, brown adipose tissue and vascular 
smooth muscle cells (19, 23). D2 has only ORD capacity and is thought to be important for 
local T3 production. However, recently Maia et al. demonstrated that D2 is present in skeletal 
muscle and could serve as a source of plasma T3 (24). D2 activity is increased in hypothyroid-
ism, and decreased in hyperthyroidism.
Type III deiodinase (D3) is the major inactivating deiodinase, facilitating the conversion of 
T3 and T4 by IRD to 3,3’-T2 and rT3 respectively (19). D3 is expressed in placenta, brain, but 
also in fetal liver and various tumors (25-28). Its main function is to protect tissues from ex-
Figure 2:  
 
I                      I                             NH2
HO                     O           CH2 CH    COOH
I                       I
I                       I                             NH2   
HO                     O CH2 CH COOH
I                      I                              NH2
HO                      O CH2 CH COOH
I
3,3'-T2
I                         I                                NH2      
HO                       O           CH2 CH    COOH
I                      rT3T3
T4
D1, D2
D1, D2 D1, D3
D1, D3
 
 
Figure 2: Structure of and relationship between the different iodothyronines, and their deiodination. 
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cess thyroid hormone, which is clearly demonstrated by Kester and colleagues, who showed 
in the human developing brain that D3 protects specific brain regions from excessive T3 
until differentiation is required (29). On the other hand, high D3 activity in tumor tissues can 
lead to a state of consumptive hypothyroidism, meaning that the inactivation rate of thyroid 
hormone exceeds the production rate (28).  
In addition to deiodination, thyroid hormones can also undergo other metabolic reactions, 
such as sulfation and glucuronidation (30) (Fig.3). Glucuronidation increases the water solu-
bility of thyroid hormones, thereby facilitating excretion in the bile (31). Sulfation is catalyzed 
by a group of cytosolic sulfotransferases (SULTs), located in different tissues such as the liver, 
kidney and brain (32).  All members of the human SULT1 family catalyze the sulfation of thyroid 
hormone (33-36). The physiological role of sulfated iodothyronines is not completely clear. 
The main function of sulfation might be the irreversible degradation of thyroid hormone (30). 
It has, however, also been suggested that sulfates represent a reservoir of inactive thyroid 
hormone, from which active thyroid hormone is recovered when required (37). The serum 
concentrations of sulfated iodothyronines, such as T4 sulfate (T4S) and T3 sulfate (T3S), are 
low under normal conditions due to rapid deiodination by D1 (30, 38-41). However, sulfated 
iodothyronines become elevated in preterm infants or during critical illness (39, 41, 42). 
tHyroiD HorMone transPort
Thyroid hormones circulate in serum bound to the carrier proteins thyroxin binding globulin 
(TBG), transthyretin (TTR) and albumin. In humans TBG, TTR and albumin carry about 75%, 
Figure 3: 
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Figure 3: Pathways of thyroid hormone metabolism.
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15% and 10% respectively, of T4 and T3 (20, 43, 44). Therefore, serum free T4 (FT4) and free T3 
(FT3) only comprise 0.02% and 0.2% of total T4 and T3 (43-45). The free fraction is responsible 
for thyroid hormone action. However, since both TRs and deiodinases are located intracel-
lularly, transport of thyroid hormone across the cell membrane is required. Based on the 
lipophilic structure of thyroid hormones, it was assumed that thyroid hormone enters the cell 
through passive diffusion. However, it has become increasingly clear that there are specific 
thyroid hormone transporters, and that the activity of these transporters in part determines 
the intracellular thyroid hormone concentration (45). 
Recently, the monocarboxylate transporter 8 (MCT8) has been characterized as an active 
and specific thyroid hormone transporter (46). Especially the finding that mutations in the 
MCT8 gene result in severe mental retardation and elevated serum T3 levels, also known 
as the Allan-Herndon-Dudley syndrome, led to great scientific interest in thyroid hormone 
transport (47, 48). In this thesis, organic anion transporting polypeptides (OATPs) have been 
studied as candidates for thyroid hormone transport.  Therefore, other proteins capable of 
thyroid hormone transport, such as Na+/taurocholate co-transporting polypeptide (NTCP) 
(49), L-type amino acid transporter (LAT) (50) and the MCTs (46, 51) will not be discussed in 
this introduction. 
Organic anion transporting polypeptides
The OATPs are a large family of transporters responsible for Na+-independent transmembrane 
transport of amphipathic organic compounds, including bile salts, bromosulfophthalein 
(BSP), steroid hormones and numerous drugs (52). So far, 11 OATPs have been identified in 
humans, whereas in mice and rats respectively 13 and 14  members have been found (Fig. 
4). 
All OATPs are proteins of 652–848 amino acids in length with 12 transmembrane domains. 
Most OATP proteins are expressed in multiple tissues, including liver, kidney, brain (blood–
brain barrier, choroid plexus), lung, heart, placenta, testis, eye, and small intestine (53). 
However, some members of the OATP family show a tissue-specific distribution; OATP1B1 
and OATP1B3 are exclusively expressed in liver (54, 55), whereas OATP1C1 is only present in 
the brain and in the Leydig cells of the testis (56). Furthermore, most OATP family members 
are expressed at the basolateral membrane of polarized cells (54, 55, 57). 
OATPs are generally involved in transport of both endo- and xenobiotics. Among the many 
ligands transported by OATPs, several members of this large family also facilitate uptake of 
iodothyronines. These include members of the OATP1 subfamily: OATP1A2 (58, 59), OATP1B1 
(58, 60), OATP1B3 (58, 61) and OATP1C1 (56); members of the OATP4 subfamily: OATP4A1 (59) 
and OATP4C1 (62); and a member of the OATP6 subfamily: OATP6C1 (63). Interestingly, all 
members of the OATP1 subfamily that transport iodothyronines, form a gene cluster together 
with a related pseudogene on human chromosome 12p and are highly homologous to each 
other (Fig. 5).
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OATP1A2, first cloned and characterized in 1995 as a transporter for bile salts and BSP in 
human liver by Kullack-Ublick (64), has been shown to transport T3 and T4 with Km values 
of 7 and 8 μM, respectively (59). Furthermore, both OATP1B1 and OATP1B3 are involved in 
uptake of thyroid hormone into the liver, besides the transport of bile salts, various drugs, 
such as HMG-CoA-reductase inhibitors and antibiotics (54, 65, 66). Like the previous OATPs, 
also OATP4A1, OATP4C1 and OATP6C1 facilitate transport of iodothyronines among a wide 
spectrum of ligands (67). A notable exception to the multi-specific transport capacity of 
OATPs is OATP1C1, previously known as OATP-F. OATP1C1 has been shown to be a high affinity 
transporter for T4 and rT3, but not T3 (56). Based on its expression in capillaries throughout 
the brain and its high affinity for T4, OATP1C1 is thought to be important for uptake of T4 into 
the brain across the blood-brain barrier.   
Variation in seruM tHyroiD HorMone leVels in tHe norMal 
PoPulation
In healthy subjects, serum thyroid parameters show substantial inter-individual variability, 
whereas the intra-individual variability is within a narrow range (68). Together with environ-
mental factors such as diet or smoking, genetic factors are thought to contribute significantly 
Figure 4: 
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 Figure 4: Phylogenetic tree of the OATP family.
General Introduction 17
to this inter-individual variability, resulting in a thyroid function set-point that is different for 
each individual. This hypothesis is supported by a classical twin study, in which heritability 
accounted for ~ 65% of the variation in serum TSH, FT4 and FT3 levels (69). In a Mexican-
American population, total heritability in serum thyroid parameters ranged from 35–64% of 
the total inter-individual variation observed (70). Slightly different numbers were found in a 
study of a large UK twin cohort (71) (Table 1).  
Genetic association studies
Approximately 99.9% of the human genome is identical between individuals. The remaining 
0.1% DNA sequence variation is in part responsible for many individual phenotypic charac-
teristics, such as eyecolour or haircolour, but also a person’s risk to develop complex diseases 
such as coronary heart disease, diabetes or cancer, or the response to treatment (72-77). Such 
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Figure 5: Genomic organization of OATP1C1, OATP1A2, OATP1B1 and OATP1B3 and the genomic structure 
of the human OATP-cluster located on chromosome 12p12 (adapted from (56)). 
Light gray blocks represent exons with identical length, and dark gray blocks represent exons with 
different lengths for the indicated genes. 
Table1: Estimates of the genetic contribution to the variation in serum thyroid hormone levels from 
different studies
Proportion of variance in serum thyroid hormone levels attributable to genetic effects
Hansen et al. (69) Samollow et al. (70) Panicker et al. (71)
TSH 64% 37% 65%
FT4 65% 35% 39%
FT3 64% 64% 23%
18 Chapter 1
genetic variations also contribute to the inter-individual variability in serum thyroid param-
eters (78-80). The most commonly observed and studied variations in the human genome are 
single nucleotide polymorphisms. Polymorphisms are variations in the nucleotide sequence 
of the genome that occur in at least 1% of the general population. Other forms of variations are 
variable number of tandem repeat polymorphisms and deletion/insertion polymorphisms. 
Different approaches can be used to study the contribution of polymorphisms to the 
phenotype of interest. However, first of all, polymorphisms need to be identified. This can 
be done by sequencing the entire gene of interest in a number of subjects. Although the 
amount of information generated by this method is impressive, it is very time-consuming 
and costly. Nowadays, more and more information is available on the Internet, in databases 
such as the HapMap Project (www.hapmap.org) and the National Center for Biotechnology 
Information dbSNP database (www.ncbi.nlm.nih.gov) (81). Information from sequencing 
efforts is collected in dbSNP, a database containing information on all common genetic vari-
ants, which currently are estimated to amount to ~15 million polymorphisms. The Hapmap 
Project is a multi-country effort to identify and catalog genetic similarities and differences in 
humans. On their website, genotype information from 270 individuals from 4 geographically 
diverse populations can be found.
Once polymorphisms have been identified, different approaches can be used to study the 
contribution of polymorphisms to a phenotypic trait. With a candidate gene approach, genes 
are selected based on their biological role (82). For instance, polymorphisms in D1 are likely 
to be associated with serum thyroid parameters since D1 converts T4 to T3. Subsequently, 
the most promising polymorphisms are chosen, such as those that lead to an amino-acid 
change in the encoded protein, e.g., non-synonymous polymorphisms. Other interesting 
polymorphisms are located in the promoter region and in the 3’ untranslated region (3’UTR), 
since these may modify mRNA expression or stability. In addition, due to linkage disequilib-
rium adjacent polymorphisms tend to be inherited as a block, a so-called haplotype block. A 
haplotype block may contain a large number of polymorphisms, yet only a few are sufficient 
to identify most polymorphisms in such a block due to high linkage disequilibrium. These 
specific polymorphisms are called tagging polymorphisms. 
The next step in the assessment of the contribution of a polymorphism to a phenotypic 
trait involves the characterization of the phenotype, such as serum TSH or osteoporosis, and 
genotyping of a representative population (83).  In the last years, Peeters and colleagues have 
identified several polymorphisms in thyroid hormone pathway genes and associated them 
with serum thyroid parameters. For instance, the T allele of the D1-C785T polymorphism is 
associated with higher serum FT4 and rT3 levels (78). In addition, carriers of the TSHR-Glu727 
allele have lower serum TSH levels than non-carriers (78).  These polymorphisms do not only 
influence serum thyroid parameters, but are also associated with thyroid hormone related 
clinical endpoints. For instance, the TSHR-Asp727Glu polymorphism is associated with insulin 
resistance in elderly men (84).   
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Currently, an increasing number of studies use a hypothesis-free approach instead of a 
candidate gene approach by performing a genome-wide association (GWA) analysis. In such 
a GWA study the genome of each individual in the population is typed for more than 500.000 
polymorphisms to search for variants that are associated with the phenotype of interest. 
Most genetic association studies performed in this thesis are based on a candidate gene ap-
proach, while chapter 10 shows the results of a pathway analysis of genes involved in thyroid 
hormone synthesis, metabolism and transport using GWA data of the Rotterdam Study.
Populations used for genetic association studies
For many of the genetic association studies, a population of 155 healthy blood donors was 
used as a ‘training’ cohort (78). A number of the studies were conducted within the Rotter-
dam Study, a population-based cohort study of 7983 men and women aged 55 years and 
older and living in a well-defined suburb of Rotterdam, the Netherlands (85). In addition, the 
Rotterdam Scan Study is an ongoing prospective population-based cohort study designed to 
study causes and consequences of age-related brain changes on MRI (86). Some studies were 
part of a nationwide project (GEMINAKAR) investigating the relative influence of genetic and 
environmental factors on a variety of different traits among Danish twins (87). Finally, a co-
hort of patients, between 18 and 70 years of age, who had been on an adequate dose of LT4 
replacement therapy as reflected by normalized serum TSH levels for primary autoimmune 
hypothyroidism for at least 6 months was used. The patients participated in a randomized 
controlled trial investigating possible superiority of therapy with a LT4/LT3 combination in a 
ratio of 5:1 or 10:1 over therapy with LT4 alone (88).
aiM anD outline of tHis tHesis
Subtle changes in serum thyroid parameters have important consequences on thyroid hor-
mone related endpoints, such as atherosclerosis, heart rate, depression and osteoporosis (7-
10). Therefore, the aim of this thesis was to determine the effect of polymorphisms in genes 
involved in thyroid hormone metabolism and transport on serum thyroid hormone levels 
and clinical endpoints, and to associate serum thyroid parameters with thyroid hormone 
related endpoints.
In the first part of this thesis several members of the OATP family were characterized for 
thyroid hormone transport. If these transporters were found to transport thyroid hormone 
significantly, a candidate gene approach was used to study the physiological relevance of 
the transporter of interest. In chapter 2 OATP1B1 was studied in relationship to serum thyroid 
parameters and estrogen levels. In chapter 3 and 4 the effect of genetic variation in OATP1C1 
on serum thyroid parameters and depression is discussed, whereas chapters 5 deals with 
OATP1A2 and OATP1B3.
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In chapter 6 we studied the contribution of the TSHR-Asp727Glu polymorphism to the 
variance in serum TSH levels. In chapter 7 the relationship between serum thyroid hormone 
levels, the TSHR-Asp727Glu polymorphism and bone parameters was analyzed. Chapter 8 
focuses on the in vivo and in vitro effects of polymorphisms in D1. Chapter 9 deals with as-
sociations between serum thyroid parameters, polymorphisms in D2 and blood pressure and 
the occurrence of hypertension. This thesis ends with chapter 10, which shows the results of a 
pathway analysis of genes involved in thyroid hormone synthesis, metabolism and transport 
using GWA data of the Rotterdam Study. Finally, in chapter 11 all results are discussed and put 
in a broader perspective in the general discussion.
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abstract
Sulfation is an important pathway in the metabolism of thyroid hormone and estrogens. 
Sulfation of estrogens is reversible by estrogen sulfatase, but sulfation of thyroid hormone ac-
celerates its degradation by the type I deiodinase (D1) in liver.  Organic anion transporters are 
capable of transporting iodothyronine sulfates such as T4 sulfate (T4S), T3 sulfate (T3S) and 
reverse T3 sulfate (rT3S) or estrogen sulfates like estrone sulfate (E1S), but the major hepatic 
transporter for these conjugates has not been identified.  A possible candidate is OATP1B1 
since model substrates for this transporter include the bilirubin mimic bromosulfophthalein 
(BSP) and E1S, and it is highly and specifically expressed in liver.  Therefore, OATP1B1-
transfected COS1 cells were studied by analysis of BSP, E1S and iodothyronine sulfate uptake 
and metabolism.  Two Caucasian populations (155 blood donors and 1012 participants of 
the Rotterdam Scan Study) were genotyped for the OATP1B1-Val174Ala polymorphism and 
associated with bilirubin, E1S and T4S levels. 
OATP1B1-transfected cells strongly induced uptake of BSP, E1S, T4S, T3S and rT3S com-
pared to mock transfected cells.  Metabolism of iodothyronine sulfates by co-transfected D1 
was greatly augmented in the presence of OATP1B1. OATP1B1-Val174 showed a 40% higher 
induction of transport and metabolism of these substrates than OATP1B1-Ala174.  Carriers of 
the OATP1B1-Ala174 allele had higher serum bilirubin, E1S and T4S levels. 
In conclusion, OATP1B1 is an important factor in hepatic transport and metabolism of 
bilirubin, E1S and iodothyronine sulfates.  OATP1B1-Ala174 displays decreased transport 
activity and thereby gives rise to higher bilirubin, E1S and T4S levels in carriers of this poly-
morphism. 
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introDuction
Sulfation is an important pathway in the metabolism of different hormones, such as thyroid 
hormone and estrogens.  This reaction is catalyzed by a group of cytosolic sulfotransferases 
(SULTs) located in different tissues such as the liver, kidney and brain (1).  All members of the 
human SULT1 family catalyze the sulfation of thyroid hormone (2-5). Sulfation of estrogen is, 
however, mainly carried out by SULT1E1 (1). 
The serum concentrations of sulfated iodothyronines, such as T4 sulfate (T4S), T3 sulfate 
(T3S) and reverse T3 sulfate (rT3S), are low under normal conditions as they are rapidly deg-
radated by the type 1 deiodinase (D1) (6-11).  However, serum iodothyronine sulfate levels 
are high in preterm infants and during critical illness, possibly due to a decreased metabolism 
(7, 9, 12).  Serum concentrations of estrone sulfate (E1S) are 10-20 times higher than those 
of the unconjugated estrogens, thereby reflecting the primary role of sulfation in estrogen 
metabolism (13).  The formation of E1S serves as a reservoir for active estrogen, since the 
sulfation of estrogens is readily reversible by estrogen sulfatase (14). 
Different organic anion transporters (OATPs) are capable of transporting iodothyronine 
and estrogen sulfates (15-17), but the major hepatic transporter for these conjugates has 
not yet been identified.  A possible candidate is OATP1B1 since model substrates for this 
transporter include the bilirubin mimic bromosulfophthalein (BSP) and E1S, and it is highly 
and specifically expressed in liver (16, 18).  Therefore, OATP1B1-transfected COS1 cells were 
studied by analysis of BSP, E1S, T4S, T3S and rT3S uptake and metabolism.
Recently, various polymorphisms in the SLCO1B1 gene, encoding OATP1B1, have been 
identified (19).  Especially, the OATP1B1-Val174Ala polymorphism is of interest, since the 
valine at position 174 is conserved in all members of the OATP1 subfamily and is located in 
a putative transmembrane region of OATP1B1, which is important for substrate recognition 
and transport (20) (Fig. 1).  In addition, this polymorphism is associated with higher serum 
bilirubin levels due to an altered transport function of the protein (21).  We, therefore, ana-
lyzed the effect of this polymorphism on the function of OATP1B1 in vivo and in vitro, as a 
transporter for sulfated iodothyronines and estrogens.
Materials anD MetHoDs
Constructs
The pCMV6-XL4-OATP1B1 plasmid was kindly provided by Prof. Dr. Peter J. Meier (Institute 
of Clinical Pharmacology and Toxicology, University Hospital Zürich, Switzerland).  The Va-
l174Ala polymorphism was introduced into the OATP1B1 expression vector by site-directed 
mutagenesis according to the Quick Change site-directed mutagenesis protocol of Strata-
gene.  The sense and antisense primers containing the nucleotide change needed to produce 
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the OATP1B1-Ala174 variant (sense 5’-CTG GGT CAT ACA TGT GGA TAT ATG CGT TCA TGG GTA 
ATA TGC-3’) were used in circular mutagenesis reactions with 100 ng plasmid template and 
1 U of Pfu DNA polymerase.  The construct with the OATP1B1-Val174Ala polymorphism was 
fully sequenced on an automated ABI 3100 capillary sequencer, using the Big Dye terminator 
cycle sequencing method (Applied Biosystems) to verify that the desired mutation had been 
generated, and that no other mutations had occurred during amplification. 
Human μ-crystallin (CRYM) cDNA was purchased from the RZPD German Resource Center 
for Genome Research (www.rzpd.de) and subcloned into pSG5 (Stratagene) using EcoRI and 
BamHI sites.  pcDNA3-hMCT8 and pcDNA3-ratD1 (rD1) plasmids were constructed as previ-
ously described (22).
Cell culture
COS1 cells were cultured in 6 or 24-well dishes (Corning, Schiphol, The Netherlands) with 
DMEM/F12 medium (Invitrogen), containing 9% heat-inactivated fetal bovine serum (Invitro-
gen) and 100 nM sodium selenite (Sigma).
BSP, E1S and iodothyronine (sulfate) transport and metabolism by OATP1B1
Materials:  FuGENE6 transfection reagent was obtained from Roche Diagnostics (Indianapolis, 
USA).  [125I]NaI, [125I]T4 and [125I]T3 were obtained from Amersham Biosciences (Little Chalfont, 
Buckinghamshire, UK).  [125I]rT3 and [3H]E1S were purchased from Perkin Elmer (Boston, USA) 
and unlabeled T4, T3, rT3 and E1S from Henning GmbH (Berlin, Germany).  BSP was obtained 
from Fluka Chemica (Buchs, Switzerland).  [125I]BSP was prepared by radioiodination of BSP 
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Figure 1: A putative two-dimensional model of the human OATP1B1 protein with localization of valine to 
alanine amino acid change caused by the Val174Ala polymorphism in the SLCO1B1 gene  (Chr 12p12) 
(adapted from (19)). 
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using the chloramine-T method, and purified on a small (~1 ml bed volume) Sephadex LH20 
column by successive rinsing with 0.1 M HCl and water, and final elution with 0.1 M NH4OH in 
ethanol.  The purity of [125I]BSP was checked by HPLC analysis.  For [125I]T4S, [125I]T3S and [125I]
rT3S synthesis, solutions of [125I]T4, [125I]T3 or [125I]rT3 were evaporated to complete dryness 
under a stream of N2.  0.2 ml ice-cold chlorosulfonic acid in dimethylformamide (1:4, v/v) 
was added to the residues.  The mixtures were incubated for 2 h at 37 C, and the reactions 
were stopped by adding 0.8 ml ice-cold water.  Sulfates thus synthesized were separated 
on a Sephadex LH-20 column (23).  The final purified preparations contained virtually no 
contamination from free iodide or native hormone as checked by HPLC analysis. 
uptake studies:  COS1 cells were cultured in 6-well culture dishes, and transfected in dupli-
cate with 500 ng pCMV6-XL4 plasmid without or with OATP1B1-Val174 or Ala174 insert using 
FuGENE6 according to the manufacturer’s guidelines.  After 36 h, cells were washed with 
incubation medium (Dulbecco’s PBS, 0.1% BSA and 0.1% glucose), and incubated for 5, 10 
or 30 min at 37 C with 1 nM (2x105 cpm) 125I-labeled BSP, T4, T3, rT3, T4S, T3S or rT3S in 1.5 ml 
incubation medium.  After incubation, medium was aspirated and cells were washed with 
incubation medium, lysed with 0.1 M NaOH and counted for radioactivity in a gamma scintil-
lation counter.  In the experiments with [3H]E1S, cells were washed with incubation medium 
(Dulbecco’s PBS with 0.1% glucose), and incubated for 1, 2, 5 or 10 min at 37 C with 100 
nM [3H]E1S in 1.5 ml incubation medium. Cells were lysed with 0.1% SDS and subsequently 
counted for radioactivity.  Except for the experiments with [125I]BSP and [3H]E1S, uptake was 
determined in cells co-transfected with the high-affinity cytosolic thyroid hormone-binding 
protein CRYM to prevent efflux of internalized iodothyronines (24).  For T4, T3 and rT3 uptake 
experiments, pcDNA3-MCT8 plasmid was used as positive control.  
Metabolism studies:  COS1 cells were cultured in 24-well culture dishes and transfected with 
100 ng  pcDNA3-rD1 and 100 ng pCMV6-XL4 plasmid without or with OATP1B1-Val174 or Ala174 
insert.  36 h after transfection, cells were incubated for 24 h at 37 C with 1 nM (1x106 cpm) [125I]
T4S, T3S or rT3S in 0.5 ml incubation medium.  After incubation, medium was harvested and 
analyzed by HPLC as described previously (22).
Study populations
Genotypes of the OATP1B1-Val174Ala polymorphism were determined in 158 healthy blood 
donors from the Sanquin Blood Bank South West region (Rotterdam, The Netherlands) (25). 
Informed consent was given by all donors.
Participants of the Rotterdam Scan Study, an ongoing prospective population-based 
cohort study designed to study causes and consequences of age-related brain changes on 
MRI (26), were also genotyped.  Data on serum thyroid parameters and the use of thyroid 
medication were available in 1045 participants.  E1S levels were determined in a subgroup 
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of 430 participants.  The Rotterdam Scan Study was conducted in accordance with the tenets 
of the Declaration of Helsinki.  The Medical Ethics Committee of the Erasmus University ap-
proved the study. 
Serum analyses
Total bilirubin was determined by the Jendrassik-Grof diazo method on the Hitachi 912 (Roche 
Diagnostics, Germany), and E1S was measured by a RIA from DSL (Webster, Texas, USA).  TSH, 
FT4 and T3 were measured by chemoluminescence assays (Vitros ECI Immunodiagnostic Sys-
tem, Ortho-Clinical Diagnostics, Amersham, Rochester, NY, USA).  RT3 was measured with an 
in-house RIA (27), while T4S was determined by a specific RIA as previously described (6). T4S 
data were only available in healthy blood donors, whereas E1S levels were only determined 
in participants of the Rotterdam Scan Study. 
Genotyping 
DNA was isolated from peripheral leucocytes by standard procedures.  The OATP1B1-Val174Ala 
(rs4149056) genotypes were determined by 5’fluorogenic Taqman assays.  Reactions were 
performed in 384-wells format on ABI9700 2x384 well PCR machines with endpoint reading 
on the ABI 7900HT Taqman machine (Applied Biosystems, Nieuwerkerk aan den IJssel, The 
Netherlands) (28).  All healthy blood donors were successfully genotyped. In the Rotterdam 
Scan Study, DNA was available from 989 of the 1012 participants.  The genotyping success 
rate was 98.8%, with 12 samples that failed genotyping. 
Statistical analysis
Data were analyzed using SPSS 10.0.7 for Windows (SPSS, Inc., Chicago, IL). P values are two-
sided throughout and were considered significant if <0.05.  
For the in vitro experiments, unpaired Student’s T-tests were used to test whether the 
iodothyronine uptake and metabolism induced by OATP1B1-Val174 was significantly different 
from that in cells transfected with OATP1B1-Ala174 or empty vector. 
For the OATP1B1-Val174Ala polymorphism, deviation from Hardy-Weinberg equilibrium 
proportions was analyzed using a Chi-square test.  Differences between genotypes were 
adjusted for age and gender and tested by analysis of covariance (ANCOVA).  The analysis of 
the effect of the polymorphism on serum thyroid parameters was carried out after exclusion 
of subjects taking thyroid medication or any other drugs known to interfere with thyroid hor-
mone metabolism and/or subjects with serum thyroid parameters indicating overt thyroid 
disease.  Hypothyroidism was defined by a serum TSH concentration above the reference 
range (0.4-4.3 mU/l) and FT4 below the reference range (11-25 pmol/l).  Hyperthyroidism was 
defined by serum TSH <0.4 mU/l and FT4 >25 pmol/l.  Based on these exclusion criteria, 3 
subjects were excluded in the population of healthy blood donors and 33 subjects in the Rot-
terdam Scan Study.  Therefore, 155 healthy blood donors and 1012 subjects of the Rotterdam 
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Scan Study were eligible for analysis.  For the analysis of the effect of the OATP1B1-Val174Ala 
polymorphism on E1S levels, subjects on estrogen drug therapy (n=6) were excluded, leaving 
424 subjects eligible for analysis. Due to non-normal distribution, bilirubin, E1S, TSH and T4S 
levels were logarithmically transformed.  
results
Transport of BSP, E1S, and (sulfated) iodothyronines by OATP1B1
Previously, BSP and E1S have been used as model substrates to characterize OATP1B1 (16, 18, 
19).  In line with results from earlier studies (16, 18, 19), uptake of BSP and E1S was strongly 
induced in cells transfected with OATP1B1 compared to mock transfected cells.  Maximum 
uptake of E1S was already obtained after 1 min, pointing towards a rapidly reached equilib-
rium between uptake and efflux of E1S in a short time period. Subsequently, the percentage 
uptake remained the same even when cells were incubated for longer time periods.
Induction of BSP and E1S uptake was approximately 50% lower for the OATP1B1-Ala174 
variant in comparison with the Val174 variant (Fig 2).  
For uptake experiments with  (sulfated) iodothyronines, cells were co-transfected with 
CRYM (24). This protein binds not only iodothyronines, but also sulfated iodothyronines 
(personal communication W.E. Visser). Co-transfection of cells with CRYM and OATP1B1 did 
not result in significant uptake of [125I]T4 and [125I]T3, in contrast to cells co-transfected with 
CRYM and MCT8, a very active T3 and T4 transporter (29) (Fig. 3).  In addition, OATP1B1-Val174 
and OATP1B1–Ala174 showed little transport of [125I]rT3 in comparison to MCT8.  However, 
uptake of the sulfated iodothyronines [125I]T4S, [125I]T3S and [125I]rT3S was clearly induced in 
cells transfected with OATP1B1 (Fig. 4) compared to cells transfected with the empty vector. 
Induction of uptake of the iodothyronine sulfates was 50-70 % lower for the Ala174 variant 
than for the Val174 variant.
Iodothyronine sulfate metabolism in cells co-transfected with OATP1B1 and D1
T4S, T3S and rT3S metabolism by rD1 was markedly increased when cells were co-transfected 
with OATP1B1 (Fig. 5).  About 20% of T4S and T3S was deiodinated by rD1 when OATP1B1-
Val174 was co-transfected, whereas no iodide was produced in cells transfected with rD1 alone. 
Only 3% of rT3S was deiodinated in D1-transfected cells, whereas almost 60% of rT3S was 
deiodinated by D1 in the presence of OATP1B1. Induction of T4S, T3S and rT3S metabolism 
was 40 to 50% lower for the OATP1B1-Ala174 than for the Val174 variant (Fig. 5).  
Association of OATP1B1-Val174Ala with serum bilirubin and hormone levels
Table 1 shows the characteristics of the population of blood donors and of the subjects par-
ticipating in the Rotterdam Scan Study.  In the cohort of healthy blood donors, 103 subjects 
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were wild type, 48 subjects were heterozygous and 3 subjects were homozygous for the 
OATP1B1-Val174Ala polymorphism, resulting in a minor-allele frequency of 17.7 %.  In the 
Rotterdam Scan Study, the genotype distribution was quite similar with 714 wild type, 236 
heterozygous and 27 homozygous subjects. In this cohort, the minor allele frequency was 
Figure 2: 
a
b
a
b
a a
a a
b b b b
Figure 2: [3H]BSP and [125I]E1S uptake by COS1 cells transfected with empty vector, OATP1B1-Val174, or 
OATP1B1-Ala174.  Cells were incubated at 37 C with 1 nM [125I]BSP or 100 nM [3H]E1S with for different time 
periods.  Data are expressed as percentage uptake of added radioactivity.  Results are the means ± SEM 
of three experiments.  a) P<0.05 for OATP1B1-Val174 vs. OATP1B1-Ala174 and vs. empty vector; b) P<0.05 for 
OATP1B1-Ala174 vs. empty vector.Figure 3: 
 
Figure 3: [125I]T4, [125I]T3 and [125I]rT3 uptake by COS1 cells transfected with empty vector, OATP1B1-Val174, 
OATP1B1-Ala174 or MCT8.  Cells were co-transfected with CRYM, an intracellular thyroid hormone-binding 
protein.  Cells were incubated for 5, 10 or 30 min at 37 C with 1 nM (2x105 cpm) 125I-labeled T4, T3 or 
rT3. Data are expressed as percentage uptake of added radioactivity.  Results are the means ± SEM of 
three experiments.  a) P<0.05 for OATP1B1-Val174 vs. OATP1B1-Ala174 and vs. empty vector; b) P<0.05 for 
OATP1B1-Ala174 vs. empty vector.
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14.8%, which is similar to previous studies in Caucasians (19). As only few homozygous sub-
jects were identified, we combined heterozygotes and homozygotes into variant carriers.  
Figure 4: 
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Figure 4: [125I]T4S, [125I]T3S and [125I]rT3S uptake by COS1 cells transfected with empty vector, OATP1B1-
Val174, or OATP1B1-Ala174. Cells were co-transfected with CRYM. Cells were incubated for 5, 10 or 30 min at 
37 C with 1 nM [125I]T4S or T3S. Data are expressed as percentage uptake of added radioactivity.  Results 
are the means ± SEM of three experiments.  a) P<0.05 for OATP1B1-Val174 vs. OATP1B1-Ala174 and vs. empty 
vector; b) P<0.05 for OATP1B1-Ala174 vs. empty vector.Figure 5: 
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Figure 5: [125I]T4S and [125I]T3S metabolism by COS1 cells transfected with either rD1 alone or rD1 together 
with OATP1B1-Val174 or OATP1B1-Ala174.  Cells were incubated for 24 h at 37 C with 1 nM (1x106 cpm) [125I]
T4S or T3S. Metabolism is shown as percentage of metabolites in the medium after 24 h incubation.  
Results are the means ± SEM of four experiments with T4S and three experiments with T3S and rT3S.  a) 
P<0.05 for OATP1B1-Val174 vs. OATP1B1-Ala174 and vs. empty vector; b) P<0.05 for OATP1B1-Ala174 vs. empty 
vector.
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In line with the in vitro findings, we found that bilirubin levels were 20 % higher in carri-
ers of the OATP1B1-Ala174 allele compared to non-carriers (Table 2).  Moreover, carriers had 
almost 40% higher E1S and 24% higher T4S than non-carriers. 
Carriers of the Ala174 allele had higher rT3 levels in the cohort of healthy blood donors; 
however, this association failed to reach significance in the larger population of elderly Cau-
casians (Table 2).  There was no association of the OATP1B1-Val174Ala polymorphism with 
serum TSH, FT4 and T3 levels (Table 2).
Discussion
In this study we demonstrate that transfection of COS1 cells with OATP1B1 strongly induces 
uptake of BSP, E1S and the iodothyronine sulfates T4S, T3S and rT3S compared to mock trans-
fected cells.  Metabolism of iodothyronine sulfates by rD1 is greatly stimulated in the pres-
ence of OATP1B1.  Moreover, OATP1B1-Val174 showed a 40% higher induction of transport and 
metabolism of these substrates than OATP1B1-Ala174.  These in vitro findings were supported 
by in vivo results showing that carriers of the OATP1B1-Ala174 allele had higher serum bilirubin, 
E1S and T4S levels.
Table 1: Baseline characteristics of the study populations
Healthy blood donors Rotterdam Scan Study
N 155 1012
Age (yrs) 46.42 ± 12.08 72.19 ± 7.38
Gender (M/F) 100 / 55 494 / 518
Bilirubin (μmol/L) 6 [5-7] 9 [7-11]a
E1S (pmol/L) - 207.6 [86.2-419.7]b
TSH (mU/L) 1.19 [0.80-1.71] 1.15 [0.73-1.74]
FT4 (pmol/L) 15.1 ± 2.4 17.9 ± 3.0
T3 (nmol/L) 1.96 ± 0.24 2.00 ± 0.25
rT3 (nmol/L) 0.31 ± 0.08 0.34 ± 0.11
T4S (pmol/L) 16 [13-20] -
OATP1B1- Val174Ala  
wild type
heterozygote
homozygote
Ala174 allele frequency
103 (66.5%)
48 (31.6%)
3 (1.9%) (P=0.30)c
17.7%
714 (73.1%)
236 (24.2%)
27 (2.8%) (P=0.17)c
14.8%
Data are shown as mean ± SD or as median [IQR]. 
a N =363, b N= 424, c P for deviation from Hardy-Weinberg equilibrium. 
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Sulfation is an important pathway in both thyroid hormone and estrogen metabolism.  The 
physiological role of sulfated iodothyronines is not completely clear.  The main function is 
probably the irreversible degradation of thyroid hormone by D1 (10).  However, iodothyro-
nine sulfates might also represent a reservoir of reversibly inactivated thyroid hormone when 
they are not degraded by D1, for instance in the fetus and during severe illness (30).  Serum 
supply of estrogen sulfates and desulfation by estrogen sulfatase, on the other hand, plays an 
important role in the local formation of estrogens in different tissues (1, 14). 
Although different OATPs are capable of sulfate conjugate transport, the major hepatic 
transporter for these conjugates has not been identified.  In this study, we showed that trans-
fection of cells with OATP1B1 induced a ~20-fold increased uptake rate of BSP. Moreover, 
OATP1B1-transfected cells showed considerable uptake of E1S, similar to previously pub-
lished findings regarding uptake of these substrates (16).  In the same way, transport of T4S, 
T3S and rT3S was greatly stimulated by OATP1B1 expression.  Likewise, metabolism of these 
iodothyronine sulfates by D1 showed a marked increase when OATP1B1 was co-transfected. 
OATP1B1-Val174 showed a 40% higher induction of transport and metabolism of these sub-
strates than OATP1B1-Ala174.  However, OATP1B1 did not induce T3 or T4 uptake, and we only 
found a minor increase in rT3 uptake.  This is in contrast with findings published by Abe et 
al., who showed T3 and T4 uptake in Xenopus oocytes injected with OATP1B1 cRNA (16).  The 
discrepancy between their and our findings might be explained by differences in expression 
efficiency of the two systems, or the higher intracellular thyroid hormone-binding capacity 
of Xenopus oocytes compared to COS1 cells.  Therefore, we co-transfected with CRYM, a high-
affinity cytosolic thyroid hormone-binding protein (24), which has recently been shown to 
greatly augment net T3 and T4 uptake by inhibition of T3 and T4 efflux (31).  Nevertheless, no 
significant uptake of T3 and T4 by OATP1B1 could be detected in the presence of CRYM either. 
Taken together, we conclude that in COS1 cells OATP1B1 has no T4 and T3 and only little rT3 
Table 2: Serum parameters by OATP1B1-Val174Ala genotype in healthy blood donors and in participants of 
the Rotterdam Scan Study
Healthy blood donors The Rotterdam Scan Study
OATP1B1-Val174Ala P-value OATP1B1-Val174Ala P-value
Wild type (103) Carriers (49+3) Wild type (714) Carriers (236+27)
Bilirubina 6.0 ± 0.3 7.2 ± 0.5 0.02 9.3 ± 0.2b 10.2 ± 0.4c 0.04
E1Sa - - 282.0 ± 16.2d 392.5 ± 27.9e <0.001
TSHa 1.36 ± 0.07 1.23 ± 0.11 0.55 1.40 ± 0.04 1.36 ± 0.06 0.77
FT4 14.8 ± 0.2 15.6 ± 0.3 0.06 17.9 ± 0.1 18.1 ± 0.2 0.19
T3 1.96 ± 0.02 1.97 ± 0.03 0.64 2.01 ± 0.01 1.98 ± 0.02 0.15
rT3 0.30 ± 0.01 0.34 ± 0.01 0.006 0.34 ± 0.01 0.35 ± 0.01 0.08
T4Sa 16.3 ± 0.6 20.1 ± 0.8 <0.001 - -
a Due to a non-normal distribution, E1S, bilirubin, T4S and TSH were logarithmically transformed in the 
analysis.
b N=268, c N=82+13, d N=317, e N=98+9
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transport activity, but does facilitate transport of iodothyronine sulfates and the previously 
used model substrates E1S and BSP. However, in a different transport assay system, OATP1B1 
specific T4 and T3 transport has been demonstrated (16).
The physiological relevance of this transporter in vivo is underlined by the observation that 
carriers of the OATP1B1-Ala174 allele had higher bilirubin, E1S and T4S levels than non-carriers. 
This is in line with the in vitro data showing that uptake and metabolism of these substrates 
by the OATP1B1-Ala174 variant was less efficient compared to the OATP1B1-Val174 variant. 
Previously, Tirona and colleagues have also shown that the OATP1B1-Ala174 variant shows 
decreased uptake of E1S and estradiol-17β-glucuronide (19).  A possible explanation for this 
altered transport function comes from a study performed by Kameyama and colleagues, who 
showed by immunocytochemistry that OATP1B1-Ala174 protein is not only localized at the 
plasma membrane, but also in the intracellular space, whereas OATP1B1-Val174 variant is only 
expressed at the plasma membrane (32).  Therefore, the decreased activity of OATP1B1-Ala174 
variant could be explained by a sorting error, resulting in decreased expression at the plasma 
membrane and thus decreased transport activity. In addition, kinetic analyses in transfected 
HEK293 cells have been performed showing that the differences in Km values were not ap-
parent between OATP1B1-Val174 and OATP1B1-Ala174 variants. However, both the Vmax value 
and the intrinsic clearance were significantly decreased in cells expressing OATP1B1-Ala174 
compared to OATP1B1-Val174, probably due to the sorting error of the OATP1B1-Ala174 variant. 
Breast cancer is one of the major causes of death in European and American women, occur-
ring most frequently in postmenopausal women. Since estrogens have an important role in 
breast cancer, therapies aim to block interaction with the estrogen receptor by use of an anti-
estrogen, or by inhibiting the conversion of androstenedione to estrone with an aromatase 
inhibitor (33, 34). Local formation of estrogens in breast tumors might be more important 
than circulating estrogens for growth and survival of estrogen-dependent breast cancer in 
post-menopausal women (35). Serum E1S is a major source of estrogens for breast tissue 
through local sulfatase activity (1). Since carriers of the OATP1B1-Val174Ala polymorphism 
have life-long higher serum E1S levels, the possible association of this polymorphism with 
risk and prognosis of breast cancer should be investigated.
In conclusion, OATP1B1 is an important factor in the hepatic transport and metabolism 
of bilirubin, E1S and iodothyronine sulfates. The OATP1B1-Ala174 variant allele displays de-
creased transport activity and thereby gives rise to higher serum bilirubin, E1S, and T4S levels 
in carriers of this polymorphism. 
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abstract
OATP1C1 has been characterized as a specific thyroid hormone transporter. Based on its 
expression in capillaries in different brain regions, OATP1C1 is thought to play a key-role in 
transporting thyroid hormone across the blood-brain barrier. For this reason, we studied the 
specificity of iodothyronine transport by OATP1C1 in detail by analysis of thyroid hormone 
uptake in OATP1C1-transfected COS1 cells. Furthermore, we examined whether OATP1C1 is 
rate limiting in subsequent thyroid hormone metabolism in cells co-transfected with deiodi-
nases. We also studied the effect of genetic variation in the OATP1C1 gene: polymorphisms 
were determined in 155 blood donors and 1192 Danish twins, and related to serum thyroid 
hormone levels. In vitro effects of the polymorphisms were analyzed in cells transfected with 
the variants.
Cells transfected with OATP1C1 showed increased transport of T4 and T4 sulfate (T4S), little 
transport of rT3 and no transport of T3 or T3S compared to mock transfected cells.  Metabo-
lism of T4, T4S and rT3 by co-transfected deiodinases was greatly augmented in the presence 
of OATP1C1. The OATP1C1-intron3C>T, Pro143Thr and C3035T polymorphisms were not 
consistently associated with TH levels, nor did they affect transport function in vitro. 
In conclusion, OATP1C1 mediates transport of T4, T4S and rT3 and increases the access 
of these substrates to the intracellular active sites of the deiodinases. No effect of genetic 
variation on the function of OATP1C1 was observed. 
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introDuction
Organic anion transporting polypeptides (OATPs) are multi-specific sodium-independent 
transport proteins that are expressed in many tissues (1). In general, OATPs exhibit broad 
substrate specificity as they facilitate transport of a large variety of amphipathic organic 
compounds such as bile salts, lipid lowering drugs, but also thyroid hormones (TH) (2-6). In 
contrast to most OATPs, OATP1C1 shows high substrate specificity. It has been characterized 
as a high-affinity T4 and rT3 transporter with Km values in the nanomolar range, while other 
OATPs display Km values for TH transport far above the serum TH concentration (2, 3, 7). 
Based on the expression of OATP1C1 in capillaries in multiple brain regions, this protein is 
thought to play an important role in delivering serum TH to the brain (7, 8). Additional sup-
port for a significant role for OATP1C1 in TH transport in the brain comes from a study from 
Sugiyama and co-workers, in which they show that OATP1c1 is up-regulated in hypothyroid 
rats and down-regulated in hyperthyroid rats (8). 
In this study, we examined the specificity of iodothyronine transport by OATP1C1 in 
transfected COS1 cells, and analyzed whether OATP1C1 is rate-limiting in subsequent io-
dothyronine metabolism in cells co-transfected with different deiodinases. In addition, we 
studied the effect of genetic variation in the OATP1C1 gene, as polymorphisms in different 
OATPs have been shown to alter the transport function of these proteins (9, 10). Identified 
polymorphisms were analyzed for association with serum thyroid parameters in two popula-
tions. In addition, the effect of the polymorphisms on the transport function of OATP1C1 
was tested by analysis of uptake and metabolism of iodothyronines in cells transfected with 
OATP1C1 variants. 
Materials anD MetHoDs
Plasmids and construction of OATP1C1 variants
Human μ-crystallin (pSG5-hCRYM), rat type 1 deiodinase (pcDNA3-rD1), human type 2 
deiodinase (pcDNA3-hD2-rD1-SECIS), and human type 3 deiodinase (pCIneo-hD3) plasmids 
were constructed as previously described (11). An OATP1C1 IMAGE clone (IMAGE 4801171) 
was purchased from the German Resource Center for Genome Research (www.rzpd.de) and 
subcloned into pcDNA3.1- (Invitrogen, Breda, The Netherlands) using NotI and Acc65I restric-
tion sites. 
The Pro143Thr polymorphism was introduced into the OATP1C1 cDNA using the Quick 
Change site-directed mutagenesis protocol (Stratagene, Amsterdam, The Netherlands) 
with forward primer 5’-CAAATATGAGAGATATTCTACTTCCTCCAATTCCACTCTCAGC-3’ and the 
complementary reverse primer. The OATP1C1-3’UTR variants were constructed as follows: 
a PCR reaction was performed on pcDNA3.1-OATP1C1 with forward primer 5’-TGTGTG-
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GAGCTGCAAAACTC -3’ and reverse primer 5’-TGCAAAATG TCAACCAATTAGAAG-3’, generating 
a PCR-product of 926 bp. A second PCR-reaction was performed on genomic DNA from a 
subject homozygous for the wild type or for the variant 3’ UTR with forward primer 5’-TG-
GGCACAGTGTCAATTCTC-3’ and reverse primer 5’-CGTCGTGTA TAAGTAGGAAGTTGC-3’, gener-
ating a product of 1107 bp. The final sequence of 1791 bp was generated by a PCR reaction 
of a 1:1 mixture of the above PCR products using the first forward primer and second reverse 
primer. This PCR-fragment was cloned into pCR-Blunt II TOPO (Invitrogen), excised with BstEII 
en Acc65I and shuttled into pcDNA3.1, yielding pcDNA3.1-OATP1C1-WT-3’UTR or VA-3’UTR.  
Cell culture
COS1 cells were cultured in 6 or 24-well dishes (Corning, Schiphol, The Netherlands) with 
DMEM/F12 medium (Invitrogen), containing 9% heat-inactivated fetal bovine serum (Invitro-
gen) and 100 nM sodium selenite (Sigma).
Iodothyronine transport and metabolism
Materials:  [125I]NaI, [125I]T4 and [125I]T3 were obtained from Amersham Biosciences (Little 
Chalfont, Buckinghamshire, UK). [125I]rT3 was purchased from Perkin Elmer (Boston, USA) and 
unlabeled T4, T3 and rT3 from Henning GmbH (Berlin, Germany). Unlabeled and 125I-labeled 
T4 sulfate (T4S) and T3 sulfate (T3S) were synthesized as described previously (12). FuGENE6 
transfection reagent was obtained from Roche Diagnostics (Indianapolis, IN). 
uptake studies: COS1 cells were cultured in 6-well plates and co-transfected with 500 ng 
empty pcDNA3.1 or pcDNA3.1-OATP1C1-Pro143, Thr143, WT-3’UTR or VA-3’UTR plus 500 ng 
pSG5-hCRYM, coding for a high-affinity cytosolic thyroid hormone-binding protein that 
prevents efflux of internalized iodothyronines (13). This protein binds not only T4 and T3, but 
also T4S and T3S (W.E. Visser, personal communication (14)).  However, the affinity of hCRYM 
for rT3 and rT3S is much lower compared to the other iodothyronines. 
After 24 h culturing, cells were washed with incubation medium (DMEM-F12 with 0.1% 
BSA), and incubated for 15, 30 or 60 min at 37 C with 1 nM (2x105 cpm) [125I]T4, [125I]T3, [125I]rT3, 
[125I]T4S or [125I]T3S in 1.5 ml incubation medium.  After incubation, cells were harvested and 
analyzed as described previously (11). For determination of kinetic parameters, cells were 
incubated with 0.01-1 µM [125I]T4 or 0.1-5 µM [125I]T4S. Data were corrected for background 
uptake in cells transfected with empty vector instead of OATP1C1.  
Metabolism studies: COS1 cells were cultured in 24-well dishes and transfected with 100 ng 
empty vector plus 100 ng rD1, hD2, or hD3 plasmid or with 100 ng deiodinase plus 100 ng 
OATP1C1 plasmid. After 24 h culturing, cells were incubated for 24 h at 37 C with 1 nM (1 x 106 
cpm) 125I-labeled T4, rT3 or T4S in 0.5 ml incubation medium. After incubation, medium was 
harvested and analyzed by HPLC as described previously (11). Production of the metabolites 
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is presented as percentage of total radioactivity in the medium, which represents >90% of 
added radioactivity. 
Identification of polymorphisms and haplotypes in the OATP1C1 gene
The structure of the OATP1C1 gene was determined using the NCBI gene database. The poly-
morphisms in the region were obtained from databases of the International Hapmap Project 
(http://www.hapmap.org) (15) and the National Center for Biotechnology Information (NCBI) 
dbSNP (http://www.ncbi.nlm.nih.gov). In addition, DNA of 25 randomly selected Caucasian 
subjects was used for sequence analysis of the complete coding region, including intron/
exon boundaries, of the OATP1C1 gene to verify polymorphisms found in different databases 
and to identify novel polymorphisms. Primers used for amplification and sequencing are 
available on request.
The haploblock structure of the gene was determined using Haploview v3.32 (16) ac-
cording to the method of Gabriel et al. (17). A haploblock is a set of statistically associated 
polymorphisms, and Haploview is a program designed to analyze and visualize patterns of 
linkage disequilibrium, i.e. non-random associations between polymorphisms. 
Study populations
We analyzed a population of 154 healthy blood donors from the Sanquin Blood Bank South 
West region (Rotterdam, The Netherlands) (18). Informed consent was given by all donors. 
Serum TSH, T4, T3 and free T4 (FT4) were determined as described previously (18). T4S was 
determined by a specific RIA (19).
The second population consisted of participants of a nation-wide project (GEMINAKAR) 
investigating the relative influence of genetic and environmental factors on a variety of traits 
among Danish twins. Based on a questionnaire survey concerning physical health and health 
related behavior performed in 1994, a representative sample of twin pairs was recruited from 
the population-based Danish Twin Registry (20). A detailed description of the ascertainment 
procedure can be found elsewhere (21-23).  In the GEMINAKAR study 1512 individuals (756 
twin pairs) were examined. Blood samples for thyroid measurements and genotype informa-
tion were available in 1266 individuals, distributed in 554 monozygotic (MZ), 474 same sex 
dizygotic (DZ) and 238 opposite sex (OS) twin individuals. In the MZ twin pairs, in which only 
one of the twins was genotyped, we assumed identical genotypes. Twin pairs in which one 
or both twins had self-reported thyroid disease (22 twin pairs) or biochemical thyroid disease 
(15 twin pairs) were excluded, leaving 1192 (524 MZ, 442 DZ and 226 OS twin individuals). Se-
rum thyroid parameters were determined as described previously (21, 24). Written informed 
consent was obtained from all participants and the study was approved by all regional Dan-
ish Scientific-Ethical Committees (case file 97/25 PMC).
In the case of significant associations the use of twins would allow us to assess the contri-
bution of these polymorphisms to the trait variation and the genetic variance.
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Genotyping 
The polymorphisms OATP1C1-intron3 C>T (rs10770704), OATP1C1-Pro143Thr (rs36010656) 
and OATP1C1-C3035T (rs10444412) were determined by 5’fluorogenic Taqman assays. Reac-
tions were performed in 384-wells format on ABI9700 PCR machines with endpoint read-
ing on the ABI 7900HT Taqman machine (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands) (25). 
Statistical analysis
Data were analyzed using SPSS 10.0.7 for Windows (SPSS, Inc., Chicago, IL) and STATA statisti-
cal software (STATA Corporation, College Station, TX). P values are two-sided throughout and 
were considered significant if P < 0.05. 
For the in vitro experiments, unpaired Student’s t-tests were used to test whether iodothy-
ronine uptake and metabolism induced by wild-type OATP1C1 was significantly different 
from cells transfected with variant OATP1C1 or empty vector. 
The polymorphisms were analyzed for deviation from Hardy-Weinberg equilibrium propor-
tions using a Chi-square test. In the cohort of blood donors, the distribution of serum TSH was 
skewed and therefore transformed by the natural logarithm. Differences between genotypes 
were adjusted for age and gender and tested by analysis of covariance (ANCOVA). In case of 
an allele dose effect for either one of the polymorphisms, a linear regression analysis was 
performed to quantify the association. 
In the Danish twins, associations between the OATP1C1-C3035T polymorphism and serum 
thyroid parameters were assessed using regression analysis. The statistical inference measures 
were computed using a technique (the cluster option in STATA) that takes the dependency 
of twin data into account. The genotype information was incorporated in the regression 
analyses by coding the noncarriers as 0, heterozygous carriers as 1 and homozygote carriers 
as 2. Due to non-normal distribution of most of the serum parameters were transformed by 
the natural logarithm, and adjustment for age and gender was performed. 
results
Transport of (sulfated) iodothyronines by OATP1C1
Incubation of OATP1C1-transfected COS1 cells with [125I]T4 resulted in a significant stimula-
tion of the uptake of this iodothyronine over cells transfected with empty vector (Fig. 1A). In 
addition, cellular uptake of [125I]rT3 was induced in cells transfected with OATP1C1 compared 
to mock transfected cells, however this failed to reach significance (Fig. 1A). The low affinity 
of rT3 for CRYM may at least in part explain why its uptake was lower than that of T4 and not 
linear with incubation time (13). Cellular uptake of [125I]T3 was not stimulated after transfec-
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tion with OATP1C1 (Fig. 1A). The high basal [125I]T3 uptake in cells transfected with empty 
vector and CRYM is probably due to T3 uptake by endogenous transporters in COS1 cells.
In addition to T4, rT3 and T3, OATP1C1-transfected cells were tested for uptake of sulfated 
iodothyronines T4S and T3S. OATP1C1 did not facilitate uptake of [125I]T3S. However, [125I]
T4S uptake was increased in OATP1C1-transfected cells compared to mock transfected cells 
(Fig. 1A). In addition, the saturation kinetics of T4 and T4S uptake by OATP1C1 were studied 
by incubation of OATP1C1-transfected COS1 cells during 30 min with 0.01-1 µM T4 or 0.1-5 
µM T4S. The results are presented in Figure 1B, showing that both T4 and T4S uptake were 
saturable with apparent Km values of 0.12 µM for T4 and 2.6 µM for T4S. Vmax values were 
similar for T4 and T4S (0.25 vs. 0.40 nmol/min).
Iodothyronine metabolism in cells co-transfected with OATP1C1 and deiodinases 
Incubation of cells transfected with D2 or D3 led to some conversion of T4. However, this was 
markedly and significantly increased, when cells were co-transfected with OATP1C1 (Fig. 2). 
Based on the transport assays, it is not entirely clear whether OATP1C1 transports [125I]
rT3 in a significant manner. However, metabolism of rT3 by either D1 or D2 was increased 
2-fold in cells co-transfected with OATP1C1 (Fig. 2). In addition, T4S metabolism by D1 was 
increased 10-fold in cells co-transfected with OATP1C1 (Fig 2).
Identification of polymorphisms in the OATP1C1 gene
Sequence analyses of 25 Caucasian subjects revealed 13 polymorphisms, among which one 
novel sequence variation in the OATP1C1 gene (Fig. 3). For this study, we preferentially select-
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Figure 1A: [125I]T4, [125I]rT3, [125I]T3, [125I]T4S and [125I]T3S uptake by COS1 cells transfected with empty vector 
or OATP1C1.  Cells were co-transfected with CRYM, an intracellular thyroid hormone-binding protein. Cells 
were incubated for 15, 30 or 60 min at 37 C with 1 nM (2x105 cpm) 125I-labeled T4, rT3, T3, T4S or T3S. Data 
are expressed as percentage uptake of added radioactivity. Results are the means ± SEM of at least two 
experiments. * P<0.05, ** P<0.01 of cells transfected with OATP1C1 versus mock transfected cells.
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ed non-synonymous polymorphisms or polymorphisms in the 3’UTR. One non-synonymous 
polymorphism, OATP1C1-Pro143Thr, and 4 polymorphisms in the 3’UTR were selected. By 
analyzing the linkage disequilibrium block structure across the gene from the Hapmap data 
(Phase II release 22) using the Haploview program (16), the identified polymorphisms in the 
3’UTR were found to be part of a haploblock spanning from exon 10 to the end of the 3’UTR 
in exon 15. Therefore, the C3035T polymorphism was genotyped as a tagging polymorphism 
for the other polymorphisms in this haploblock. In an attempt to cover the remainder of the 
gene, a C>T polymorphism in intron 3 (rs10770704) was genotyped as a tagging polymor-
phism for the first haploblock encompassing the first 4 exons (Fig. 3). 
OATP1C1 polymorphisms in healthy blood donors
The baseline characteristics of the population of blood donors are shown in Table 1. One 
subject failed genotyping for the OATP1C1-intron3C>T polymorphism. All polymorphisms 
were in Hardy-Weinberg equilibrium. 
The OATP1C1-intron3C>T polymorph ism was not associated with serum thyroid parameters 
(data not shown). For the OATP1C1-Pro143Thr polymorphism, all serum thyroid parameters 
were similar between carriers and non-carriers, except for rT3, which was higher in carriers 
of the OATP1C1-Thr143 allele (Table 2). The OATP1C1-C3035T polymorphism was in a dose-
dependent manner associated with a higher serum FT4 and a higher rT3 (Table 2).
Figure 1B: 
Figure 1B: Ligand concentration-dependent uptake of T4 and T4S by OATP1C1-transfected COS1 cells. 
Cells were incubated for 30 min with 0.01-1 µM [125I]T4 or 0.1-5 µM [125I]T4S. Data were corrected for 
background uptake in cells transfected with empty vector instead of OATP1C1.Curve-fitting was 
performed using the Michaelis-Menten equation v = Vmax/(1+Km/S). Results are the means ± SEM of 4-6 
observations.
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Figure 2: 
Figure 2:  [125I]T4, [125I]rT3 and [125I]T4S metabolism by COS1 cells transfected with either D1, D2 or D3 alone 
or together with OATP1C1. Cells were incubated for 24 h at 37 C with 1 nM (1x106 cpm) 125I-labeled T4, 
rT3 or T4S. Metabolism is shown as percentage of  metabolites in the medium after 24 h incubation. 
Results are the means ± SEM of at least three experiments. * P<0.05, ** P<0.01 of cells co-transfected with 
OATP1C1 and deiodinase versus cells co-transfected with empty vector and deiodinase.
Figure 3: 
Figure 3: Schematic overview of the OATP1C1 gene (Chr. 12p12.2). Nucleotide numbers are based on 
Genbank accession number NM 017435.2. The vertical black boxes represent the 15 exons of the OATP1C1 
gene, and the vertical lines represent the polymorphisms found by direct sequencing of 25 Caucasian 
blood donors. The numbers between parentheses represent the minor allele frequencies of the different 
polymorphisms. The horizontal lines above the gene structure are a schematic representation of the 3 
linkage disequilibrium (LD) blocks according to Hapmap data (Hapmap release II, phase 21).
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OATP1C1 polymorphisms in healthy Danish Twins
Based on the results of the association analysis of the OATP1C1 polymorphisms in the cohort 
of blood donors, we only genotyped the OATP1C1-C3035T polymorphism in the population 
of Danish twins. The baseline characteristics of this population are shown in Table 1. The al-
lele frequency of the OATP1C1-C3035T polymorphism was 41.7%, which is almost 6% lower 
than the frequency observed in the population of healthy blood donors.
In contrast to our findings in the blood donors, no significant differences in serum thyroid 
parameters were observed between subjects carrying 0, 1 or 2 copies of this polymorphism 
(Table 3). Therefore, we refrained from assessing the contribution of this polymorphism to 
the variation in serum thyroid parameters and the genetic variance.
Effect of OATP1C1 polymorphisms in vitro
The in vitro effect of OATP1C1-Pro143Thr and the polymorphisms in the 3’UTR was tested 
by transfecting COS1 cells with these variants and analyzing them for differences in T4 and 
rT3 uptake and metabolism from wild-type OATP1C1. For OATP1C1-Pro143Thr no significant 
Table 1: Baseline characteristics of the study populations
Dutch blood donors Danish twins
N 154 1192
Age (yrs) 46.32 ± 12.06 36.67 ± 10.72
Gender (M/F) 99 / 55 601/591
TSH (mU/L) 1.19 [0.80-1.71] 1.56 [1.14-2.17]
FT4 (pmol/L) 15.08 ± 2.40 12.82 ± 1.63
T4 (nmol/L) 87 ± 16 111 [100 - 127]
T3 (nmol/L) 1.96 ± 0.24 1.84 [1.66 - 2.09]
rT3 (nmol/L) 0.31 ± 0.08 0.35 [0.29 - 0.43]
T4S 16 [13-20] -
Intron3C>T wild-type (%)
   heterozygote (%)
   homozygote (%)
   allele frequency (%)
   HWE-p-value
50 (32.7)
70 (45.8)
33 (21.6) 
44.4
0.36
-
Pro143Thr wild-type (%)
   heterozygote (%)
   homozygote (%)
   allele frequency (%)
   HWE-p-value
140 (90.9)
14 (9.1)
0 (0.0) 
4.5
0.55
-
C3035T  wild-type (%)
   heterozygote (%)
   homozygote (%)
   allele frequency (%)
   HWE-p-value
45 (29.2)
73 (47.4)
36 (23.4) 
47.1
0.55
398 (33.4)
594 (49.8)
200 (16.8)
41.7
0.39
Data are shown as mean ± SD or as median [IQR]. HWE-p-value represents the p-value for deviation from 
Hardy-Weinberg equilibrium.
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differences in uptake and metabolism of T4 compared to wild-type OATP1C1 were observed 
(Fig. 4A, B). In addition, no difference in T4 uptake and T4 metabolism was observed between 
cells transfected with OATP1C1- WT-3’UTR or VA-3’UTR  (Fig. 4A,B). Neither could we detect 
any differences in rT3 uptake and metabolism between the different OATP1C1 variants (data 
not shown).
Discussion
In this study we demonstrated that T4, T4S and to some extent rT3 uptake was induced in 
cells transfected with OATP1C1 compared to mock transfected cells. In addition, metabolism 
of T4, T4S and rT3 by transfected deiodinases was markedly stimulated in the presence of 
OATP1C1. Although, the OATP1C1-Pro143Thr and OATP1C1-C3035T polymorphisms were 
associated with serum thyroid parameters in 155 blood donors, we could not replicate these 
findings in a much larger cohort of Danish twins. Nor did we observe any difference in uptake 
and metabolism of T4 and rT3 between these variants and wild-type OATP1C1.
Table 2: Serum thyroid parameters by OATP1C1 genotypes in a population of Dutch blood donors
OATP1C1-Pro143Thr Pa OATP1C1-C3035T Pb
wild-types (140) carriers (14) wild-types (45) heterozygotes (73) homozygotes (36)
TSH 1.31 ± 0.06 1.33 ±0.11 0.69 1.29 ± 0.11 1.29 ± 0.09 1.39 ± 0.13 0.36
T4 87.47± 1.30 91.91 ± 4.11 0.30 86.51 ± 2.31 87.82 ± 1.81 89.68 ± 2.58 0.36
FT4 15.01 ± 0.20 15.71 ± 0.64 0.30 14.38 ± 0.35 15.27 ± 0.28 15.56 ± 0.39 0.02
T3 1.96 ± 0.02 2.02 ± 0.05 0.33 2.01 ± 0.04 1.96 ± 0.03 1.91 ± 0.04 0.06
rT3 0.31 ± 0.01 0.36 ± 0.02 0.03 0.29 ± 0.01 0.31 ± 0.01 0.34 ± 0.01 0.008
T4S 17.5 ± 0.5 18.5 ± 1.6 0.41 17.0 ± 0.9 17.3 ± 0.7 18.8 ± 1.0 0.16
Data are shown as mean ± SE.
a P-value for ANOVA, adjusted for age and gender
b P-value for linear regression, adjusted for age and gender
Table 3: Serum thyroid parameters by OATP1C1-C3035T genotype in a population of Danish twins
OATP1C1-C3035T Pa
wild-types (398) heterozygotes (594) homozygotes (200)
TSH 1.73 ± 0.89 1.77 ± 0.95 1.76 ± 0.94 0.54
T4 114.4 ± 25.3 117.1 ± 25.4 117.5 ± 25.1 0.06
FT4 12.73 ± 1.59 12.87 ± 1.65 12.84 ± 1.67 0.37
T3 1.89 ± 0.37 1.92 ± 0.41 1.91 ± 0.36 0.52
rT3 0.36 ± 0.11 0.37 ± 0.11 0.36 ± 0.10 0.85
Data are shown as mean ± SD
a P-value for linear regression on the transformed values, adjusted for age and gender
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Figure 4A: Uptake of [125I]T4 by COS1 cells transfected with empty vector or one of the OATP1C1 variants. 
Cells were co-transfected with CRYM. Cells were incubated for 15, 30 or 60 min at 37 C with 1 nM (2x105 
cpm) [125I]T4. Data are expressed as percentage uptake of added radioactivity. Results are the means ± 
SEM of at least three experiments. * P<0.05, ** P<0.01 of cells transfected with wild-type OATP1C1 versus 
cells transfected with variant OATP1C1
Figure 4B: 
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Figure 4B: Metabolism of [125I]T4 by COS1 cells transfected with either D2 or D3 alone or together with 
one of the OATP1C1 variants. Cells were incubated for 24 h at 37 C with 1 nM (1x106 cpm) 125I-labeled T4. 
Metabolism is shown as percentage of metabolites in the medium after 24 h incubation. Results are the 
means ± SEM of at least three experiments. * P<0.05, ** P<0.01 of cells co-transfected with wild-type 
OATP1C1 and deiodinase versus cells co-transfected with variant OATP1C1 and deiodinase
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Based on its lipophilic structure, it was assumed that thyroid hormone enters the cell 
through passive diffusion (26). However, with the discovery of MCT8 as a specific thyroid 
hormone transporter and the fact that mutations in this transporter lead to the Allan-
Herndon-Dudley syndrome (OMIM 300523), the interest in this area of research has greatly 
increased (27-29). In this paper we focused on OATP1C1, which was first described by Piz-
zagalli and colleagues as a specific thyroid hormone transporter (7).  OATP1C1 is expressed 
in multiple brain regions and in the testis. In line with findings by Pizzagalli et al., we found a 
clear induction of T4 uptake and to some extent also of rT3 uptake by cells transfected with 
OATP1C1. Furthermore, metabolism of T4 and rT3 by D1, D2 or D3 was markedly increased if 
OATP1C1 was co-transfected. This demonstrates that OATP1C1 expression is rate limiting in 
iodothyronine metabolism by the deiodinases. It thus supports the hypothesis that OATP1C1 
indeed increases the intracellular availability of these iodothyronines, since the deiodinases 
are membrane proteins with their active sites located intracellularly (30).
It should be noted that co-transfection with deiodinases was done to monitor the increase 
in intracellular iodothyronine concentration by OATP1C1 rather than to mimic particular tis-
sue cells. OATP1C1 is probably only co-expressed with D2 in vivo. Both OATP1C1 and D2 are 
expressed in tanycytes that line the third ventricle (31). Conversion of T4 to T3 in these cells 
plays an important role in the negative feedback of thyroid hormone at the hypothalamus. 
OATP1C1 and D2 are also co-expressed in the testis, which may also facilitate local T3 forma-
tion in this tissue (32).
We further extended the findings from Pizzagalli et al., by showing that OATP1C1 also 
facilitates transport and subsequent metabolism of T4S, but not of T3S. The serum concen-
trations of T4S and T3S are low under normal conditions as sulfation of thyroid hormone 
accelerates its degradation by D1 (19, 30, 33-36). However, serum iodothyronine sulfate levels 
are high in preterm infants and during critical illness (33, 35, 37). Under these conditions, the 
sulfates might serve as a reservoir of inactive thyroid hormone, from which active thyroid 
hormone can be recruited when necessary. It is, therefore, interesting that T4S is a ligand for 
OATP1C1-mediated transport. Since Oatp1c1 is localized both on the luminal and abluminal 
membrane of brain capillaries in rats and mice, this protein could play a role in uptake as well 
as efflux of T4S across the blood-brain barrier (8). During embryonic development, uptake of 
T4S across the blood-brain barrier by OATP1C1, may serve as source of T4 for the brain after 
local hydrolysis by sulfatases. OATP1C1 might, however, also serve as an export pump for T4S. 
Several sulfotransferases are expressed in different brain regions (38, 39). Among these are 
the most potent iodothyronine sulfotransferases SULT1A1 and SULT1E1 (40, 41). In addition 
to the action of the deiodinases, these enzymes might tightly regulate T4 levels in different 
brain regions. 
The Michaelis-Menten transport kinetics of T4 and T4S transport by OATP1C1 were deter-
mined. Both were saturable with apparent Km values of 0.12 µM for T4 and 2.6 µM for T4S. It is 
important to realize that these are approximate values as in addition to OATP1C1 binding of 
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T4 and T4S to BSA and CRYM are also saturable processes. Nevertheless, our Km value for T4 
is in good agreement with that previously reported by Pizzagalli et al. (90 nM) (7).
Based on the function of OATP1C1, polymorphisms in the OATP1C1 gene might be associ-
ated with T4, T4S and rT3 levels (7). As the serum FT4 concentration (~15 pM) is orders of 
magnitude lower than the apparent Km value (~100 nM), the rate of T4 transport by OATP1C1 
in vivo is linearly dependent on the Vmax/Km ratio. Polymorphisms that change the Vmax or 
Km value would directly affect tissue T4 uptake by OATP1C1. 
Carriers of the OATP1C1-Pro143Thr polymorphism indeed had higher rT3 levels than 
non-carriers in a population of healthy blood donors. Furthermore, the OATP1C1-C3035T 
polymorphism was in a dose-dependent manner associated with higher serum FT4 and 
serum rT3 in this same cohort. In contrast to our findings in the Dutch blood donors, no 
significant differences in serum thyroid parameters were observed between carriers of 0, 1, 
or 2 copies of the OATP1C1-C3035T polymorphism in the Danish twins. In addition, in a third 
population of approximately 1000 Caucasian subjects, the OATP1C1-C3035T polymorphism 
was not significantly associated with serum thyroid hormone levels (unpublished data by 
W.M. van der Deure, R.P. Peeters and T.J. Visser).
Furthermore, uptake and metabolism of T4 and rT3 by COS1 cells transfected with the 
OATP1C1 variants was similar to cells transfected with cDNA coding for the wild-type form 
of the OATP1C1 protein. It is, therefore, likely that our initial findings in the blood donors 
were chance findings, which might be caused by the small sample size of this cohort (42). 
However, differences in age and environmental factors such as iodine intake between the 
two populations might also in part explain the inconsistent findings. 
Although we did not observe an effect of polymorphisms in the OATP1C1 gene on serum 
thyroid parameters, this might not rule out local effects of genetic variation. For instance, 
the Thr92Ala polymorphism in D2 is not associated with serum thyroid parameters or differ-
ences in iodothyronine metabolism in transiently transfected COS1 cells (18), but has been 
associated with insulin resistance in different populations (43, 44).  Therefore, we cannot 
exclude that polymorphisms in the OATP1C1 gene could be associated with brain-related 
phenotypes, such as depression or cognition.
In conclusion, our findings indicate that OATP1C1 mediates plasma membrane transport 
of T4, T4S and rT3 and is rate limiting in iodothyronine metabolism by the deiodinases. Poly-
morphisms in the OATP1C1 gene are not associated with serum thyroid parameters, nor do 
they alter the transport function of OATP1C1.
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abstract
introduction: Some hypothyroid patients continue to have significant impairments in 
psychological well-being, despite adequate treatment with levothyroxine (LT4).  T4 transport 
across the blood-brain barrier is one of the crucial processes for thyroid hormone action in 
the brain. OATP1C1, a thyroid hormone transporter expressed at the blood-brain barrier, is 
thought to play a key role in delivering serum T4 to the brain. 
objective: To examine whether polymorphisms in OATP1C1 are determinants of well-being, 
neurocognitive functioning and preference for replacement therapy with a combination of 
LT4 and liothyronine (LT3).
Design and participants: We studied 141 patients with primary autoimmune hypothyroid-
ism, adequately treated with LT4 monotherapy and participating in a randomized clinical trial 
comparing LT4 therapy with LT4/LT3 combination therapy. 
outcome measurements: Different questionnaires on well-being and neurocognitive tests 
were performed at baseline. Serum thyroid parameters, OATP1C1-intron3C>T, OATP1C1-
Pro143Thr and OATP1C1-C3035T polymorphisms were determined. 
results: Allele frequencies of the OATP1C1 polymorphisms in patients with primary hy-
pothyroidism were similar to those of healthy controls. Both the OATP1C1-intron3C>T and 
the OATP1C1-C3035T polymorphism, but not the OATP1C1-Pro143Thr polymorphism, were 
associated with symptoms of fatigue and depression. OATP1C1 polymorphisms were not 
associated with measures of neurocognitive functioning or preference for combined LT4/
LT3 therapy. 
conclusions: OATP1C1 polymorphisms are associated with fatigue and depression, but do 
not explain differences in neurocognitive functioning or appreciation of LT4/LT3 combination 
therapy. Future studies are needed to confirm these findings.
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introDuction
Adequate levels of thyroid hormone are critical for normal brain function. This is clearly 
demonstrated by the increased prevalence of mood disorders in patients with overt thyroid 
disease (1). Some hypothyroid patients remain to have significant impairments in psycho-
logical well-being (2) and neurocognitive functioning (3), despite adequate treatment with 
levothyroxine (LT4). This might be because standard replacement therapy is not sufficient 
to restore euthyroidism in all tissues (4). One randomized clinical trial of combined LT4 and 
liothyronine (LT3) therapy versus LT4 monotherapy in hypothyroid patients showed that 
combination therapy improved mood, well-being and cognitive functioning in comparison 
with treatment with LT4 alone (5). However, several more recent trials, including our own, 
have not replicated this finding (6-10). 
Hypothyroid patients treated with LT4 probably derive T3 exclusively from exogenously 
administered LT4, as these patients lack normal T3 production by the thyroid gland. Therefore, 
proper function of key-proteins involved in transport and metabolism of T4 are of utmost 
importance. By inference, polymorphisms in the genes encoding these proteins might well 
be determinants of well-being in this group of patients. For instance the type 2 deiodinase 
(D2), which regulates the conversion of T4 to T3 in the brain, might be essential (11). However, 
we have recently shown that polymorphisms in D2 are not associated with differences in 
well-being or neurocognitive functioning in patients adequately treated for hypothyroidism 
(12). 
Since all T4 in the brain is derived from serum, thyroid hormone transport across the 
blood-brain barrier is a crucial process for thyroid hormone action in the brain. Several pro-
teins capable of thyroid hormone transport have been identified, such as members of the 
monocarboxylate (MCT) and organic anion transporting polypeptide (OATP) families (13). 
MCT8 has been characterized as an active thyroid hormone transporter and mutations in this 
transporter lead to the Allan-Herndon-Dudley syndrome (OMIM 300523) (14-16).  OATP1C1, 
located on chromosome 12p12, is capable of T4 and rT3 transport (17). Based on its expres-
sion at the blood-brain barrier, OATP1C1 is thought to play a key role in delivering serum T4 
to the brain (17, 18). Additional support for a significant role for OATP1C1 in thyroid hormone 
transport in the brain comes from a study from Sugiyama and co-workers, in which they 
show that OATP1c1 is up-regulated in hypothyroid rats and down-regulated in hyperthyroid 
rats (18). Hence, subtle changes in transporter function may influence transport of thyroid 
hormone into the brain and thus alter local T4 concentrations in the brain. 
Recently, we identified several polymorphisms in the OATP1C1 gene (Fig. 1) (19), of which 
OATP1C1-intron3C>T, OATP1C1-Pro143Thr and OATP1C1-C305T were genotyped in this 
study. OATP1C1-intron3C>T is a tagging polymorphism for a haploblock encompassing the 
first four exons of the OATP1C1 gene, whereas OATP1C1-C3035T captures most of the genetic 
variation in a haploblock, spanning from exon 10 until the end of the OATP1C1 gene (Fig. 1) 
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(19). To date, OATP1C1-Pro143Thr is the only non-synonymous polymorphism identified in 
the OATP1C1 gene. We analyzed whether these polymorphisms are determinants of well-
being and neurocognitive functioning in hypothyroid patients on adequate LT4 therapy. 
Secondly, we investigated whether OATP1C1 genotypes are associated with a preference for 
LT4 or LT4 and LT3 replacement therapy. 
Patients anD MetHoDs
Patients
Patients, between 18 and 70 years of age, who had been on an adequate dose of LT4 re-
placement therapy as reflected by normalized serum TSH levels for primary autoimmune 
hypothyroidism for at least 6 months, were recruited from 13 general practices in the cities 
of Amsterdam and Almere. The patients participated in a randomized controlled trial inves-
tigating possible superiority of therapy with a LT4/LT3 combination in a ratio of 5:1 or 10:1 
over therapy with LT4 alone (9). For more detailed information on the patients and the study 
design, please refer to (9). The protocol was approved by the institutional review board of the 
Academic Medical Center of the University of Amsterdam. Informed consent was obtained 
from all participants.
Questionnaires and neurocognitive tests
Well-being of patients was measured by means of self-report questionnaires and neurocog-
nitive functioning by tests administered by a trained psychometrician under supervision of 
a clinical neuropsychologist, all performed before the study medication of the randomized 
trial was supplied. Subjective appreciation of the study medication, compared with the usual 
LT4 medication from before the trial, was rated at every visit and at endpoint after 15 weeks. 
The set of questionnaires included the 32-item Profile of Moods States Dutch shortened ver-
Chapter 4, figure 1: 
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Figure 1: Schematic overview of the OATP1C1 gene on chromosome 12p12.2 (NM 017435) showing the 
polymorphisms genotyped in this population together with haploblocks based on the Hapmap project 
(Hapmap release II, phase 21).
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sion (POMS), designed to monitor changes in mood states (20); the original Dutch version of 
the Multidimensional Fatigue Inventory (MFI-20), consisting of 20 questions and designed 
to measure (changes in) fatigue (21); the mental health and vitality subscales of the Rand 
36-item health survey (Rand-36) (22); and the Dutch version of the Symptom Checklist 
(SCL-90), a 90 item self-report scale containing eight subscales measuring multidimensional 
psychopathology (23).
Measurement of neurocognitive functioning included tests of attention and working 
memory (Digit Span subtest of the Wechsler Adult Intelligence Scale) (24); learning and 
memory (Dutch version of the Story Recall from the Rivermead Behavioral Memory Test 
(RBMT)) (25, 26), and the Dutch adaptation of the California Verbal Learning Test (CVLT) (27, 
28); psychomotor speed (Dutch adaptation of the Digit Symbol subtest of the Wechsler Adult 
Intelligence Scale-III) (24, 29); speed of memory processing (Memory Comparison Task (MCT), 
computer version (30), and paper-and-pencil version (31); and attention (Dutch adaptation of 
the Paced Auditory Serial Attention Task) (32, 33).
Serum analyses
All blood samples were collected in the morning before medication was ingested, ap-
proximately 24 h after the LT4 dose. Serum TSH and FT4 were measured by time-resolved 
fluoroimmunoassay (Wallac Oy, Turku, Finland). Serum T4 and T3 were measured by in-house 
RIA methods (34).
Genotyping 
DNA was isolated from peripheral leucocytes by standard procedures. Three polymorphisms 
in the OATP1C1 gene (OATP1C1-intron3C>T (rs10770704), OATP1C1-Pro143Thr (rs36010656) 
and OATP1C1-C3035T (rs10444412)) were determined by 5’fluorogenic Taqman assays. 
Reactions were performed in 384-wells format on ABI9700 2x384 well PCR machines with 
endpoint reading on the ABI 7900HT Taqman machine (Applied Biosystems, Nieuwerkerk aan 
den IJssel, The Netherlands) (35). 
DNA was available of 141 patients. The genotyping success rate for OATP1C1-Pro143Thr 
and OATP1C1-C3035T was 100%. For OATP1C1-intron3C>T one sample failed genotyping.
Statistical analyses
Data were analyzed using SPSS 10.0.7 for Windows (SPSS, Inc., Chicago, IL).  For the three 
polymorphisms, deviation from Hardy-Weinberg equilibrium proportions was analyzed us-
ing a Chi-square test.  Differences between genotypes in serum thyroid parameters, scores 
of well-being and neurocognitive functioning were adjusted for age, gender and tested 
by analysis of covariance (ANCOVA). In case of an allele dose effect, we performed a linear 
regression analysis to quantify association. Statistical significance was defined as a two-tailed 
P < 0.05.
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results
The frequencies of the OATP1C1-intron3C>T, OATP1C1-Thr143 and OATP1C1-3035T alleles were 
46.1%, 3.2% and 42.9% respectively and similar to those found in public databases such as 
NCBI SNP database (http://www.ncbi.nlm.nih.gov) and the Hapmap Project (www.hapmap.
org) (36) (Table 1). All polymorphisms were in Hardy-Weinberg equilibrium. No associations 
were found between the polymorphisms and serum thyroid parameters (data not shown).
OATP1C1 polymorphisms and scores on well-being questionnaires
Table 2 shows the scores on well-being questionnaires by genotype. OATP1C1-intron3C>T 
was significantly associated, in an allele dose-dependent manner, with 7 out of 8 fatigue-
subscales in different questionnaires. Patients homozygous for this polymorphism were 
consistently least fatigued as indicated by their scores on all subscales of a questionnaire 
specifically designed to measure several aspects of fatigue (MFI-20), and on the subscales of 
other well-being questionnaires measuring fatigue (POMS fatigue) or the opposite (POMS 
vigor; Rand-36 vitality). Wild-type patients were most fatigued, and the fatigue-scores of 
patients heterozygous for the polymorphism were intermediate. In the same manner, this 
polymorphism was associated with the three subscales measuring symptoms of depression. 
Again, homozygous patients had the least complaints of depression indicated by lower 
scores, whereas wild-type patients had the highest scores on subscales of depression.  The 
association was significant for one of the three subscales (SCL-90 depression), for the two 
other subscales (POMS depression and Rand mental health) there was a trend towards sig-
nificance. 
Like OATP1C1-intron3C>T, OATP1C1-C3035T was significantly associated with scores on 
all three questionnaire subscales measuring depression, again in an allele dose-dependent 
manner. Wild-type patients consistently had the worst depression scores (indicating more 
complaints of depression), whereas homozygous carriers were the least depressed. For 
instance, on the POMS depression subscale, wild-type patients had a mean score of 7.6 ± 1.0, 
compared to homozygous variant carriers who had an average score of 3.8 ± 1.3 (P=0.01). 
Table 1: OATP1C1 genotype frequencies in a population of patients on T4 replacement therapy for primary 
autoimmune hypothyroidism
Genotypes
wild-types heterozygotes homozygotes allele frequency Pa
Intron3C>T 43 65 32 0.46 0.44
Pro143Thr 132 9 0 0.03 0.70
C3035T 46 69 26 0.43 0.99
a P for deviation from Hardy-Weinberg equilibrium
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Table 3: Scores on neurocognitive tests by OATP1C1 genotype
OATP1C1-intron3C>T
wild-types heterzygotes homozygotes P
N 43 65 32
Digit Symbol
Raw score (sec) 74.0 ± 2.8 71.7 ± 2.3 72.9 ± 3.2 0.75
MCT (paper & pencil version)
1 letter (sec) 27.6 ± 1.0 25.3 ± 0.8 26.2 ± 1.1 0.28
2 letters (sec) 37.1 ± 1.4 36.6 ± 1.2 36.2 ± 1.6 0.65
3 letters (sec) 45.8 ± 1.8 44.2 ± 1.5 45.8 ± 2.1 0.94
4 letters (sec) 58.5 ± 2.4 55.2 ± 2.0 58.8 ± 2.8 0.95
MCT (computer version)
3 letters (sec) 621.7 ± 14.1 628.7 ± 11.8 638.0 ± 16.6 0.45
4 letters (sec) 616.8 ± 12.1 628.6 ± 10.1 622.0 ± 14.2 0.72
5 letters (sec) 678.9 ± 11.9 681.4 ± 10.0 677.6 ± 14.0 0.96
Intercept (sec) 553.3 ± 21.1 567.4 ± 17.7 586.4 ± 24.8 0.31
Slope 28.7 ± 5.0 26.3 ± 4.2 19.8 ± 5.9 0.26
Pasat
Total score (No) 223.6 ± 7.8 223.5 ± 6.5 212.3 ± 9.2 0.38
Digit Symbol
Pairs 12.4 ± 0.7 11.5 ± 0.5 11.0 ± 0.8 0.17
Free reproduction 7.6 ± 0.2 7.3 ± 0.2 7.1 ± 0.2 0.11
Digit Span
Forward recall 8.6 ± 0.3 8.6 ± 0.2 8.2 ± 0.3 0.36
Backward recall 5.9 ± 0.3 5.9 ± 0.3 5.4 ± 0.4 0.35
CVLT
Immediate recall (No) 51.8 ± 1.5 51.4 ± 1.2 50.1 ± 1.7 0.46
Delayed recall (No) 12.2 ± 0.4 12.5 ± 0.4 11.4 ± 0.5 0.37
Recognition (No) 1.1 ± 0.2 0.9 ± 0.2 1.5 ± 0.3 0.28
Rivermead (stories)
Immediate recall (No) 16.5 ± 1.0 16.9 ± 0.8 16.8 ± 1.1 0.80
Delayed recall (No) 13.5 ± 1.0 14.1 ± 0.8 13.8 ± 1.1 0.79
Proportion recalled (%) 78.3 ± 2.6 81.9 ± 2.1 81.0 ± 3.0 0.45
Table 4: Preference for LT4/LT3 therapy over LT4 treatment alone by OATP1C1 genotype
OATP1C1-intron 3C>T
Preference for LT4/LT3 over LT4 wild-types heterozygotes homozygotes
No (number of subjects and %) 10 (45.5) 25 (56.8) 13 (52.0)
Yes (number of subjects and %) 12 (54.5) 19 (43.2) 12 (48.0)
0.68a
a P-value for χ2 –test.
OATP1C1 polymorphisms and depression 69
OATP1C1-Pro143Thr OATP1C1-C3035T
wild-types heterozygotes P wild-types heterozygotes homozygotes
132 9 46 69 26
72.7 ± 1.6 74.4 ± 6.1 0.79 71.7 ± 2.7 73.6 ± 2.2 72.6 ± 3.6 0.01
26.1 ± 0.6 26.8 ± 2.2 0.77 27.4 ± 1.0 25.9 ± 0.8 24.8 ± 1.3 0.09
36.5 ± 0.8 38.7 ± 3.1 0.48 38.4 ± 1.3 36.1 ± 1.1 34.7 ± 1.8 0.09
44.9 ± 1.1 46.1 ± 4.0 0.79 47.8 ± 1.8 44.0 ± 1.4 42.9 ± 2.4 0.07
57.0 ± 1.4 57.3 ± 5.3 0.95 59.6 ± 2.3 55.7 ± 1.9 55.9 ± 3.2 0.27
628.1 ± 8.1 630.8 ± 30.7 0.93 635.0 ± 13.9 625.5 ± 11.3 623.7 ± 18.4 0.58
622.5 ± 7.0 635.8 ± 26.3 0.63 626.8 ± 11.9 618.5 ± 9.7 629.8 ± 15.8 0.99
680.1 ± 6.8 672.6 ± 25.9 0.78 682.1 ± 11.7 678.8 ± 9.6 677.6 ± 15.5 0.80
565.6 ± 12.2 583.7 ± 46.1 0.71 577.6 ± 20.9 561.2 ± 17.0 562.7 ± 27.6 0.61
26.0 ± 2.9 20.8 ± 10.9 0.65 23.5 ± 4.9 26.6 ± 4.0 27.0 ± 6.5 0.63
220.9 ± 4.5 226.6 ± 17.9 0.76 215.0 ± 7.6 224.6 ± 6.3 223.2 ± 10.3 0.43
11.7 ± 0.4 11.9 ± 1.5 0.88 11.4 ± 0.6 11.8 ± 0.5 12.1 ± 0.9 0.55
7.4 ± 0.1 7.3 ± 0.4 0.79 7.3 ± 0.2 7.4 ± 0.2 7.4 ± 0.3 0.87
8.5 ± 0.2 9.3 ± 0.7 0.27 8.3 ± 0.3 8.6 ± 0.2 8.7 ± 0.4 0.41
5.8 ± 0.2 6.3 ± 0.7 0.44 5.7 ± 0.3 6.1 ± 0.3 5.3 ± 0.4 0.60
50.9 ± 0.8 55.4 ± 3.2 0.18 49.8 ± 1.4 51.6 ± 1.2 52.4 ± 1.9 0.25
12.0 ± 0.3 13.6 ± 1.0 0.12 11.7 ± 0.4 12.2 ± 0.4 12.8 ± 0.6 0.11
1.1 ± 0.1 0.8 ± 0.5 0.57 1.2 ± 0.2 1.2 ± 0.2 0.8 ± 0.3 0.38
16.9 ± 0.5 14.1 ± 2.1 0.20 17.1 ± 0.9 16.6 ± 0.8 15.9 ± 1.2 0.48
13.9 ± 0.5 11.7 ± 2.1 0.30 14.1 ± 0.9 13.6 ± 0.8 13.8 ± 1.2 0.77
80.5 ± 1.5 81.3 ± 5.6 0.89 79.6 ± 2.5 80.1 ± 2.0 83.6 ± 3.4 0.39
OATP1C1-Pro143Thr OATP1C1-C3035T
wild-types heterozygotes wild-types heterozygotes homozygotes
45 (51.7) 4 (80.0) 16 (55.2) 25 (53.2) 8 (50.0)
42 (48.3) 1 (20.0) 13 (44.8) 22 (46.8) 8 (50.0)
0.22a 0.95a
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Similar associations were found on the Rand mental health and the SLC90 depression sub-
scales.
Concerning OATP1C1-Pro143Thr, carriers of the Thr143 allele (n= 9) had slightly worse 
scores on all but one of the 8 fatigue subscales, however the associations failed to reach 
significance. 
OATP1C1 polymorphisms and scores on neurocognitive functioning tests
With regard to neurocognitive function, no significant associations were found between any 
of the polymorphisms and scores on neurocognitive functioning tests for cognitive speed, 
attention and memory (Table 3).
OATP1C1 polymorphisms and preference for LT4/LT3 therapy over T4 treatment alone
Data for T4/T3 preference were available for 140 out of 141 participants. After baseline 
measurements, 92 patients received combined LT4/LT3 therapy in a ratio of 5:1 or 10:1 for 15 
weeks. The proportion of patients indicating at endpoint that they preferred study medica-
tion (i.e. combined LT4/LT3 treatment) over LT4 monotherapy prior to study entry was not 
significantly associated with the different genotypes (Table 4).
Discussion
In this study of 141 patients with adequately treated hypothyroidism, we analyzed whether 
genetic variation in the brain-specific thyroid hormone transporter OATP1C1 is a determi-
nant of well-being and neurocognitive functioning. Secondly, we investigated if OATP1C1 
genotypes are associated with preference for combined LT4/LT3 therapy. 
Two polymorphisms, spanning two large haploblocks in the OATP1C1 gene, were associ-
ated with symptoms of fatigue and depression in an allele dose-dependent manner. OAT-
P1C1-intron3C>T was significantly associated with fatigue. Wild-type patients consistently 
displayed the highest levels of symptoms, and homozygous variant carriers the lowest levels. 
The same allele dose-dependent association was observed with the subscales measuring 
depression. In addition, OATP1C1-C3035T was associated with depression. Again, wild-type 
patients had the highest levels of symptoms whereas homozygous variant carriers reported 
the least depression. 
The extent of the effect of OATP1C1 genotypes on measurements of well-being is best illus-
trated with an example. The mean SCL-90 depression subscale scores in our study population 
were 29.3.  In the general population scores in this range (25-35) are labeled as ‘high’ meaning 
that these scores are between the 80th and 95th percentile (3). Regarding OATP1C1-C3035T, 
wild-type patients had a mean score of 32.2 on the SLC-90 depression subscale, whereas 
homozygote carriers of the 3035T-allele had an average score of 26.8 (Table 2).  Whether one 
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should consider this to be a clinically relevant effect is open to debate. Single polymorphisms 
generally have a subtle effect, while clinically significant effects usually result from the addi-
tion of cumulative effects of many genes each contributing only slightly to the variance. Thus, 
genetic variation in OATP1C1 is one of many determinants of well-being. The associations 
between polymorphisms in OATP1C1 and symptoms like depression strengthen the notion 
that OATP1C1 is important for thyroid hormone transport across the blood-brain barrier. 
One may hypothesize that, if the delivery of T4 across the blood-brain barrier by OATP1C1 is 
decreased due to polymorphisms in OATP1C1, these patients would benefit from combined 
therapy with both LT4 and LT3 through adding a direct source of T3. Nonetheless, in this 
study we found no association between OATP1C1 genotypes and a preference for combined 
treatment. However, no data are available about the extent to which exogenous T3 is ef-
fectively transported into different brain regions in man, while only sparse data are present 
from animal experimental studies (37). 
No associations were found between OATP1C1 genotypes and scores on neurocognitive 
functioning tests. This is in concordance with the fact that, as we have shown in an earlier 
publication, the SCL-90 total score, regarded as the main summarizing measure of well-being 
in this study, was only weakly correlated with some, but not all of the neurocognitive test 
results (3). In fact, the determinants of decreased levels of well-being on the one hand, and 
impaired neurocognitive functioning on the other, may well be of a different origin. 
This is the first study to find associations between polymorphisms in the brain-specific thy-
roid hormone transporter OATP1C1 and scores on well-being questionnaires in adequately 
treated hypothyroid patients. However, limitations of our study have to be mentioned. 
For instance, the four questionnaires chosen to investigate different aspects of well-being 
all had several subscales, 21 subscales in total. Due to multiple comparisons this increases 
the possibility of type I errors, warranting cautious interpretation of the results. However, 
the consistency and specificity of the associations with fatigue and depression are highly 
supportive of the validity of these findings. For example, 8 out of the 21 subscales address 
symptoms of fatigue and on 7 of these 8 subscales a significant dose-allele relation was 
found for OATP1C1-intron3C>T (Table 2). Similarly, a significant and allele-dose dependent 
association between OATP1C1-C3035T and symptoms of depression was found for all three 
subscales addressing these symptoms (Table 2).  
In summary, in a population of patients with adequately treated hypothyroidism OATP1C1 
polymorphisms are associated with fatigue and depression, but they do not explain differ-
ences in neurocognitive functioning or preference for LT4/LT3 combination therapy. Further 
studies are needed to confirm our findings and to elucidate the determinants of neurocogni-
tive impairments and a preference for combined LT4/LT3 treatment. In addition, demonstra-
tion of a functional effect of these polymorphisms on the OATP1C1 protein is necessary.
72 Chapter 4
acKnoWleDGMents
This study is supported by the Netherlands Organization of Scientific Research (NWO) Re-
search Institute for Diseases in the Elderly (grant 6730040) and a grant from the Academic 
Medical Center Anton Meelmeijer Fund (SAG 05002).
OATP1C1 polymorphisms and depression 73
references
 1. Dugbartey at 1998 Neurocognitive aspects of hypothyroidism. Arch Intern Med 158:1413-1418
 2. saravanan P, chau Wf, roberts n, Vedhara K, Greenwood r, Dayan cM 2002 Psychological 
well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-
based questionnaire study. Clin Endocrinol (Oxf ) 57:577-585
 3. Wekking eM, appelhof bc, fliers e, schene aH, Huyser J, tijssen JG, Wiersinga WM 2005 
Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for 
primary hypothyroidism. Eur J Endocrinol 153:747-753
 4. escobar-Morreale Hf, obregon MJ, escobar del rey f, Morreale de escobar G 1995 Replace-
ment therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all 
tissues, as studied in thyroidectomized rats. J Clin Invest 96:2828-2838
 5. bunevicius r, Kazanavicius G, Zalinkevicius r, Prange aJ, Jr. 1999 Effects of thyroxine as 
compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 
340:424-429
 6. sawka aM, Gerstein Hc, Marriott MJ, MacQueen GM, Joffe rt 2003 Does a combination regi-
men of thyroxine (T4) and 3,5,3’-triiodothyronine improve depressive symptoms better than T4 
alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J 
Clin Endocrinol Metab 88:4551-4555
 7. Walsh JP, shiels l, lim eM, bhagat ci, Ward lc, stuckey bG, Dhaliwal ss, chew Gt, bhagat 
Mc, cussons aJ 2003 Combined thyroxine/liothyronine treatment does not improve well-being, 
quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in 
patients with primary hypothyroidism. J Clin Endocrinol Metab 88:4543-4550
 8. clyde PW, Harari ae, Getka eJ, shakir KM 2003 Combined levothyroxine plus liothyronine 
compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. 
Jama 290:2952-2958
 9. appelhof bc, fliers e, Wekking eM, schene aH, Huyser J, tijssen JG, endert e, van Weert 
Hc, Wiersinga WM 2005 Combined therapy with levothyroxine and liothyronine in two ratios, 
compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, random-
ized, controlled clinical trial. J Clin Endocrinol Metab 90:2666-2674
 10. Grozinsky-Glasberg s, fraser a, nahshoni e, Weizman a, leibovici l 2006 Thyroxine-tri-
iodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: 
meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 91:2592-2599
 11. bianco ac, salvatore D, Gereben b, berry MJ, larsen Pr 2002 Biochemistry, cellular and 
molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 
23:38-89
 12. appelhof bc, Peeters rP, Wiersinga WM, Visser tJ, Wekking eM, Huyser J, schene aH, 
tijssen JG, Hoogendijk WJ, fliers e 2005 Polymorphisms in type 2 deiodinase are not associ-
ated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3’-
triiodothyronine therapy. J Clin Endocrinol Metab 90:6296-6299
 13. Jansen J, friesema ec, Milici c, Visser tJ 2005 Thyroid hormone transporters in health and 
disease. Thyroid 15:757-768
 14. Jansen J, friesema ec, Kester MH, schwartz ce, Visser tJ 2008 Genotype-phenotype relation-
ship in patients with mutations in thyroid hormone transporter MCT8. Endocrinology 149:2184-
2190
 15. friesema ec, Grueters a, biebermann H, Krude H, von Moers a, reeser M, barrett tG, Man-
cilla ee, svensson J, Kester MH, Kuiper GG, balkassmi s, uitterlinden aG, Koehrle J, rodien 
P, Halestrap aP, Visser tJ 2004 Association between mutations in a thyroid hormone transporter 
and severe X-linked psychomotor retardation. Lancet 364:1435-1437
 16. Dumitrescu aM, liao xH, best tb, brockmann K, refetoff s 2004 A novel syndrome combin-
ing thyroid and neurological abnormalities is associated with mutations in a monocarboxylate 
transporter gene. Am J Hum Genet 74:168-175
 17. Pizzagalli f, Hagenbuch b, stieger b, Klenk u, folkers G, Meier PJ 2002 Identification of a 
novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol 
Endocrinol 16:2283-2296
74 Chapter 5
 18. sugiyama D, Kusuhara H, taniguchi H, ishikawa s, nozaki y, aburatani H, sugiyama y 2003 
Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-
brain barrier: high affinity transporter for thyroxine. J Biol Chem 278:43489-43495
 19. Van der Deure WM, Hansen Ps, Peeters rP, fenger M, sorensen tia, Kyvik Ko, Hegedus l, Vis-
ser tJ 2006 Polymorphisms in the SLCO1C1 gene are associated with serum thyroid parameters. 
Hot Thyroidology: abstract book of 31st Annual Meeting of the European Thyroid Assocation:22; 
O43
 20. Wald fDM, Mellenberg GJ 1990 De verkorte versie van de Nederlandse vertaling van de Profile 
of Mood States (POMS)(The shortened version of the Dutch translation of the Profile of Moods 
States (POMS). Ned Tijdschr Psychol 45:86-90
 21. smets eM, Garssen b, bonke b, De Haes Jc 1995 The Multidimensional Fatigue Inventory (MFI) 
psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315-325
 22. aaronson nK, Muller M, cohen PD, essink-bot Ml, fekkes M, sanderman r, sprangers Ma, 
te Velde a, Verrips e 1998 Translation, validation, and norming of the Dutch language version 
of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 
51:1055-1068
 23. arrindell Wa, ettema JHM 1986 Klachtenlijst Symptom Check List (SCL-90). Lisse, The Nether-
lands: Swets, Zeitlinger
 24. Wechsler D 1997 Wechsler Adult Intelligence Scale III: the technical manual. San Antonio, TX: The 
Psychological Corp.
 25. Wilson b, cockburn J, baddeley aD 1985 The Rivermead Behavioural Memory Test. Bury St. 
Edmunds, UK: Thames Valley Test Co.
 26. Wimmers WfHG, van balen HGG 1987 Rivermead Behavrioural Memory Test, Nederlandstalige 
bewerking. Lisse, The Netherlands: Swets, Zeitlinger
 27. Delis Dc, Kramer JH, Kaplan e, ober ba 1987 California Verbal Learning Test (CLVT) manual. 
New York: Psychological Corp.
 28. Mulder Jl, Dekker r, Dekker PH 1996 Verbale Leer en Geheugen Test: Handleiding. Lisse, The 
Netherlands: Swets, Zeitlinger
 29. uterwijk J 2000 WAIS-III. Nederlandstalige bewerking. Technische handleiding. Lisse, The Neth-
erlands: Swets, Zeitlinger
 30. brand an 1999 MINDS: tool for research in health psychology and neuropsychology. In: Den 
Brinker BPLM, Beek PJ, Brand AN, Maarse FJ, Mulder JLM eds. Cognitive ergonomics, clinical as-
sessment and computer-assisted learning. Lisse, The Netherlands: Swets, Zeitlinger; 155-168
 31. brand n, Jolles J 1987 Information processing in depression and anxiety. Psychol Med 17:145-
153
 32. Gronwall DMa, sampson H 1974 The psychological effects of concussion. Auckland, New Zea-
land: Auckland University Press
 33. spikman JM, van Zomeren aH, Deelman bG 1996 Deficits of attention after closed-head injury: 
slowness only? J Clin Exp Neuropsychol 18:755-767
 34. Wiersinga WM, chopra iJ 1982 Radioimmunoassay of thyroxine (T4), 3,5,3’-triiodothyronine 
(T3), 3,3’,5’-triiodothyronine (reverse T3, rT3), and 3,3’-diiodothyronine (T2). Methods Enzymol 
84:272-303
 35. fang y, van Meurs Jb, d’alesio a, Jhamai M, Zhao H, rivadeneira f, Hofman a, van leeuwen 
JP, Jehan f, Pols Ha, uitterlinden aG 2005 Promoter and 3’-untranslated-region haplotypes in 
the vitamin d receptor gene predispose to osteoporotic fracture: the rotterdam study. Am J Hum 
Genet 77:807-823
 36. 2003 The International HapMap Project. Nature 426:789-796
 37. Dratman Mb, crutchfield fl, schoenhoff Mb 1991 Transport of iodothyronines from blood-
stream to brain: contributions by blood:brain and choroid plexus:cerebrospinal fluid barriers. 
Brain Res 554:229-236
Chapter 5
Thyroid hormone transport by OATP1A2 
and OATP1B3: functional comparison with 
other human OATP1 family members
Wendy M. van der Deure, Edith C.H. Friesema, Robin P. Peeters and Theo J. Visser 
Submitted
76 Chapter 5
abstract
As a prerequisite for intracellular processes like deiodination, sulfoconjugation or binding to 
the thyroid hormone receptor, thyroid hormone is actively transported across the cell mem-
brane by thyroid hormone transporters, such as members of the organic anion transporting 
polypeptide family (OATPs). We have previously demonstrated that OATP1B1 strongly induces 
uptake of iodothyronine sulfates T4 sulfate (T4S), T3 sulfate (T3S) and reverse T3 sulfate (rT3S), 
but has no T4 and T3 and only little rT3 transport activity. OATP1C1 transports T4 and rT3, and 
to some extent T4S. In this study, we examined the specificity of iodothyronine transport 
by the two remaining human members of the OATP1 subfamily, OATP1A2 and OATP1B3, by 
analysis of iodothyronine uptake and metabolism. 
Functional expression studies in Xenopus laevis oocytes and COS1 cells indicate that OAT-
P1A2 significantly induced uptake of T4, T3, rT3, T4S, T3S and rT3S. In addition, metabolism 
of these substrates by co-transfected deiodinases was greatly augmented in the presence of 
OATP1A2. OATP1B3, however, predominantly transports rT3 and the sulfated iodothyronines. 
Metabolism of these substrates by type 1 deiodinase (D1) was markedly increased when cells 
were co-transfected with OATP1B3.  
In conclusion, these four human members of the OATP1 subfamily exhibit overlapping sub-
strate specificities. OATP1A2 is unique in transporting all (sulfated) iodothyronines, whereas 
OATP1C1 has much narrower substrate specificity. OATP1B1 and OATP1B3, both expressed 
exclusively in the liver, preferentially transport rT3 and iodothyronine sulfates, probably 
facilitating their degradation by liver D1.
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introDuction
As a prerequisite for intracellular processes like deiodination, sulfoconjugation or binding 
to its nuclear receptor (1-3), thyroid hormone is actively transported across the cell mem-
brane by thyroid hormone transporters. Several proteins can facilitate this transport, such 
as members of the organic anion transporting polypeptide family (OATPs) (4), amino acid 
transporters (5) or monocarboxylate transporters (6).
OATPs are a large family of multi-specific sodium-independent transport proteins that 
are expressed in many tissues (Fig. 1A). Among the many substrates transported by OATPs 
are thyroid hormones (7-11).  All four human members of the OATP1 subfamily, OATP1A2, 
OATP1B1 and OATP1B3 and OATP1C1, are located in a gene cluster on chromosome 12p12, 
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Figure 1A: Phylogenetic tree of human and rodent (rat and mouse) members of the OATP1 subfamily. 
Multiple sequence aligment of amino acid sequences and phylogenetic tree construction were carried 
out using Clustal W (http://www.ebi.ac.uk/clustalw). The phylogenetic tree was made by Treeview (http://
taxonomy.zoology.gla.ac.uk/rod/treeview.html). This figure is based on Genebank accession numbers 
NM013797 (mOATP1A1), NM017111 (rOATP1A1), NM134431 (hOATP1A2), NM030837 (rOATP1A3), 
NM030687 (mOATP1A4), NM131906 (rOATP1A4), NM130861 (mOATP1A5), NM030838 (rOATP1A5), 
NM023718 (mOATP1A6), NM130736 (rOATP1A6), NM006446 (hOATP1B1), NM020495 (mOATP1B2),  
NM031650 (rOATP1B2), NM019844 (hOATP1B3), NM017435 (hOATP1C1), NM021471 (mOATP1C1), 
NM053441 (rOATP1C1).
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together with a pseudogene (Fig. 1B). These OATPs have a similar genomic organization, i.e. 
in all four transporter genes the open reading frame is composed of 14 exons.  In addition, 
they share on average almost 50% amino acid identity and are considered to be 12 trans-
membrane domain glycoproteins  (4, 11). 
Recently, we have shown that OATP1B1 strongly induces uptake of iodothyronine sulfates 
T4 sulfate (T4S), T3 sulfate (T3S) and reverse T3 sulfate (rT3S), but has only little T4, T3 and 
rT3 transport activity (12). A different member of the OATP1 subfamily, OATP1C1, shows high 
substrate specificity as it only transports T4 and rT3, and to some extent also T4S (11, 13). 
In this study, we examined the specificity of iodothyronine transport by OATP1A2 and 
OATP1B3 and analyzed whether these transporters are rate-limiting in subsequent iodothy-
ronine metabolism in cells co-transfected with different deiodinases.  In addition, these 
transporter proteins were functionally compared with OATP1B1 and OATP1C1, the other two 
human members of the OATP1 subfamily.
Materials anD MetHoDs
Materials
FuGENE6 transfection reagent was obtained from Roche Diagnostics (Indianapolis, USA). 
[125I]NaI, [125I]T4 and [125I]T3 were obtained from Amersham Biosciences (Little Chalfont, Buck-
inghamshire, UK).  [125I]rT3 was obtained from Perkin Elmer (Boston, MA). Unlabeled T4, T3 
and rT3 were bought from Henning GmbH (Berlin, Germany).  [125I]T4S,  [125I]T3S and [125I]rT3S 
were synthesized as described previously (14).  
Plasmids
The pSPORT1-OATP1A2 plasmid was kindly provided by Prof. Dr. Peter J. Meier (Institute of 
Clinical Pharmacology and Toxicology, University Hospital Zürich, Switzerland).  OATP1A2 
Figuur 1B : 
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Figure 1B: Overview of the genomic structure of the human OATP1 cluster on chromosome 12p12.
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was subcloned into pSG5 (Stratagene, La Jolla, USA) using NotI and Acc65I restriction sites. 
Prof. Dr. Dietrich Keppler (German Cancer Research Center, Heidelberg, Germany) provided 
us with the pcDNA3.1-Hygro-OATP1B3 plasmid. OATP1B3 was subcloned into pSG5 via a 
BstX1 restriction site. pSG5-μ-crystallin (CRYM), pcDNA3-ratD1 (rD1) and pCIneo-D3 plasmids 
were constructed as previously described (15). 
For the experiments with X. laevis oocytes, the pSPORT1-OATP1A2 plasmid was linearized 
with the restriction enzyme XbaI to create 5’-protroding ends, and transcribed using the 
Ampliscribe High Yield T7 RNA transcription kit (Epicentre Technologies, Madison, WI). The 
cRNA was capped with the m7G (5’)ppp(5’)G cap analog (Epicentre) and stored in RNAase 
free water at -80 C.
COS1 cell culture
COS1 cells were cultured in 6 or 24-well dishes (Corning, Schiphol, The Netherlands) with 
DMEM/F12 medium (Invitrogen), containing 9% heat-inactivated fetal bovine serum (Invitro-
gen) and 100 nM sodium selenite (Sigma).
Iodothyronine (sulfate) transport and metabolism in COS1 cells
uptake studies:  COS1 cells were cultured in 6-well culture dishes, and transfected in du-
plicate with 500 ng pSG5 plasmid without or with OATP1A2 or OATP1B3 using FuGENE6 ac-
cording to the manufacturer’s guidelines.  Cells were co-transfected with 500 ng pSG5-CRYM, 
coding for a high-affinity cytosolic thyroid hormone-binding protein that prevents efflux of 
internalized iodothyronines (16). This protein binds not only T4 and T3, but also T4S and T3S 
(personal communication W.E. Visser).  The affnity of CRYM for rT3 and rT3S is much lower 
compared to the other iodothyronines (12, 13). After 48 h, cells were washed with incubation 
medium (Dulbecco’s PBS, 0.1% BSA and 0.1% glucose), and incubated for 5, 10 or 30 min at 37 
C with 1 nM (2x105 cpm) 125I-labeled T4, T3, rT3, T4S, T3S or rT3S in 1.5 ml incubation medium. 
After incubation, cells were harvested and analyzed as described previously (15). 
Metabolism studies:  COS1 cells were cultured in 24-well culture dishes and transfected 
with 100 ng pCIneo-D3 or pcDNA3-rD1 and 100 ng pSG5-OATP1A2 or pSG5-OATP1B3.  48 h 
after transfection, cells were incubated for 4 or 24 h at 37 C with 1 nM (1x106 cpm) 125I-labeled 
T4, T3, rT3, T4S, T3S or rT3S in 0.5 ml incubation medium.  After incubation, medium was 
harvested and analyzed by HPLC as described previously (15).
Iodothyronine transport in X. laevis oocytes
Oocytes were prepared as described previously (17). After isolation, oocytes were sorted 
on morphological criteria and defolliculated manually. Healthy-looking stage V–VI oocytes 
were kept at 18 C in modified Barth’s solution containing 20 IU/ml penicillin and 20 µg/ml 
streptomycin. The next day, oocytes were injected with 2.3 ng OATP1A2 cRNA in 23 nl water 
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using the Nanoject system (Drummond Scientific, Broomall, PA). Uninjected oocytes were 
used as controls, as similar results were obtained using water-injected oocytes. Injected and 
uninjected oocytes were kept for 3-4 d at 18 C in modified Barth’s solution. 
Uptake assays were performed as reported previously (17). Groups of 10 oocytes were incu-
bated for 1 h at 25 C with 100 nM [125I]T4, [125I]T3 or [125I]rT3 in 0.1 ml incubation medium [100 
mM NaCl, 2 mM KCl, 1 mM CaCl2, 1
 mM MgCl2, 10 mM HEPES, and 10 mM Tris, pH 7.5]. After 
incubation, oocytes were washed 4 times with 2.5 ml ice-cold incubation medium containing 
0.1% BSA. Oocytes were transferred to new tubes and counted individually.
results
Iodothyronine (sulfate) transport by OATP1A2 and OATP1B3 in transfected COS1 cells
OATP1A2 significantly induced uptake of all iodothyronines tested in this study (Fig. 2). After 
30 min incubation, T4, T3 and rT3 uptake were almost 2-fold higher in OATP1A2 transfected 
cells than in mock transfected cells. In addition, OATP1A2 clearly induced iodothyronine 
sulfate uptake: in OATP1A2 transfected cells the uptake of T4S and T3S was almost 10 times 
higher than in cells transfected with empty vector. This also holds true for rT3S, with a 4-fold 
higher induction in uptake by OATP1A2 compared with empty vector.
In contrast to OATP1A2, OATP1B3 did not or only poorly enhance T4 and T3 uptake. How-
ever, transport of rT3 and the iodothyronine sulfates T4S, T3S and rT3S was clearly induced 
by OATP1B3.
Iodothyronine (sulfate) metabolism by OATP1A2 and OATP1B3 in transfected COS1 cells
Cells were transfected with D3 for the metabolism experiments with T4 and T3, since T4 and 
T3 are good substrates for D3 (3). For the metabolism assays with rT3, we co-transfected 
OATP1A2 or OATP1B3 with D1 as rT3 is the preferred substrate of this deiodinase. This also 
holds for iodothyronine sulfates which are are only deiodinated by D1. 
Incubation of cells transfected with D1 or D3 alone already led to some conversion of T4, 
T3 and rT3 (Fig. 3). However, this was markedly and significantly increased, when cells were 
co-transfected with OATP1A2 (Fig. 3). In a similar manner, we found that metabolism of T4S, 
T3S and rT3S by D1 was clearly augmented by co-transfection of OATP1A2. 
Co-transfection of cells with OATP1B3 increased metabolism of T4, but not of T3, by D3. 
In addition, metabolism of rT3 and iodothyronine sulfates by D1 was significantly increased 
when OATP1B3 was co-transfected (Fig. 3). About 40% of T4S, 10% of T3S and 40% of rT3S was 
deiodinated by D1 when OATP1B3 was co-transfected, whereas no iodide was produced in 
cells transfected with D1 alone (Fig. 3).  
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Iodothyronine transport by OATP1A2 in X. laevis oocytes
Analogous to the results of the experiments in transiently transfected COS1 cells, oocytes ex-
pressing OATP1A2 clearly showed induced uptake of all iodothyronines tested (Fig. 4). After 
1 h incubation, T4, T3 and rT3 uptake was 1.5 to 1.9-fold increased in OATP1A2 expressing 
oocytes compared with uninjected oocytes. 
Figure 2 : 
Figure 2; [125I]T4, [125I]T3, [125I]rT3, [125I]T4S, [125I]T3S and [125I]rT3S uptake by COS1 cells transfected with 
empty vector, OATP1A2 or OATP1B3.  Cells were co-transfected with CRYM, an intracellular thyroid 
hormone-binding protein.  Cells were incubated for 5, 10 or 30 min at 37 C with 1 nM (2x105 cpm) 
125I-labeled T4, T3, rT3, T4S, T3S or rT3S. Data are expressed as percentage uptake of added radioactivity.  
Data are presented as the means ± SEM of three experiments.  
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Functional comparison of OATP1A2, OATP1B1, OATP1B3 and OATP1C1
Figure 5 gives an overview of iodothyronine uptake by the four human OATP1 subfamily 
members. For all experiments, cells were co-transfected with CRYM. CRYM binds T4, T3, T4S 
and T3S very well, but it has a low affinity for rT3 and rT3S. Therefore, rT3 and rT3S are not 
included in Figure 5.  
It becomes apparent that OATP1A2 facilitates uptake of all (sulfated) iodothyronines, 
whereas OATP1C1 only transports T4 and T4S in a significant manner. OATP1B1 and OATP1B3 
show similar preference for sulfated versus non-sulfated iodothyronines as ligands.
Figure 3 : 
Figure 3: [125I]T4, [125I]T3, [125I]rT3, [125I]T4S, [125I]T3S and [125I]rT3S metabolism by COS1 cells transfected with 
either D1 or D3 alone or D1 or D3 together with OATP1A2 or OATP1B3.  Cells were incubated for 4 h at 37 
C with 1 nM (1x106 cpm) 125I-labeled T4, T3 or rT3. Cells were incubated for 24 h at 37 C with 1 nM (1x106 
cpm) 125I-labeled T4S, T3S or rT3S.  Metabolism is shown as percentage of metabolites in the medium 
after incubation for the indicated time period.  Data are presented as the means ± SEM of at least three 
experiments. Data for [125I]rT3S metabolism are the means ± SEM of two experiments.
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Figure 4: 
Figure 4: [125I]T4, [125I]T3 and [125I]rT3 uptake by X. laevis oocytes uninjected or injected with OATP1A2. 
Oocytes were incubated for 1 h at 25 C with 100 nM (4x105 cpm) 125I-labeled T4, T3 or rT3. Data are 
expressed as percentage uptake per oocyte of added radioactivity. Data are presented as the means ± 
SEM of 9-10 oocytes.
Discussion
Our study indicates that all four human members of the OATP1 subfamily can transport 
iodothyronines. OATP1A2 is unique in transporting all sulfated and nonsulfated iodothy-
ronines, whereas OATP1C1 has much narrower substrate specificity. OATP1B1 and OATP1B3 
preferentially transport rT3 and iodothyronine sulfates.
Until now, several transporter families have been identified, among which the OATP family. 
OATPs mediate sodium-independent transport of a variety of organic compounds, such as 
bile acids, steroid hormones and numerous drugs (4). Different OATP family members have 
been extensively studied, as they take up endo- and xenobiotics from the blood into the 
liver, where they are transformed into water-soluble products that can be excreted into the 
bile (18). For instance, polymorphisms leading to decreased function of these transporter 
proteins have been associated with increased systemic bioavailability of drugs (19, 20). In this 
study, we examined the specificity of iodothyronine transport by OATP1A2 and OATP1B3. In 
addition, we compared these transporters with OATP1B1 and OATP1C1, the other two human 
members of the OATP1 subfamily that transport iodothyronines.
Functional expression studies in transfected COS1 cells indicate that OATP1A2 significantly 
induced uptake of T4, T3, rT3, T4S, T3S and rT3S. In addition, metabolism of these substrates 
by co-transfected deiodinases was greatly augmented in the presence of OATP1A2.  Similar 
results regarding uptake of T4, T3 and rT3 by OATP1A2 were obtained in injected X. laevis 
oocytes, even though there are numerous differences between these two transport as-
says.  First of all, there are clear differences in transfection efficiency. Every tested oocyte is 
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injected with cRNA coding for the protein of interest, whereas COS1 cells only show about 
25% transfection efficiency. In addition, X. laevis oocytes have a higher intracellular thyroid 
hormone-binding capacity compared to COS1 cells.  This difference was partially overcome 
by co-transfection with CRYM, a high-affinity cytosolic thyroid hormone-binding protein (16), 
which has recently been shown to greatly augment net T3 and T4 uptake by inhibition of 
T3 and T4 efflux (21).  CRYM shows high affinity for T4 and T3, but also binds T4S and T3S. 
However, it has to be noted that the affnity of CRYM for rT3 and rT3S is much lower compared 
to the other iodothyronines (12). Finally, in the experiments performed with oocytes no albu-
min was present in the incubation medium and 100 nM of substrate was used. The incubation 
medium of COS1 cells was, however, supplemented with 0.1% BSA and a more physiological 
concentration of substrates, e.g. 1 nM, was used. Since similar results were obtained regarding 
Figure 4 : 
 
Figure 5: [125I]T4, [125I]T3, [125I]T4S and [125I]T3S uptake by COS1 cells transfected with one of the human 
OATP1 subfamily members.  Cells were co-transfected with CRYM, an intracellular thyroid hormone-
binding protein.  Cells were incubated for 30 min at 37 C with 1 nM (2x105 cpm) 125I-labeled T4, T3, T4S 
or T3S. All incubations were performed in Dulbecco’s PBS with 0.1% BSA and 0.1% glucose, except for 
experiments with OATP1C1, which were performed in DMEM/F12 incubation medium supplemented 
with 0.1% BSA. Data were corrected for background uptake by subtraction of radioactivity taken up by 
cells transfected with empty vector instead of OATP. Data are presented as the means ± SEM of three 
experiments.  
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iodothyronine uptake by OATP1A2 in these different transport assays, it is clear that OATP1A2 
indeed facilitates transport of thyroid hormones. 
OATP1A2 is expressed in multiple tissues, among which liver, brain and kidney (8, 22). 
Based on its expression pattern, OATP1A2 could play a role in the delivery of thyroid hormone 
across the blood-brain barrier. Alternatively, it could also play a role in the removal of thyroid 
hormone from different tissues for degradation and eventual elimination via bile or urine. 
OATP1B3 is exclusively expressed in liver (23). In transfected COS1 cells, OATP1B3 pref-
erentially transports rT3 and the sulfated iodothyronines. In addition, metabolism of these 
substrates by D1 was markedly increased when cells were co-transfected with OATP1B3.  It 
is thought that D1 in the liver under normal conditions rapidly degradates rT3 and sulfated 
iodothyronines, like T4S, T3S and rT3S, keeping the serum concentrations of these substrates 
low (1, 3, 24-27).   It is, therefore, of interest that OATP1B3 only facilitates transport of these 
substrates, probably reflecting its role of transporter of endo- and xenobiotics that are me-
tabolized in the liver and excreted in the bile. Moreover, OATP1B1, which has 80% amino 
acid sequence identity to OATP1B3 and is also exclusively expressed in the liver (4), showed 
identical substrate specificity (12).   
OATP1C1, the fourth human member of the OATP1 subfamily, only transported T4 and rT3, 
and to some extent also T4S (11, 28). Based on the expression of OATP1C1 in capillaries in 
multiple brain regions, this protein is thought to play an important role in delivering serum 
thyroid hormone to the brain (11, 29). Additional support for a significant role for OATP1C1 in 
thyroid hormone transport in the brain comes from a study from Sugiyama and co-workers, 
in which they show that OATP1c1 is up-regulated in hypothyroid rats and down-regulated in 
hyperthyroid rats (29).  Moreover, we have recently shown that polymorphisms in the OATP1C1 
gene are associated with fatigue and depression in a cohort of hypothyroid patients (30).
In this study, we show that iodothyronine sulfates are novel substrates for OATP1A2 and 
OATP1B3. To more fully characterize their transport, Michaelis-Menten kinetics could be 
determined. However, this would not yield reliable Km values because of interfering factors. 
For instance, all experiments were performed in medium containing 0.1% BSA and all cells 
were co-transfected with CRYM, which have their own affinity for the iodothyronine sulfates. 
Therefore, we refrained form performing these experiments.
In conclusion, these four human members of the OATP1 subfamily exhibit overlapping 
substrate specificities. OATP1A2 transports all (sulfated) iodothyronines, whereas OATP1C1 
has a much narrower substrate specificity. OATP1B1 and OATP1B3, both expressed exclusively 
in the liver, preferentially transport rT3 and iodothyronine sulfates, probably facilitating their 
degradation by liver D1.
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abstract
objective: The Asp727Glu polymorphism in the thyrotropin receptor (TSHR) gene is associ-
ated with serum TSH levels. However, the proportion of genetic variation accounted for by 
this polymorphism is unknown. In this study, we 1) examine the association of the Asp727Glu 
polymorphism with thyroid size, serum levels of TSH, thyroid hormones, and thyroid antibod-
ies in 1241 healthy Danish twin individuals and 2) assess the contribution of the polymor-
phism to the trait variation and the genetic variance.
Measurements: The effect of the genotype on the traits (mean±SD) was established; asso-
ciations between the TSHR-Asp727Glu polymorphism and measures of thyroid homeostasis 
were assessed and the effect of the polymorphism on the trait’s phenotypic variability was 
quantified by incorporating the genotype information in structural equation modeling.
results: The genotype distribution was Asp/Asp 84.9%; Asp/Glu 14.5% and Glu/Glu 0.6%. 
Carriers of the TSHR-Glu727 allele had lower TSH levels (non-carriers vs. carriers: 1.78±0.93 
vs. 1.60±0.84mU/l, p=0.04). Regression analysis showed an association between the TSHR-
Asp727Glu polymorphism and serum TSH (p=0.007). The polymorphism accounted for 0.91% 
of the total phenotypic variance in serum TSH levels. Including the genotype in quantitative 
genetic modeling improved model fit (p=0.001); however, the genetic influence on serum 
TSH not attributable to this specific genetic variant was only reduced from 68.2% to 67.8%. 
The polymorphism was not significantly associated with thyroid size, thyroid hormones or 
thyroid antibody levels. 
conclusion: The TSHR-727Glu allele was associated with decreasing TSH levels; however, the 
contribution to the genetic variance was very small. No association was found with other 
thyroid related measures.
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introDuction
The circulating levels of serum thyroid stimulating hormone (TSH) and thyroid hormones 
represent biochemical phenotypes reflecting thyroid homeostasis. It is the combined ef-
fect of genetic and environmental factors that gives rise to these endophenotypes. Various 
groups (1-4) including our own (5-8) have previously established that the measures reflecting 
thyroid homeostasis have a substantial heritable component. However, the genetic variants 
underlying the genetic contribution to each of these traits are so far largely unknown. By 
including measured genotypes (for which an association has been established) into quantita-
tive genetic models, it is possible to identify genetic variants that affect the variability as well 
as the hereditary component of a trait (9).  
An obvious candidate gene involved in the control of the pituitary-thyroid axis is the TSH 
receptor (TSHR) gene, which is located on chromosome 14q31 (10). A variety of activating as 
well as inactivating mutations have been identified within the TSHR gene (11, 12). One of the 
best-studied polymorphisms within the TSHR gene is the Asp727Glu polymorphism. A C-G 
transition at position 2281 within codon 727 in this gene results in the aspartate to glutamate 
substitution within the cytoplasmic tail of the TSHR (13).  Using a cohort of 156 healthy Dutch 
Caucasian blood donors, we recently found that the TSHR-Glu727 allele was associated with 
lower plasma TSH levels (10).  However, initial positive findings in genetic association studies 
have proved to be difficult to confirm due to a large number of false positive findings, and 
cautious replication of promising findings are required (14-16).
Using the exact same polymorphism as in our initial studies, the current study was un-
dertaken to evaluate the association of the Asp727Glu polymorphism in the TSHR gene and 
quantitative measures of thyroid homeostasis in a much larger and independent healthy 
Danish twin population. Moreover, by integrating measured environmental exposures such 
as iodine intake and cigarette smoking in the analyses, we examined whether the effect 
of the genotype on the phenotype was influenced by the presence of such environmental 
risk factors. Finally, using quantitative trait analysis we wanted to quantify the effect of this 
particular polymorphism on the genetic variation.
Materials anD MetHoDs
Subjects
The present study is part of a nationwide project (GEMINAKAR) investigating the relative 
influence of genetic and environmental factors on a variety of different traits among Danish 
twins. Based on a questionnaire survey concerning physical health and health related behav-
ior performed in 1994, a representative sample of complete twin pairs was recruited from 
the population-based Danish Twin Registry (17).  A detailed description of the ascertainment 
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procedure can be found elsewhere (5, 8). Briefly, the twins included in the GEMINAKAR study 
were healthy as reported by themselves. With the exception of contraceptives, no twins were 
taking medicine known to affect the pituitary-thyroid axis or thyroid size. In order to get an 
equal distribution of twin pairs, sampling was stratified according to age, sex, and zygosity. 
The twins in a pair were examined on the same day. All twins with at least one partner living 
in the Western part of Denmark were examined in Odense, whereas all those where both 
partners were living in the Eastern part of Denmark were examined in Copenhagen. With 
the exception of 39 twin pairs, both twins in a pair lived in the same geographic region of 
Denmark. Blood and urine samples as well as DNA were collected between 8 and 9 a.m. after 
a twelve-hour fast. Thereafter, a clinical examination was performed and the twins filled in 
health related questionnaires including questions regarding thyroid disease, smoking habits 
and medicine intake. 
In the GEMINAKAR study 1512 individuals (756 twin pairs) were examined. Blood samples 
for thyroid measurements were available from 1473 individuals. Serum TSH, serum free thy-
roxine (free T4), serum free triiodothyronine (free T3), serum thyroid peroxidase antibodies 
(TPOab) and thyroglobulin antibodies (Tgab) were measured. In all, DNA from 1079 individu-
als was genotyped. Due to problems with identification and genotyping, 17 and 18 individu-
als, respectively, were excluded leaving l044 individuals distributed in 289 monozygotic (MZ), 
515 same sex dizygotic (DZ) and 240 opposite sex (OS) twin individuals. In 277 MZ twin pairs, 
in which only one of the twins was genotyped, we assumed identical genotypes. Thus, geno-
type information was available in 1321 individuals (566 MZ, 515 DZ, 240 OS) within 283 MZ, 
269 DZ and 121 OS twin pairs. Twin pairs in which one or both twins had self-reported thyroid 
disease or overt biochemical thyroid disease were excluded (80 persons within 42 twin pairs), 
leaving 1241 (536 MZ, 477 DZ and 228 OS twin individuals) healthy, euthyroid individuals 
within 268 MZ, 248 DZ and 115 OS twin pairs. 593 complete twin pairs were without sub-
clinical thyroid disease, and 531 twin pairs were thyroid antibody negative. Within the 1241 
healthy twin individuals, 469 individuals had a thyroid ultrasound performed as previously 
described (5). Spot urine samples were available from 678 individuals. 
Written informed consent was obtained from all participants and the study was approved 
by all regional Danish Scientific-Ethical Committees (case file 97/25 PMC).
Assays
Serum TSH was measured using a time-resolved fluoroimmunometric assay (AutoDELFIA 
hTSH Ultra Kit, Perkin Elmer/Wallac, Turku, Finland). Reference range is 0.30-4.00 mU/l. Serum 
free T4 and serum free T3 were determined using the AutoDELFIA FT4 and FT3 (Perkin Elmer/
Wallac, Turku, Finland), respectively. For free T4 the reference range is 9.9-17.7 pmol/l, and 
for free T3 it is 4.3-7.4 pmol/l. TPOab and Tgab were measured by solid phases, two step, 
time-resolved fluoroimmunoassays (AutoDELFIA TPOab kit and hTgab kit, respectively, Perkin 
Elmer/ Wallac, Turku; Finland). Values above 60 kIU/l were regarded as positive for TPOab as 
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well as for Tgab. Twin pairs were analyzed within the same run. All the serum samples were 
analyzed at the same laboratory in Odense. Zygosity was confirmed by analysis of nine highly 
polymorphic restriction fragment length polymorphisms and microsatellite markers widely 
scattered through the genome with an Applied Biosystems AmpFISTR Profiles Plus kit (The 
Perkin-Elmer corporation) (18).
The iodine concentration in the spot urine samples was analyzed by the cerium/arsenic 
method after digestion by alkaline ashing as described elsewhere (19). Individuals examined 
in Copenhagen (and therefore living in the Eastern part of Denmark) had a significantly 
higher iodine excretion than the twins examined and living in the Western part of Denmark 
(median 93.5 µg/l versus 71.0 µg/l). These results are in accordance with previous Danish epi-
demiological studies (19).  According to WHO criteria (20), the Western part of Denmark can 
be classified as moderately iodine-deficient, and the Eastern part as mildly iodine deficient. 
Therefore, examination place was regarded as a marker for iodine intake.
Genotyping
Participants were genotyped for the TSHR-Asp727Glu polymorphism (rs1991517). Genomic 
DNA was isolated form peripheral leucocytes using standard procedures. Genotypes were 
determined in 10 ng genomic DNA using the Taqman allelic discrimination assay (Applied 
Biossytems, Nieuwerkerk a/d Ijssel, The Netherlands). Primer and probe sequences were 
optimized using the SNP assay-by-design service of Applied Biosystems. Reactions were 
performed on the Taqman 7900HT in 384-wells format in 2 μl reaction volume.  
Statistical methods
Association between genotype and phenotype
These statistical analyses were carried out using STATA statistical software (21). 
The distribution of thyroid size and serum TSH, TPOab, and Tgab levels was skewed and 
therefore transformed by the natural logarithm. Initially, the TSHR-Asp727Glu polymorphism 
was defined as a 3-level variable representing the 3 possible genotypes (homozygous 
non-carrier, heterozygous, and homozygous variant). However, only few individuals were 
homozygous for the TSHR-Glu727 allele, and they were therefore combined with the 
heterozygous group in the analyses assuming a dominant model - i.e. non-carriers of the 
TSHR-Glu727 allele were compared with carriers. The effect of the genotype on the trait 
means was established. Results are presented as means ± SD. A modified Wilcoxon test was 
used testing the differences between the groups (22). Moreover, associations between the 
Asp727Glu polymorphism in the TSHR gene and measures of thyroid homeostasis in the 
whole population were assessed using regression analysis. The statistical inference measures 
(i.e. p-values and CI) were computed using a technique (the cluster option in STATA), which 
takes the dependency of twin data into account. The genotype information was incorporated 
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in the regression analyses by coding the non-carriers as 0 and carriers as 1. In these analyses, 
adjustment for age and gender was performed. 
To test whether the genotype-phenotype relationship is affected by the presence of spe-
cific environmental factors (iodine intake, examination place and/or smoking) these environ-
mental exposures were added in the regression analyses using a stepwise procedure, and the 
regression coefficients were compared. Moreover, interaction terms defined as the product 
of the genotype and the environmental exposure were added in the regression analyses and 
the significance of the interaction term was evaluated. Examination place was incorporated 
in the analyses as a dichotomized variable: Odense was coded as 0 and Copenhagen as 1. 
Smoking was also considered as a categorical variable: non-smokers coded as 0 vs. former or 
current smokers coded as 1. The measured urine iodine excretion was included as a continu-
ous variable.
Quantitative genetic analyses
The proportion of variance of lnTSH accounted for by the variant of the TSHR-polymorphism 
was estimated as Var(βTSHRXTSHR)/Var(lnTSH), where XTSHR=1 for carriers and 0 otherwise, and 
βTSHR is the estimated regression coefficient for TSHR, controlling for age and sex.
Quantitative genetic analyses followed principles and methods as outlined elsewhere (23). 
Model fitting was done with Mx (24). In these analyses, the phenotypic variances are de-
composed into genetic and environmental contributions (23). The genetic variance is further 
subdivided into an additive (A) component and a dominance (D) component. The environ-
mental contribution is divided into a shared environmental component (C) and a unique (E) 
environmental component. The heritability is defined as the proportion of the total variance 
attributable to total additive genetic variance (23, 25). Series of univariate models were fitted 
in the five zygosity groups MZ males, DZ males, MZ females, DZ females and OS, separately. 
The ACE model was selected as a starting point of the modeling, and the significance of A, C, 
and E were tested by removing them sequentially in specific nested submodels.23 Model fit 
was assessed using the –2 log likelihood (–2LL). To evaluate whether the (genotype) variation 
at the locus contributes to a significant fraction of the trait variation, models including and 
excluding the genotype (non-carriers versus carriers) as a covariate in the means model were 
compared, using hierarchical likelihood ratio chi-square tests. The difference between minus 
twice the log-likelihood for a reduced model (in which the effect of the genotype is set to 
zero) and that of the full model (including genotype information) is approximately chi-square 
distributed. The degrees of freedom (df ) for this test are equal to the difference between the 
df for the reduced model and the full model. This gives a chi-square test with 1 df.  In these 
analyses, the standardized genetic and environmental variance components estimates were 
assumed to be equal across gender. Being able to compare these hierarchical models, only 
twin pairs in which genotype information was available in both of the twins were included 
in these analyses. According to standard biometric practice (23), we assumed equal environ-
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ment for MZ and DZ twins, no epistasis (gene-gene-interaction), and no gene-environment 
interaction or correlation.
results
Characteristics of the study population are given in table 1. The genotype distribution for the 
polymorphism was: Asp/Asp: 1053 (84.9%); Asp/Glu: 180 (14.5%) and Glu/Glu: 8 (0.6%). The 
allele frequencies did not deviate significantly from Hardy-Weinberg equilibrium. As evident 
from table 2, serum TSH levels decreased with the number of Glu727 alleles (1.78±0.93 vs. 
1.61±0.85 vs. 1.53±0.75 mU/l). Carriers of the Glu727 allele had lower TSH levels (non-carriers 
vs. carriers: 1.78±0.93 vs. 1.60±0.84 mU/l, p=0.04). No significant differences were found for 
thyroid hormone levels, thyroid antibody levels or thyroid size. These findings were unchanged 
when excluding individuals with subclinical thyroid disease and/or positive thyroid antibody 
status (data not shown). With the exception of serum free T3 levels in smokers which were 
lower among carriers than non-carriers, neither stratification according to smoking status 
nor exclusion of individuals with ultrasonographically demonstrated thyroid nodules had a 
significant influence on the data (data not shown). 
The results of the regression analyses are shown in table 3. Circulating serum TSH was 
significantly associated with the polymorphism, and the regression coefficient was not 
influenced by including iodine intake, examination place or tobacco smoking in the analyses 
(data not shown). A consistent genotype-phenotype relationship seemed to be the case. 
Moreover, no statistically significant evidence of interaction effects between the genotype 
and any of the environmental exposures was detected: (genotype × examination place inter-
Table 1: Characteristics of the study population. 
Number of individuals 1241
Female/male ratio 623/618
Age (years) 36.7 ± 10.7
TSH  mU/l 1.56 (1.03)
Free T4 (pmol/l) 12.82 ± 1.64
Free T3 (pmol/l) 6.19 ±  0.88
TPOab  (kIU/l) 4.74 (3.07)
Tgab (kIU/l) 7.5 (4.99)
Non-smokers/smokers ratio 626/615
Examination place Odense/Copenhagen 692/549
Body mass index (kg/m2) 24.5 ± 3.6
Thyroid size (ml) a 15.0 (6.4)
a n= 469
Twins with subclinical thyroid disease and positive thyroid antibody status are included. Values are 
means±SD or median (interquartile range) for variables with skewed distribution.
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action, p = 0.966); (genotype × iodine excretion interaction, p = 0.926); (genotype × smoking 
interaction, p = 0.115).
Quantitative genetic modeling
As evident from table 4, the TSHR-Asp727Glu polymorphism accounted for only 0.91% of the 
total phenotypic variance in circulating serum TSH levels. For all phenotypes the best fitting 
model was an AE model. The inclusion of the Asp727Glu genotype as a covariate significantly 
improved the fit of the model (p=0.001), however the estimate for additive genetic effects 
without adjustment for the genotype was 68.2% (95% CI 62–73%), whereas inclusion of 
genotype status altered the estimate to 67.8 % (95% CI 61–73%). These results suggest that 
the Asp727Glu polymorphism accounts for a very small, but statistically significant, fraction 
of the total genetic variation in circulating serum TSH levels. The polymorphism accounted 
for 0.15-0.38% of the total phenotypic variance in thyroid hormone levels and thyroid size, 
and no significant differences on the point estimates of additive genetic influence were 
found. These results were unaltered when individuals with subclinical thyroid disease and/or 
positive thyroid antibody status were excluded (data not shown). 
Table 2: The effect of the TSHR-Asp727Glu genotype on traits reflecting thyroid homeostasis. 
Genotype n TSH
mU/l
Free T4
pmol/l
Free T3
pmol/l
TPOab
kIU/l
Tgab
kIU/l
Size a
ml
Asp/Asp 1053 1.78 (0.93) 12.85 (1.67) 6.21 (0.89) 64.7 (1298.4) 51.2 (1086.6) 16.1 (5.8) 
Asp/Glu 180 1.61 (0.85) 12.65 (1.49) 6.11 (0.84) 15.4 (66.2) 15.3 (63.5) 14.9 (5.3) 
Glu/Glu 8 1.53 (0.75) 12.81 (0.90) 6.23 (0.75) 34.7 (71.8) 6.8 (3.7) 14.8 (5.6) 
Non-carriers 1053 1.78 (0.93) b 12.85 (1.67) c  6.21 (0.89)  c 64.7 (1298.4) c 51.2 (1086.6) c 16.1 (5.8) c
Carriers 188 1.60 (0.84) 12.66 (1.47) 6.11 (0.83) 16.2 (66.3) 15.0 (62.1) 14.9 (5.3) 
Results are presented as means ± SD
a In all, 469 individuals had an ultrasound scan to determine thyroid size. The genotype distribution was: 
Asp/Asp= 393; Asp/Glu=69; Glu/Glu=7.  
b Non-carriers versus carriers: p=0.04  
c Non-carriers versus carriers: non-significant
Table 3: Association between the Asp727Glu polymorphism in the TSH receptor gene and measures of 
thyroid homeostasis assessed by regression analysis. 
Phenotype n β (95% CI) p
lnTSH 1241 -0.14 (-0.24 - -0.04) 0.007
Free T4 1241 -0.18 (-0.42- 0.07) 0.158
Free T3 1241 -0.11 (-0.24- 0.02) 0.106
lnTPO 1241 -0.004 (-0.16- 0.15) 0.961
lnTgab 1240  0.02 (-0.09- 0.14) 0.694
lnThyroid size 469 -0.06 (-0.16- 0.03) 0.174
β signifies the regression coefficient of the polymorphism (non-carriers vs. carriers) with age and gender 
adjustment.
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Discussion
In the current study, we demonstrated that the Asp727Glu polymorphism in the TSHR gene is 
associated with circulating TSH levels in a healthy Danish population. Serum TSH decreased 
with the number of Glu727 alleles in a dose-dependent manner. 
This replication of our initial findings (10), but in an independent and much larger study 
population clearly minimizes the risk of a false positive finding. On the other hand, our results 
demonstrate that the proportion of genetic influence explained by this particular polymor-
phism is small. Although the biological effect of the polymorphism is limited, the result is 
highly significant due to our large sample size. Thus, a substantial proportion of genetic 
variation, not accounted for by this TSHR gene polymorphism, still exists. This clearly sug-
gests that multiple loci are involved in the control of serum TSH concentration (26). Such an 
organization may be regarded as an advantage for the overall control of thyroid homeostasis, 
which is then not as vulnerable to genetic mutations as if each polymorphism had a strong 
genetic impact. Thereby a more stable control is secured. Moreover, no associations with 
other measures of thyroid homeostasis were found. Circulating levels of thyroid hormones 
as well as thyroid size were all similar across the three genotype groups, perhaps due to 
the effect of the TSHR gene polymorphism on thyroid function being compensated by the 
associated change in serum TSH. Thus, the polymorphism may be regarded as a trait specific 
genetic influence. 
The suggested association seems biologically plausible and functionally relevant. The fact 
that the TSHR-Glu727 allele in our study is associated with lower levels of serum TSH, but 
without effect on free T4 could imply a higher sensitivity of the variant versus the wild-type 
Table 4: Heritability estimates with and without adjustment for the TSHR-Asp727Glu polymorphism
Phenotype a Number
of individuals b
Variation explained
(%)
Heritability
estimate c
Heritability estimate c
adjusted for
TSHR-Asp727Glu
polymorphism
p-value d
lnTSH 1220 0.91% 0.682 (0.62 - 0.73) 0.678  (0.61 - 0.73) 0.001
Free T4 1220 0.15% 0.599  (0.52 - 0.66) 0.598  (0.52 - 0.66) 0.215
Free T3 1220 0.19% 0.590  (0.51 - 0.66) 0.589 (0.51 - 0.66) 0.072
lnTPOab 1220 <0.01% 0.716  (0.66 - 0.76) 0.716 (0.66 - 0.76) 0.256
lnTgab 1220 0.01% 0.534  (0.43 - 0.62) 0.533  (0.43 - 0.62) 0.332
lnThyroid size 466 0.38% 0.802  (0.72 - 0.86) 0.800  (0.72 - 0.86) 0.252
a Twins with subclinical thyroid disease and positive thyroid antibody status are included.
b Only complete twin pairs are included in these analyses
c The proportion of the total variance attributable to total additive genetic variance. All heritability 
estimates are adjusted for age and gender
d Tested using a likelihood ratio chi-square test with 1 degrees of freedom. The difference between minus 
twice the log-likelihood for a reduced model (in which the effect of the genotype is set to zero) and that 
of the full model (including genotype information) is approximately chi-square distributed.
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TSHR, since less TSH is needed to produce normal free T4 levels. This hypothesis is supported 
by an in vitro study showing that the TSHR-Glu727 variant results in an exaggerated cAMP 
response of the receptor to TSH stimulation (13). However, others have not been able to 
replicate this finding (27, 28). 
The TSH receptor gene is regarded as a thyroid specific candidate gene in the susceptibility 
to Graves’ disease (29). Based on case-control association analyses, it has been found that the 
Asp727Glu polymorphism is more frequent in patients with Graves’ disease than in healthy 
controls (30, 31). Other studies have been unable to replicate such an association (13, 30, 
32-34). Moreover, in patients with Graves’ disease the polymorphism does not seem to influ-
ence pre-treatment thyroid antibody levels (33). Neither was the polymorphism related with 
antibody levels in our healthy study population. The Asp727Glu polymorphism has also been 
found to be significantly more frequent in patients with toxic multinodular goiter than in nor-
mal individuals (13). Again, other studies have failed to demonstrate such an association (34, 
35). Consequently, the polymorphism seems to have a weak influence on a broad variety of 
thyroid phenotypes (11). Whether the polymorphism exerts a weak primary disease-causing 
effect or is related to disease severity remains unclarified. In the current study, as well as in 
our previous studies, we have found that the Glu727 allele located in this thyroid specific 
gene contributes to decreasing TSH levels in healthy individuals. It is possible that the effect 
of this allele is related to thyroid function homeostasis in the clinical phenotypes as well - 
providing a link between the different thyroid dysfunction entities. In addition, circulating 
levels of TSH and thyroid hormones as well as thyroid size are of importance in the assess-
ment and classification of thyroid dysfunction. Thus, investigation of these endophenotypes 
in the asymptomatic period may have the potential to improve our understanding of the 
development of thyroid disease (26).
A single, nominally significant association should be viewed as tentative until it has been 
independently replicated (36). In our study, the frequency of the Glu727 allele was compa-
rable with those reported in other healthy populations, and using this large sample we were 
able to replicate our previous results (10) fulfilling the independent replication criterion. 
However, identification of this genetic polymorphism, accounting for a significant albeit very 
modest fraction of the total genetic variation in circulating TSH levels, should open the door 
for further genetic analyses, because unmeasured confounders – that is other associated 
genetic loci and/or environmental exposures - may be of importance (36). Our study popula-
tion is recruited from a single European geographic area, and we expect that population 
stratification effects are of limited importance.
 To further characterize the genotype phenotype relationship, we investigated the pos-
sibility of interaction between the Asp727Glu polymorphism and relevant environmental 
exposures. Yet, studying the interplay between measured genetic and environmental factors 
may require larger sample sizes; and with a simple interaction model we were unable to de-
tect that the effect of the polymorphism was modified by iodine intake (measured as iodine 
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excretion) or cigarette smoking. In these analyses, the variable “examination place” served as 
a surrogate for iodine intake. This allowed us to use the whole study population. However, the 
results were consistent using the actually measured urinary iodine excretion levels.
To conclude, our results confirm previous data showing that the TSHR-727Glu variant is 
associated with lower plasma TSH levels and extend them by showing the proportion of 
genetic variation accounted for by this TSHR gene polymorphism is small. The polymorphism 
was not associated with circulating thyroid hormone levels, thyroid antibody levels or thyroid 
size.  
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abstract
introduction: TSH and thyroid hormone may have independent effects on bone. In this study 
we investigated the association of TSH and FT4 with different bone parameters in humans. 
TSH and FT4 are known to be associated with BMI and a higher BMI gives a higher bone 
mineral density (BMD). Thus, we analyzed if the effects of TSH and FT4 on bone are mediated 
by BMI. Since TSH exerts its biological effect through the TSH receptor (TSHR), the TSHR gene 
might be a candidate gene affecting bone mass. The TSHR-Asp727Glu polymorphism is as-
sociated with lower TSH levels. Therefore, we examined the association of this polymorphism 
with bone parameters.
Methods: Genotypes were determined by Taqman assay in 4934 elderly Caucasian men and 
women of the Rotterdam Study, of whom BMD and bone geometry data were available. In a 
random set of 1327 subjects serum thyroid parameters were available.
results: Femoral neck BMD as well as narrow neck BMD and cortical thickness increased with 
serum TSH. However, FT4 was more strongly and negatively associated with bone parameters. 
Regression models showed BMI-dependent and -independent effects of both TSH and FT4 on 
bone. Carriers of the TSHR-Glu727 allele had a 2.3% higher femoral neck BMD. 
conclusion: In line with the effect of TSH on bone in mice, serum TSH shows a positive trend 
with BMD in humans, a finding which is strengthened by the association between the TSHR-
Asp727Glu polymorphism and femoral neck BMD. However, serum FT4 has a much greater 
influence on bone than TSH. 
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introDuction
Thyroid hormone plays an important role in skeletal growth and bone homeostasis. Chil-
dren with hypothyroidism show delayed bone maturation and lower height (1), whereas in 
adults excessive thyroid hormone levels are associated with bone loss and a reduction in 
bone mineral density (BMD) at multiple skeletal sites (2). Studies in patients with subclinical 
hyperthyroidism show that minor changes in thyroid hormone and/or thyroid stimulating 
hormone (TSH) levels can already have important consequences for BMD (3). 
Since thyroid hormone is necessary for normal bone function, mechanisms of thyroid 
hormone action on bone have been studied extensively (4, 5). In addition to effects of thy-
roid hormone on the skeleton, TSH has recently been shown to have a direct effect on bone 
(6, 7). TSHR knockout mice die by 10 weeks of age and display high-turnover osteoporosis, 
which supplementation with thyroid hormone fails to reverse. Heterozygous TSHR+/- mice 
thrive normally, but still have pronounced osteoporosis. TSH inhibits through the TSHR both 
osteoclastic bone resorption and osteoblastic bone formation. In this study we analyzed 
whether serum TSH and free T4 (FT4) levels are associated with bone parameters in a large 
and homogeneous population-based sample of Caucasian elderly men and women. 
While bone mass is also determined by environmental factors such as physical activity and 
smoking, genetic factors have been estimated to determine up to 80% of the variation in 
BMD (8-10). The heritable component is mediated by multiple genes, each having a small, but 
cumulative effect. Since TSH exerts its biological effect through the TSHR, we analyzed the 
TSHR gene as a possible candidate gene impacting on BMD and fracture risk. We studied a 
common polymorphism in the TSHR gene, i.e. the TSHR-Asp727Glu polymorphism. The TSHR-
Glu727 variant is associated with lower serum TSH but not with FT4 levels in several Caucasian 
populations (11, 12), which suggests a higher activity of the Glu727 variant versus the Asp727 
form of the receptor. 
It is difficult to discriminate direct effects of TSH from those of thyroid hormones on 
peripheral tissues such as bone.  In an attempt to make this distinction, we studied the TSHR-
Asp727Glu polymorphism, since this polymorphism has been found to be associated with 
only serum TSH levels, and not with other serum thyroid parameters. Potential effects of this 
polymorphism on bone parameters are therefore likely to be direct effects of TSH.
subJects anD MetHoDs
Study population
The Rotterdam Study is a population-based, prospective cohort study of men and women, 
aged 55 years and over. The study was designed to investigate the incidence and determi-
nants of chronic disabling diseases in an aging population (13) The Rotterdam Study was 
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approved by the Medical Ethics Committee of Erasmus University Medical School and written 
informed consent was obtained from 7806 subjects. 
Subjects
Association analyses between serum thyroid parameters, the TSHR-Asp727Glu polymorphism 
and bone parameters were first performed in a randomly selected subgroup of 1327 subjects 
of the Rotterdam Study, in which serum TSH, FT4 and antibodies to thyroid peroxidase (TPO-
Abs) were available.  Secondly, analyses were performed in 4934 subjects for whom complete 
data on bone parameters were available. The subjects, in which serum thyroid parameters 
and TPO-Abs were available, are also part of this group. 
Plasma analyses
TSH levels were measured with TSH Lumitest (Henning, Berlin, Germany). Serum FT4 was 
measured by a chemoluminescence assay (Vitros, ECI Immunodiagnostic System, Ortho-
Clinical Diagnostics, Amersham, UK). TPO-Abs were assessed by ELISA (Milenia, DPC, Los 
Angeles, USA).
Measurement of bone parameters and anthropometry
BMD (expressed in grams per square centimeter) was measured at the femoral neck and the 
lumbar spine (vertebrae L2-L4) by dual energy x-ray absorptiometry (DXA; Lunar DPX-L den-
sitometer, Lunar Corp., Madison, WI). The hip structural analysis (HSA) software developed by 
Thomas J. Beck (14) was used to measure hip bone geometry and structure parameters from 
the DXA scans of the narrow-neck region across the narrowest point of the femoral neck, as 
described previously (15).
Anthropometric measurements were obtained at the research center. Body mass index 
(BMI) was calculated as weight in kilograms divided by height in meters squared. 
Fracture follow-up 
Both at baseline (1990-1993) and at the third follow-up visit thoracolumbar radiographs of 
the spine were obtained. The presence of vertebral fractures was assessed by the McCloskey/
Kanis method and analyzed as described previously (16, 17). The follow-up radiographs were 
available for 2699 individuals, who survived after an average follow-up period of 8.7 years 
after baseline center visit and who were still able to come to the research center. The non-
vertebral fracture analysis is based on follow-up data collected from baseline until January 
1st, 2002, comprising an average follow-up period of 8.1 years. Fracture events were retrieved 
by research physicians as described previously (15). 
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Genotyping
Participants were genotyped for the Asp727Glu polymorphism (rs1991517) (11) of the TSHR 
gene. We refrained from analyzing other polymorphisms in the TSHR gene, such as TSHR-
Pro52Thr and TSHR-Asp36His, since these either have a low frequency or have not been 
associated with serum thyroid parameters in vivo to date (11). Genotypes were determined 
in 2 ng genomic DNA using the Taqman allelic discrimination assay (Applied Biosystems, 
Nieuwerkerk a/d IJssel, The Netherlands). Reactions were performed on the Taqman Prism 
7900HT in 384 wells format in 2 μl reaction volume.
Statistical analysis
In the subgroup, in which serum thyroid parameters were available, analyses were carried 
out after exclusion of subjects on thyroid medication and/or amiodarone, with clinical hypo- 
or hyperthyroidism (FT4 <11.0 or >25.0 pmol/L) and with TPO-Abs >35 IU/L  (n=176). Due 
to a non-normal distribution, TSH was logarithmically transformed and relations between 
variables were assessed using linear regression, adjusted for age, gender and BMI. For the 
TSHR-Asp727Glu polymorphism, deviation from Hardy-Weinberg equilibrium proportions 
was analyzed using a Chi-square test. Genotype-related differences were adjusted for age, 
gender and BMI and tested by analysis of covariance (ANCOVA). Fisher’s LSD correction for 
multiple testing was used.
In the complete cohort, association of the TSHR-Asp727Glu polymorphism with bone 
parameters was tested after exclusion of subjects with thyroid pathology, leaving   4801 
subjects eligible for analysis. 
To estimate non-vertebral fracture risk, we used Cox proportional hazard models, taking 
potential differences in follow-up time into account. The relative risk and 95% confidence 
interval of vertebral fractures were calculated by a logistic regression model. 
Spearman’s correlation coefficient was used to assess the association between serum TSH 
and FT4. P values are two-sided throughout and were considered significant if P < 0.05. Data 
were analyzed using SPSS 10.0.7 for Windows (SPSS, Inc., Chicago, IL).
results
Serum TSH and FT4 and bone parameters
Baseline characteristics of the subgroup, in which serum thyroid parameters were available, 
and the complete study cohort are shown in Table 1. 
Table 2 shows the associations between serum TSH and bone parameters. Femoral neck 
BMD increased with serum TSH level (P=0.06). Also femoral narrow neck BMD (P=0.01) and 
cortical thickness (P=0.01) increased with serum TSH concentrations (Table 2). Since serum 
TSH levels are positively associated with BMI (18, 19) and obese subjects have a higher BMD 
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(9, 20), we tested whether the association between serum TSH levels and BMD was (partly) 
driven by the positive relation with BMI. Serum TSH was positively associated with BMI 
(βlnTSH=0.34, p=0.02) and we observed a close association of BMI and femoral neck BMD (data 
not shown). So, in addition to age and gender, we adjusted for BMI in the analysis of serum 
TSH and bone parameters. The same trends were observed, but the associations became 
borderline significant (Table 2). We also analyzed covariance of the different bone parameters 
with both serum TSH and BMI in a regression model, together with an interaction term (serum 
TSH x BMI). This model showed no evidence of interaction, but suggested independent and 
additive effects of serum TSH and BMI on bone parameters.
Table 3 shows the associations between serum FT4 and bone parameters. Serum FT4 was 
significantly and consistently associated with all bone parameters, except narrow neck width. 
For instance, femoral neck BMD and cortical thickness decreased with increasing FT4. In the 
regression model when BMI was added as a covariate, FT4 remained significantly associated 
with bone parameters. 
Serum TSH and FT4 are tightly coupled in the pituitary-thyroid axis (2). In this population, 
lnTSH and FT4 were also correlated with a correlation coefficient of –0.206 (P<0.001) (Fig. 1). 
Since both serum TSH and FT4 were associated with bone parameters, we included both 
variables in a multivariate regression model. Only serum FT4 remained significantly associ-
ated with bone parameters in this model (data not shown).
When we performed gender-specific analyses of the association of serum TSH and FT4 
with bone parameters, similar trends were observed. To maximize power, we combined men 
Table 1: Baseline characteristics of the study populations
Subgroup with serum thyroid 
parameters
Complete Study Cohort P
N 1151 4801
Age (yrs) 68.72 ± 7.54 67.65 ± 7.78 <0.001a
Gender (M/F) 479 / 672 2101 / 2700 0.19a
BMI (kg/m²) 26.30 ± 3.63 26.26 ± 3.55 0.99b
Femoral Neck BMD (g/cm²) 0.86 ± 0.14 0.87 ± 0.14 0.98b
Narrow Neck BMD (g/cm²) 0.68 ± 0.14 0.70 ± 0.14 0.09b
Narrow Neck Width (cm) 3.21 ± 0.33 3.21 ± 0.32 0.23b
Cross Sectional Area (cm²) 2.09 ± 0.49 2.14 ± 0.49 0.27b
Average Cortical Thickness (cm) 0.130 ± 0.027 0.133 ± 0.028 0.09b
Average Buckling Ratio 14.25 ± 4.23 13.88 ± 3.93 0.17b
Lumbar Spine BMD (g/cm²) 1.09 ± 0.20 1.09 ± 0.20 0.72b
TSH (mU/L) 1.48 [0.98-2.23]
FT4 (pmol/L) 16.34 ± 2.68
Data are shown as mean ± SD or as median [IQR]. 
a Chi-square for gender, Anova for age
b Anova, adjusted for age and gender
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and women in the analyses. Since subjects of the Rotterdam Study were all aged 55 years or 
older, we were not able to analyze women according to their menopausal status. However, 
additional adjustment for age at menopause did not essentially change the observed as-
sociations. 
The TSHR-Asp727Glu polymorphism and bone parameters
DNA from participants of the Rotterdam Study was genotyped for the TSHR-Asp727Glu 
polymorphism. In the subgroup, DNA was available from 1089 subjects for genotyping. 
The genotyping success rate was 98.1%, with 21 samples that failed genotyping. Genotype 
frequencies of the TSHR-Asp727Glu polymorphism (Asp/Asp = 947 (88.7%), Asp/Glu = 119 
(11.1%) and Glu/Glu = 2 (0.2%) did not deviate from Hardy Weinberg equilibrium proportions. 
The Glu727 allele had a frequency of 5.8 %, which is similar to previous studies in Caucasians 
(11). As only few homozygous subjects were identified for the polymorphism, we combined 
heterozygotes and homozygotes into variant carriers. Carriers of the TSHR-Glu727 variant had 
a 2.3% higher femoral neck BMD (P=0.03) and had a 12.6% lower TSH level (P=0.04) (Fig. 2, 
Table 4).  In agreement with previous studies, the TSHR-Asp727Glu polymorphism was not 
associated with serum FT4 levels. Since Glu727 carriers showed a trend towards lower TSH 
Table 2: Linear regression coefficients (ß) for the relationships of serum lnTSH with bone parameters
Adjusted for age and gender Adjusted for age, gender and BMI
ß (95%CI) P ß (95%CI) P
BMI  0.343 (0.068-0.618) 0.02
Lumbar spine BMD 0.009 (-0.006-0.023) 0.24 0.004(-0.010-0.018) 0.59
Femoral Neck BMD  0.009 (0.000-0.019) 0.06  0.006 (-0.003-0.015) 0.20
Narrow Neck BMD  0.014 (0.003-0.024) 0.01  0.009 (-0.001-0.019) 0.07
Cross Sectional Area 0.039 (0.006-0.073) 0.02  0.026 (-0.005-0.057) 0.10
Narrow Neck Width  -0.007 (-0.028-0.014) 0.53  -0.007 (-0.028-0.014) 0.51
Cortical Thickness 0.003 (0.001-0.005) 0.01  0.002 (0.000-0.004) 0.07
Buckling Ratio  -0.297 (-0.531-0.145) 0.10  -0.193 (-0.531-0.145) 0.26
Table 3: Linear regression coefficients (ß) for the relationships of serum FT4 with bone parameters
Adjusted for age and gender Adjusted for age, gender and BMI
ß (95%CI) P ß (95%CI) P
BMI  -0.093 (-0.170--0.015) 0.02
Lumbar spine BMD -0.005 (-0.010--0.001) 0.009 -0.004(-0.008-0.000) 0.04
Femoral Neck BMD  -0.003 (-0.006--0.001) 0.01  -0.003 (-0.005-0.000) 0.05
Narrow Neck BMD  -0.005 (-0.008--0.002) 0.001  -0.004 (-0.007--0.001) 0.004
Cross Sectional Area -0.019 (-0.028--0.010) <0.001  -0.016 (-0.024--0.007) <0.001
Narrow Neck Width  -0.004 (-0.010-0.002) 0.19  -0.004(-0.010-0.002) 0.20
Cortical Thickness -0.001 (-0.002-0.000) 0.001  -0.001 (-0.001-0.000) 0.005
Buckling Ratio  0.127 (0.028-0.225) 0.01  0.098 (0.003-0.193) 0.04
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levels, this might mask the associations between the TSHR-Asp727Glu polymorphism and 
bone parameters. For this reason, TSH was added as a covariate in the analysis of the poly-
morphism with bone parameters. The results essentially remained the same (Table 4).  
In the complete study cohort the genotype frequencies of the TSHR-Asp727Glu poly-
morphism (Asp/Asp = 4170, Asp/Glu = 600 and Glu/Glu = 31) were also consistent with 
Hardy-Weinberg equilibrium proportions. In this group similar results were found for femoral 
Chapter 7, figure 1: 
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Figure 1: Scatterplot between serum lnTSH and FT4.Figure 2: 
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Figure 2: Differences in serum TSH levels (A) and femoral neck BMD (B) between wild type and carriers of 
the TSHR-Glu727allele in the subgroup, in which serum thyroid parameters were available. The data were 
adjusted for age, gender and BMI. 
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neck BMD: carriers of the Glu727 allele had a higher femoral neck BMD than non-carriers. In 
addition, the TSHR-Asp727Glu polymorphism was in a dose-dependent manner associated 
with higher femoral neck BMD (Asp/Asp: 0.87 ± 0.01; Asp/Glu: 0.88 ± 0.01; Glu/Glu: 0.89 ± 0.01 
g/cm2, Ptr=0.009). 
Both in the subgroup and in the complete cohort, the TSHR-Asp727Glu polymorphism was 
not associated with BMI.
The TSHR-Asp727Glu polymorphism and fracture risk
We analyzed the risk for vertebral and non-vertebral fractures by the TSHR-Asp727Glu 
polymorphism in the subgroup in which serum thyroid parameters were available and in the 
complete study cohort, but no associations were found. Also, serum TSH and FT4 were not 
associated with fracture risk (data not shown). 
Discussion
In this study we examined whether serum TSH and FT4 levels and a polymorphism in the 
TSHR gene have an impact on BMD, bone geometry and the risk of osteoporotic fracture. 
We showed in a population of elderly Caucasians that femoral neck BMD as well as femoral 
narrow neck BMD and cortical thickness increased with serum TSH. Furthermore, serum FT4 
was significantly and consistently associated with bone parameters in a negative manner. 
The TSHR-Glu727 allele was associated with a higher BMD at the femoral neck and lower serum 
Table 4: Bone parameters by TSHR-Asp727Glu genotype
TSHR-Asp727Glu subgroup TSHR-Asp727Glu complete study cohort
Asp/Asp Asp/Glu + 
Glu/Glu
P PTSH Asp/Asp Asp/Glu + 
Glu/Glu
P
N 947 121 4170 631
BMI 26.27 ± 0.12 26.53 ± 0.33 0.44 0.37 26.29 ± 0.05 26.06 ± 0.14 0.12
Lumbar spine BMD 1.09 ± 0.01 1.10 ± 0.02 0.42 0.40 1.09 ± 0.01 1.10 ± 0.01 0.50
Femoral Neck BMD 0.86 ± 0.01 0.88 ± 0.01 0.03 0.02 0.87 ± 0.01 0.88 ± 0.01 0.01
TSH 1.68 ± 0.03 1.55 ± 0.07 0.04
FT4 16.35 ± 0.09 16.38 ± 0.24 0.89
N 748 100 P PTSH 3372 520 P
Narrow Neck BMD 0.68 ± 0.01 0.70 ± 0.01 0.16 0.12 0.70 ± 0.01 0.71 ± 0.01 0.16
Narrow Neck Width 3.21 ± 0.01 3.20 ± 0.02 0.63 0.60 3.21 ± 0.01 3.21 ± 0.01 0.83
Cross sectional Area 2.09 ± 0.01 2.13 ± 0.04 0.32 0.26 2.14 ± 0.01 2.16 ± 0.02 0.15
Cortical Thickness 0.129 ± 0.001 0.133 ± 0.002 0.13 0.10 0.133 ± 0.001 0.134 ± 0.001 0.15
Buckling Ratio 14.29 ± 0.15 14.05 ± 0.40 0.58 0.52 13.90 ± 0.06 13.72 ± 0.16 0.27
Data are shown as mean ± SEM. Logarithmic transformations were used for serum TSH levels. All data 
were adjusted for age, gender and BMI. PTSH represents the P-value, when additionally corrected for serum 
TSH.
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TSH, but not FT4 levels. No association of the TSHR polymorphism or serum TSH or FT4 with 
fracture risk was found.
Only a few studies have been published on the expression of TSHR in human bone cells or 
the influence of serum TSH on bone in humans. Tsai et al. found weak evidence for the pres-
ence of the TSHR in primary cultures of human osteoblast-like cells (21). On the other hand, 
a recent study conducted by Morimura et al. (22) demonstrated the presence of TSHR mRNA 
in human osteoblast cell lines. Recently, Mazziotti et al. showed that an increase in serum 
TSH levels accomplished by short-term recombinant human TSH stimulation, is accompanied 
by a reversible inhibition of bone resorption (23). Moreover, in a study of more than 600 
postmenopausal women, Bauer et al. showed that women who have low serum TSH levels, 
have an increased risk for hip and vertebral fractures (24). In this study, low serum TSH was 
also negatively associated with femoral neck BMD, narrow neck BMD and cortical thickness. 
These results confirm the findings of Mazziotti et al. and suggest direct effects of TSH on bone 
in humans, similar to those recently demonstrated in a study of TSHR KO mice (7). We did not 
find an association of serum TSH with lumbar spine BMD. This might be due to the fact that 
the BMD measurements of the lumbar spine are influenced by osteoarthritis and therefore 
cannot be accurately assessed (25).  
Recent studies have shown that serum TSH levels are positively associated with BMI and 
the occurrence of obesity (18, 19). In our study serum TSH also showed a positive association 
with BMI. Since obese subjects have a higher BMD (9, 20), we tested whether the association 
between serum TSH levels and BMD is explained by the positive relation with BMI. The effect 
of serum TSH on bone seems partially mediated through BMI and partly through a direct 
effect of TSH itself, since the regression models suggested independent and additive effects 
of serum TSH and BMI on bone parameters. 
The associations between serum TSH and bone parameters are consistent with a direct ef-
fect of TSH. However, these findings could also result from altered levels of thyroid hormone, 
since TSH and FT4 are tightly coupled in the pituitary-thyroid axis (2). In this population, 
serum FT4 showed a strong negative association with several bone parameters pointing to 
an important role of thyroid hormone itself on bone function. Considering the strength of 
the associations of serum TSH and FT4 with bone parameters, FT4 appears to have a greater 
impact on bone development and turnover than any direct effect of TSH. This notion is 
strengthened by the observation that only serum FT4 remains significantly associated with 
bone parameters in the multivariate regression model including both serum TSH and FT4, 
besides the other co-variables age, gender and BMI. This is in accordance with studies de-
scribed in a recent paper by Bassett et al (26), who conclude that FT4 excess rather than TSH 
deficiency explains the detrimental effects of hyperthyroidism on bone. 
In an attempt to distinguish between direct effects of TSH on bone and those mediated by 
FT4 we studied the effect of the Asp727Glu polymorphism in the TSHR gene. This polymor-
phism is associated with relatively low TSH levels, but normal FT4 levels (11, 12), a finding we 
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were able to replicate in this study population, but also in another independent population 
of more than a thousand subjects (unpublished data by Van der Deure, Peeters and Visser). 
This would suggest a higher activity of the receptor in carriers of the Glu727 allele, since less 
TSH is needed to produce normal FT4 levels. There is indeed one in vitro study showing that 
the TSHR-Glu727 variant results in an increased cAMP response of the receptor to TSH (27); 
however, others have not been able to replicate this (28, 29), which may suggest that the 
Asp727Glu polymorphism is linked to another functional polymorphism elsewhere in the 
TSHR gene. 
The TSHR-Glu727 allele was associated with a higher femoral neck BMD and showed a trend 
towards thicker cortices. These data support the finding of a direct effect of TSH on bone 
as previously observed in mice (7). When we additionally added serum TSH as a covariate 
in our model, the estimated means for the TSHR-Asp727Glu genotypes of the different 
bone parameters remained essentially the same; however, the associations became slightly 
stronger, suggesting that the effect of the Glu727 variant on bone was partially masked by the 
compensatory decrease in serum TSH levels. Although the TSHR-Glu727 variant was associated 
with higher bone mass, we did not observe an increased fracture risk in subjects with the 
wild-type TSHR versus the variant carriers.  In this respect, it should be noted that we could 
have detected a relative risk for non-vertebral fractures of 1.5 with 80% power at a 5% type 
I error probability in this study. However, we cannot exclude a relative risk of 1.5 or less. A 
larger study population would be required to demonstrate such an effect. 
Since no increased fracture risk was observed and the difference in femoral neck BMD 
between carriers and non-carriers of TSHR-Asp727Glu polymorphism was small, one could 
wonder if this polymorphism is clinically relevant. However, it is important to realize that 
people carry this polymorphism for life.  Since this polymorphism is associated with altered 
serum TSH levels, this might, for instance, point to a lifelong altered thyroid function set point. 
Furthermore, new insights can be obtained about the physiological role of thyroid pathway 
genes. Our finding that the TSHR-Asp727Glu polymorphism is associated with femoral neck 
BMD is in support of a direct albeit modest effect of serum TSH on bone.
This study finds associations between serum TSH and FT4 levels and a polymorphism in 
the TSHR gene with bone parameters. The results suggest that the TSHR-Asp727Glu poly-
morphism is associated with higher bone mass and that increased serum TSH levels give 
rise to less fragile bone in humans via BMI-dependent and independent pathways. However, 
thyroid hormone itself has a much larger effect on bone, suggesting that the negative effect 
of (subclinical) hyperthyroidism on bone is more likely to be the effect of high FT4 instead 
of low TSH. Further studies are needed to confirm our findings and to elucidate the exact 
mechanisms by which both serum TSH, FT4 and the polymorphism in the TSHR affect bone 
parameters.
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abstract
introduction: Genetic factors have a considerable influence on serum thyroid hormone 
levels. The C785T and A1814G polymorphisms, located in the 3’ untranslated region of the 
type 1 deiodinase (D1) gene have been associated with serum FT4 and rT3 levels.
objective: In healthy Danish twins, we examined the association of these polymorphisms 
with serum thyroid hormone levels and determined the proportion of genetic influence ex-
plained by these variants. We analyzed the underlying functional mechanism by performing 
mRNA stability measurements and analyzed the effect of these variants on D1 activity.
Methods: Serum thyroid measurements and genotypes of the D1-C785T and D1-A1814G 
polymorphisms were determined in 1192 twins. Structural equation modeling was used to 
determine heritability estimates. Functional analyses were carried out in D1-transfected JEG3 
cells.
results: Carriers of the D1-785T allele had 3.8% higher FT4 and 14.3 % higher rT3 levels, 
resulting in a lower T3/T4 and T3/rT3 ratio and a higher rT3/T4 ratio. This polymorphism ex-
plained 0.87% and 1.79%, respectively, of the variation in serum FT4 and rT3. The D1-A1814G 
polymorphism was not associated with serum thyroid hormone levels. No differences in D1 
mRNA decay rate or D1 activity were observed between wild-type D1 and the 2 variants.
conclusion: The D1-C785T polymorphism is consistently and significantly associated with 
serum thyroid hormone levels. However, the proportion of genetic influence explained by 
this particular polymorphism is small. No effect of the polymorphism on D1 mRNA decay rate 
or D1 activity was observed. The underlying functional mechanism needs to be elucidated. 
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introDuction
The thyroid gland produces predominantly the pro-hormone thyroxine (T4), which has to be 
deiodinated to 3,3’5-triiodo-L-thyronine (T3) to become biologically active. The conversion 
of thyroid hormones is regulated by three different iodothyronine deiodinases (D1-D3) (1). 
The tissue distribution and enzymatic activity of the deiodinases differ and they all play a 
distinct physiological role. For instance, D1 is highly expressed in liver and kidney and plays 
an important role in the production of T3 from T4 and in the clearance of reverse T3 (rT3). 
Polymorphisms in D1 have been associated with serum thyroid hormone levels (2): the 
D1-C785T polymorphism in the 3’ untranslated region (3’UTR) is associated with higher rT3 
levels and a lower T3/rT3 ratio, pointing towards a lower D1 activity in carriers of the T allele 
(2, 3). Another polymorphism in the 3’UTR of D1, D1-A1814G, is associated with a higher T3/
rT3 ratio, suggesting that the D1-1814G variant might result in increased D1 activity (2, 3). 
Recently, these findings have been replicated in a large population of elderly Caucasians of 
the Rotterdam Scan Study (4). To date only 1 polymorphism in D2 and no polymorphisms in 
D3 have been associated with serum thyroid hormone levels (3). The D2-ORFa-Gly3Asp was 
associated with serum thyroid parameters in a population of 156 healthy blood donors, but 
this could not be replicated in a population of approximately 350 elderly men, nor in a cohort 
of more than 1000 elderly Caucasians (4, 5).
Genetic factors exert considerable influence on most of the thyroid function measurements, 
with heritability estimates ranging between 23-65% (6, 7). Recently, we have determined the 
contribution of the thyrotropin (TSH) receptor Asp727Glu polymorphism to the genetic vari-
ance in serum TSH levels (8). In this study, we examined the association of the D1-C785T and 
D1-A1814G polymorphisms with thyroid function measurements in healthy Danish twins and 
determined the contribution of the polymorphisms to the overall variance in serum thyroid 
hormone levels. To analyze the underlying functional mechanism, we determined mRNA 
degradation rates, as these polymorphisms in the 3’UTR might alter D1 mRNA stability (9). In 
addition, we studied the effect of these variants on D1 activity by analysis of rT3 deiodination 
in JEG3 cells transfected with wild-type or variant D1.
Materials anD MetHoDs
Study population
The present study is part of a nationwide project (GEMINAKAR) investigating the relative 
influence of genetic and environmental factors on various traits related to the metabolic 
syndrome and cardiovascular risk factors. Based on a questionnaire survey concerning physi-
cal health and health related behavior performed in 1994, a representative sample of self-
reported healthy twin pairs was recruited from the population-based Danish Twin Registry 
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(10). A detailed description of the ascertainment procedure can be found elsewhere (6, 11, 
12).  In the GEMINAKAR study 1512 individuals (756 twin pairs) were examined. Blood samples 
for thyroid measurements and genotype information were available in 1266 individuals, 
distributed in 554 monozygotic (MZ), 474 same sex dizygotic (DZ) and 238 opposite sex (OS) 
twin individuals. In the MZ twin pairs, in which only one of the twins was genotyped, we 
assumed identical genotypes. Zygosity was established by analysis of nine highly polymor-
phic restriction fragment length polymorphisms and microsatellite markers widely scattered 
through the genome with an Applied Biosystems AmpFISTR Profiles Plus kit, according to the 
manufacturer’s instructions (Perkin-Elmer Co. Foster City, CA, USA).
Twin pairs in which one or both twins had self-reported thyroid disease (22 twin pairs) or 
biochemical thyroid disease (15 twin pairs) were excluded, leaving 1192 (524 MZ, 442 DZ and 
226 OS twin individuals). Due to missing genotype data, the D1-A1814G polymorphism was 
only established in 1076 individuals. 
Written informed consent was obtained from all participants and the study was approved 
by all regional Danish Scientific-Ethical Committees (case file 97/25 PMC).
Serum analyses
Serum TSH was measured using a time-resolved fluoroimmunometric assay (AutoDELFIA 
hTSH Ultra Kit, Perkin Elmer/Wallac, Turku, Finland). Serum free T4 (FT4) and serum free T3 
(FT3) were determined using the AutoDELFIA FT4 and FT3 kits (Perkin Elmer/Wallac, Turku, 
Finland). Twin pairs were analyzed within the same run. Total T4 (T4), total T3 (T3) and reverse 
rT3 (rT3) were measured with in-house RIA’s (6, 13).
Genotyping 
DNA was isolated from peripheral leukocytes according to standard procedures. The D1-
C785T (rs11206244) and D1-A1814G (rs12095080) polymorphisms were determined by 
5’fluorogenic Taqman assays. For both polymorphisms, we used Assays-by-Design (www.
appliedbiosystems.com). PCR cycling reactions were performed in 384 wells format in a 2 μl 
reaction volume on an ABI 9700 PCR system (Applied Biosystems Inc., Foster City, CA, USA). 
Results were analyzed by the ABI Taqman Prism 7900HT using the sequence detection system 
2.22 software (Applied Biosystems). 
Plasmids and construction of D1-C785T and D1-A1814G variant
Human D1 inserted in the pCDM plasmid (pCDM-hD1) was kindly provided by Drs Antonio 
C. Bianco and Ann Marie Zavacki (Brigham and Women’s Hospital, Harvard Institutes of Medi-
cine, Boston, MA).  This clone was shuttled into pcDNA3 (Invitrogen, Breda, The Netherlands) 
using HindIII and NotI restriction sites. 
The C785T and A1814G polymorphisms were introduced in the D1 cDNA as follows: a PCR 
reaction was performed on DNA of subjects wild-type or homozygous variant for either one 
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of the polymorphisms with forward primer GGAATGCCTGATTCGTTCTC and AGATCACACG-
GAAGCCATC as reverse primer, generating a PCR-product of 1207 bp. This PCR-fragment was 
exchanged with part of the D1 cDNA in pcDNA3 via XcmI en NotI. The constructs were fully 
sequenced on an automated ABI 3100 capillary sequencer, using the Big Dye terminator cycle 
sequencing method (Applied Biosystems). These plasmids are devoid of regulatory elements 
involved in the regulation of D1 expression by cell- and tissue-specific factors. pcDNA3-
hMCT8 was constructed as previously described (14).
Cell culture
JEG3 cells were cultured in 6 or 24-well dishes (Corning, Schiphol, The Netherlands) with 
DMEM/F12 medium (Invitrogen), containing 9% heat-inactivated fetal bovine serum (Invitro-
gen) and 100 nM sodium selenite (Sigma, Zwijndrecht, The Netherlands).
mRNA stability assays
JEG3 cells were cultured in 6-well dishes and transfected with 500 ng wild-type or variant D1. 
After 48 h culturing, cells were put on fresh medium with 7.5 μl/ml actinomycin D (Sigma). 
Cells were harvested 0, 8 and 24 h after addition of actinomycin D. Subsequently, cells were 
washed with PBS and RNA was isolated using the high pure RNA isolation kit (Roche Diag-
nostics, Almere, The Netherlands). For cDNA synthesis 500 ng RNA and TaqMan RT reagents 
(Roche Diagnostics) were used in a total volume of 50 µl. 
Two µl cDNA was used for real-time PCR on the ABI Prism 7700 sequence detection system 
(Applied Biosystems). Real-time PCRs were performed as described previously (15). 
rT3 metabolism assay
[125I]rT3 was purchased from Perkin Elmer (Boston, USA) and unlabeled rT3 from Henning 
GmbH (Berlin, Germany). FuGENE6 transfection reagent was obtained from Roche Diagnos-
tics (Indianapolis, USA).  
JEG3 cells were cultured in 24-well dishes and transfected with 1) 100 ng pcDNA3-hMCT8 
and 100 ng empty vector, or 2) 100 ng pcDNA3-D1, D1-785T or D1-1814G plus 100 ng 
pcDNA3-MCT8. After 48 h culturing, cells were incubated for 4 h at 37 C with 1 nM [125I]rT3 
in 0.25 ml Dulbecco’s PBS with 0.1% BSA and 0.1% glucose. After incubation, medium was 
harvested and analyzed by HPLC as described previously (14).
Statistical analysis
Data were analyzed using STATA statistical software (STATA Corporation, College Station, TX) 
and SPSS 10.1.0 for Windows (SPSS inc., Chicago, IL). P values are two-sided throughout and 
were considered significant if P < 0.05. If not stated otherwise, results are displayed as mean 
± SD. For the polymorphisms, deviation from Hardy-Weinberg equilibrium proportions was 
analyzed using a Chi-square test. The program PHASE was used for reconstructing haplotypes 
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from the genotype data (16). The haplotype alleles were defined as “C-A” representing a C 
nucleotide for the C785T polymorphism and an A nucleotide for the A1814G polymorphism. 
Haplotype alleles were coded as haplotype numbers 1 through 4 in order of decreasing 
frequency in the population. 
Associations between the polymorphisms, haplotypes and serum thyroid hormone levels were 
assessed using regression analysis. The statistical inference measures (i.e, p-values and CI) were 
computed using a technique (the cluster option in STATA) that takes the dependency of twin 
data into account. The genotype or haplotype information was incorporated in the regression 
analyses by coding the non-carriers as 0, heterozygous carriers as 1 and homozygote carriers 
as 2. Due to non-normal distribution of most of the serum thyroid hormone levels, these were 
transformed by the natural logarithm, and adjustment for age and gender was performed. 
In the case of significant associations between polymorphisms and serum thyroid variables, 
the proportion of the total phenotypic variance was determined as described previously (8). 
Furthermore, the effect of the polymorphisms on the heritability estimates was quantified 
by incorporating the genotype information into structural equation modeling using the Mx 
program (17, 18). To evaluate whether the (genotype) variation at the locus contributes to a 
significant fraction of the genetic variation, models including and excluding the genotype 
(non-carriers versus carriers) as a covariate in the means model were compared, using hierar-
chical likelihood ratio chi-square tests (8).
For the in vitro experiments, Mann-Whitney U-tests were used to test whether there were 
statistically significant differences between wild-type and variant D1.
results
D1 gene polymorphisms and haplotypes in healthy Danish Twins
Characteristics of the study population are shown in Table 1, together with the genotype 
data of the two polymorphisms in the D1 gene. The minor allele frequencies are similar to 
those observed in other Caucasian populations (2, 4, 19).
The D1-C785T polymorphism was in a dose-dependent manner associated with higher 
serum rT3 as well as higher serum FT4 (Table 2). In addition, carriers of the D1-785T allele had 
a lower T3/T4 ratio and T3/rT3 ratio and a higher rT3/T4 ratio. The D1-A1814G polymorphism 
showed an opposite trend towards higher serum T3, a higher T3/rT3 and a higher T3/T4 ratio, 
however the associations failed to reach significance (Table 2). Power calculations indicated 
that population was large enough to observe an effect of this polymorphism on serum thy-
roid hormone levels. For instance, we could have detected a difference in the T3/rT3 ratio of 
at least 0.17 between non-carriers and carriers of the D1-A1814G polymorphism with α at 
0.05 and β at 0.80.
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The D1-C785T and D1-A1814G polymorphisms were analyzed for linkage disequilibrium 
and haplotypes were constructed. We observed three possible haplotype alleles in this 
population in the following frequencies: haplotype 1 (C-A) 55.6%, haplotype 2 (T-A) 33.1%, 
haplotype 3 (C-G) 11.3%. Haplotype 4 (T-G) was absent in 2152 chromosomes (Fig. 1). These 
frequencies were similar to those observed in other Caucasian populations (2, 19). Haplotype 
1 (C-A) showed no association with serum thyroid hormone levels (data not shown). Hap-
Table 1: Characteristics of the population of Danish twins
Danish Twins
N 1192
Age (yrs) 36.67 ± 10.72
Gender (M/F) 601/591
TSH (mU/L) 1.56 [1.14-2.17]
FT4 (pmol/L) 12.8 [11.6-13.8]
T4 (nmol/L) 111 [100 - 127]
T3 (nmol/L) 1.84 [1.66 - 2.09]
rT3 (nmol/L) 0.35 [0.29 - 0.43]
T3/rT3 (molar ratio) 5.32 [4.36 - 6.62]
T3/T4 (molar ratio) 1.65 [1.49 – 1.81]
rT3/T4 (molar ratio) 0.31 [0.26 - 0.36]
D1-C785T wild-type (C/C) (%)
 heterozygote (C/T) (%)
 homozygote (T/T) (%)
 T-allele frequency (%)
532 (44.6)
516 (43.3)
144 (12.1)
33.7
D1-A1814G wild-type (A/A) (%)
 heterozygote (A/G) (%)
 homozygote (G/G( (%)
 G-allele frequency (%)
839 (78.0)
231 (21.5)
6 (0.5)
11.3
Data are shown as mean ± SD or as median and [interquartile range].
Table 2: Serum thyroid hormone levels by D1 genotypes in a population of Danish twins
D1-C785T Pa D1-A1814G Pa
wild-type (532) heterozygote 
(516)
homozygote 
(144)
wild-type 
(839)
carrier 
(231+6)
TSH 1.72 ± 0.89 1.82 ±0.98 1.71 ±0.89 0.41 1.72 ± 0.93 1.84 ± 0.95 0.07
T4 114.9 ± 25.3 117.4 ± 25.7 117.1 ± 23.8 0.16 116.5 ± 25.0 117.3 ± 27.1 0.75
FT4 12.67 ± 1.61 12.89 ± 1.62 13.15 ± 1.71 0.004 12.85 ± 1.65 12.72 ± 1.55 0.30
T3 1.92 ± 0.39 1.91 ± 0.41 1.87 ± 0.32 0.12 1.90 ± 0.37 1.96 ± 0.45 0.07
FT3 6.21 ± 0.86 6.18 ± 0.89 6.15 ± 0.94 0.16 6.19 ± 0.91 6.22 ± 0.83 0.55
rT3 0.35 ± 0.10 0.37 ± 0.11 0.40 ± 0.12 <0.001 0.37 ± 0.11 0.36 ± 0.11 0.33
T3/rT3 5.88 ± 1.79 5.51 ± 1.78 5.09 ± 1.72 <0.001 5.53 ± 1.73 5.85 ± 1.89 0.05
T3/T4 1.70 ± 0.27 1.65 ± 0.28 1.63 ± 0.29 <0.001 1.66 ± 0.26 1.70 ± 0.31 0.07
rT3/T4 0.31 ± 0.08 0.32 ± 0.08 0.34 ± 0.09 <0.001 0.32 ± 0.08 0.31 ± 0.08 0.20
Data are shown as mean ± SD.
a P-value for linear regression on the transformed values, adjusted for age and gender.
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Figure 1: Location of the two polymorphisms in the DIO1 gene (Chromosome 1p32-33, NM 000792) and the 
four haplotype alleles that were constructed from these polymorphisms, together with their frequencies 
in the Danish twin population. The coding region is represented by solid grey boxes, whereas dashed 
boxes indicate the untranslated regions.
Figure 2: 
 
Figure 2: Differences in FT4 and rT3 levels and rT3/T4 and T3/rT3 ratios by haplotype 2. P-values represents 
linear regression on the transformed values, adjusted for age and gender. Data are shown as mean ± SEM. 
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lotype 2 (T-A) was associated with higher serum rT3, FT4 and rT3/T4 ratio and lower T3/rT3 
ratio (Fig. 2). Only 6 subjects had 2 copies of haplotype 3 (C-G). Therefore, subjects carrying 
1 and 2 copies were combined into carriers, whereas subjects with 0 copies were defined as 
non-carriers. Carriers had lower FT4 levels (p=0.07) and higher T3/rT3 ratio (p=0.05), however 
these associations failed to reach significance. 
Quantitative genetic modeling
The use of this twin population allowed us to assess the contribution of these polymorphisms 
to the variation in serum thyroid variables. The D1-C785T polymorphism explained 0.87% 
and 1.79% of the variation in serum FT4 and rT3 respectively. 
Since D1 plays an important role in the production of T3 from T4 and in the clearance of 
rT3, we expect polymorphisms in D1 to affect not only serum thyroid hormone levels, but 
in particular ratios between serum iodothyronines, such as the T3/rT3 ratio. The D1-C785T 
explained 1.48% and 2.50% of the variation in rT3/T4 and T3/rT3 ratios (Table 3). In addition, 
1.24% of the variation in the T3/T4 ratio is accounted for by the D1-C785T polymorphism.
Since the associations between D1-A1814G and serum thyroid variables failed to reach 
significance, we refrained from calculating heritability estimates for this polymorphism.
mRNA stability of D1 variants
To analyze the underlying functional mechanism, we performed mRNA degradation rate 
measurements after blocking transcription with actinomycin D, as these polymorphisms in 
the 3’UTR might alter D1 mRNA stability.  Transfected JEG3 cells were treated with actinomy-
Table 3: Heritability estimates with and without adjustment for the D1-C785T polymorphism
Phenotype Number of 
individuals
Variation 
explained
(%)
Heritability
Estimatea
Heritability estimatea
adjusted for D1-
C785T
polymorphism
P-valueb
lnTSH 1192 0.6796 (0.61 - 0.73) 0.6795  (0.61 - 0.73) 0.36
ln Free T4 1192 0.87% 0.5979  (0.52 - 0.66) 0.5923  (0.58 - 0.59) 0.005
lnFree T3 1192 0.5845  (0.50 - 0.65) 0.5846 (0.50 - 0.65) 0.10
ln T4 1190 0.6087  (0.54 - 0.67) 0.6087 (0.54 - 0.67) 0.21
lnT3 1190 0.6044  (0.53 - 0.67) 0.6029  (0.53 - 0.67) 0.24
ln rT3 1190 1.79% 0.6658  (0.61 - 0.67) 0.6592  (0.60 - 0.71) <0.001
lnT3rT3 ratio 1190 2.50% 0.7108 (0.66 - 0.76) 0.7027  (0.64 - 0.75) <0.001
lnT3T4 ratio 1190 1.24% 0.6154 (0.61 - 0.62) 0.6092  (0.60 - 0.61) <0.001
ln rT3/T4 ratio 1190 1.48% 0.7011 (0.64 -  0.73) 0.6956  (0.64 - 0.74) 0.001
a The proportion of the total variance attributable to total additive genetic variance. All heritability 
estimates are adjusted for age and gender
b Tested using a likelihood ratio chi-square test with 1 degree of freedom. The difference between minus 
twice the log-likelihood for a reduced model (in which the effect of the genotype is set to zero) and that 
of the full model (including genotype information) is approximately chi-square distributed.
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cin D for 0, 8 or 24 h.  There were no significant differences in D1 mRNA levels between cells 
transfected with wild-type D1, D1-785T or D1-1814G cDNA (data not shown).  In addition, 
there was little or no difference in D1 mRNA half-life between wild-type D1 and either one of 
the variants (Fig. 3). 
rT3 metabolism by D1 variants
In addition to the mRNA stability experiments, we attempted to mimic in vivo D1 metabolism. 
Since the active site of D1 is located intracellulary (1), iodothyronines need to be transported 
across the plasma membrane for subsequent metabolism by D1. Therefore, JEG3 cells were 
co-transfected with MCT8 (14), an active thyroid hormone transporter which is also expressed 
in the liver, together with cDNA encoding for wild-type or variant D1. Subsequently, cells 
were incubated with [125I]rT3 and analyzed for metabolism.
Cells transfected with MCT8 alone did not show significant metabolism of rT3 (data not 
shown). Co-transfection of cells with D1 and MCT8 greatly increased rT3 metabolism. How-
ever, no differences in rT3 metabolism were observed between wild-type D1, D1-785T or 
D1-1814G (Fig. 4).
Figure 3 
 
 
Figure 3: Decay rate of  D1 mRNA levels after 0, 8 and 24 h of actinomycin D treatment. mRNA levels at 0 h 
are set at 100%. (100% corresponds to Ct-values ± SD of 18.97 ± 0.64 for D1-WT, 18.65 ± 0.56 for D1-785T 
and 19.84 ± 0.52 for D1-1814G respectively). Results are means ± SEM of three independent experiments. 
There was no significant difference in decay rate of wild-type D1, D1-785T or D1-1814G. 
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Discussion
Our study show that genetic variation in the D1 gene alters serum thyroid hormone levels in 
a cohort of healthy Danish twins. The D1-C785T polymorphism in particular was consistently 
and significantly associated with serum FT4, rT3, T3/rT3, T3/T4 and rT3/T4 ratios. Moreover, 
we have quantitated the proportion of genetic variation in serum thyroid variables accounted 
for by this polymorphism and analyzed the underlying functional mechanism.  
D1 plays an important role in the conversion of T4 to T3. However, rT3 is the preferred sub-
strate, reflecting the important role of D1 in the degradation of thyroid hormone (1). There-
fore, one would expect polymorphisms in D1 to be associated with rT3 levels and to some 
extent also with T3 and T4 levels. In healthy Danish twins, carriers of the D1-C785T indeed 
had 3.8% higher FT4 levels than non-carriers, however T4 levels were not significantly differ-
ent between wild-type and carriers of this polymorphism, probably reflecting differences in 
TBG in this population of both men and women. Carriers of the D1-C785T polymorphism had 
14.3 % higher rT3. In addition, the D1-785T allele was associated with a lower T3/rT3 and T3/
T4 ratio, whereas the rT3/T4 ratio was higher in carriers of the T allele. These findings are not 
only consistent with the physiological role of D1, but also with previous findings regarding 
this polymorphism and clearly minimize the risk of a false positive finding (2, 4, 19). 
Figure 4: 
 Figure 4: [125I]rT3 metabolism by JEG3 cells transfected with wild-type D1, D1-785T or D1-1814G, together 
with MCT8.  Cells were incubated for 4 h at 37 C with 1 nM [125I]rT3.  Metabolism is shown as percentage 
of metabolites in the medium.  100% metabolism corresponds to complete conversion of 1 nM [125I]rT3 
into [125I]T2 and/or [125I]I-.  Results are the means ± SEM of three experiments.  There were no significant 
differences in metabolism between wild-type D1, D1-785T and D1-1814G.
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Although the D1-C785T polymorphism was consistently and significantly associated with 
serum thyroid hormone levels, our results also demonstrate that the proportion of genetic 
influence explained by this particular polymorphism is small. For instance, the D1-C785T 
polymorphism explained only 0.87% of the variation in serum FT4 levels. Thus, a substantial 
proportion of genetic variation, not accounted for by this polymorphism, still exists. This 
clearly suggests that multiple loci are involved in the control of serum thyroid variables. This 
is in agreement with the general notion that single polymorphisms usually have a subtle 
effect, while clinically significant effects generally result from many genes each contributing 
only slightly to the variance. Moreover, such a multi-gene organization may be regarded as 
an advantage for the overall control of thyroid homeostasis, which is tightly regulated and 
under this scenario not as vulnerable to genetic mutations when a few polymorphisms had 
a strong genetic impact. 
Differences in ratios of serum iodothyronines might better reflect the effect of polymor-
phisms in D1 than differences in serum thyroid variables themselves (3). Serum thyroid 
hormone levels depend not only on the activities of the different deiodinases, but also on 
thyroid function and serum thyroid hormone-binding capacity. Because of the confounding 
effect of variable concentrations of thyroid hormone-binding proteins, the ratios of serum 
iodothyronines most accurately reflect the activity of the different deiodinases (20). For 
instance, a low D1 activity will result in reduced T3 production and rT3 clearance, and will 
thereby give rise to a lower T3/rT3 ratio. It is, therefore, interesting to note that the D1-C785T 
polymorphism explained 2.50% of the variation in T3/rT3 ratio, while the variation explained 
in T3/T4 ratio was relatively lower with 1.24%. This indicates that D1 expression has a larger 
impact on the serum T3/rT3 ratio than on the T3/T4 ratio, which is understandable in view of 
the quantitatively more important role of D1 in rT3 than in T4 metabolism. 
The D1-A1814G polymorphism was not, or only borderline, significantly, associated with 
serum thyroid variables. Since this polymorphism is partially linked to D1-C785T, we per-
formed haplotype-based analyses to determine which variant drives the associations. Only 
haplotype 2, i.e., D1-785T/1814A, was significantly associated with serum thyroid hormone 
levels, which demonstrates that D1-C785T is driving the associations and, undoubtedly, has 
a greater effect on serum thyroid hormone concentrations than the D1-A1814G polymor-
phism. This has been determined in different populations, including those recently reported 
by Panicker et al (2, 4, 21). 
Since the D1-C785T and D1-A1814G polymorphism are located in the 3’UTR of the D1 
mRNA, we hypothesized that these polymorphisms might influence D1 mRNA levels. For 
instance, Fang et al. have demonstrated that polymorphisms located in the 3’UTR of the 
vitamin D gene result in lower mRNA levels and increased mRNA decay rate (9). Therefore, 
we studied D1 mRNA stability in D1-transfected JEG3 cells, which were treated for 0, 8 or 24 
h with actinomycin D. Although actinomycin D effectively reduced D1 mRNA levels after 24 
hrs, we did not observe differences in mRNA level or decay rate between wild-type D1 or D1 
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carrying the C785T or A1814G polymorphisms. In addition, no differences were observed 
between wild-type or variant D1 at the protein level. Reverse T3 metabolism induced by 
wild-type or variant D1, in cells co-transfected with the thyroid hormone transporter MCT8 
(14) was virtually identical. Since we did not observe any differences between wild-type and 
variant D1, this might suggest that these polymorphisms are linked to another functional 
polymorphism elsewhere in the DIO1 gene.  However, no polymorphisms in Hapmap (www.
hapmap.org) in the coding region of the DIO1 gene are in high linkage disequilibrium with 
our polymorphisms.  Our polymorphisms could also be linked to variants located in the 
promoter region or in intronic regions of the DIO1 gene. The latter may affect the splicing of 
the D1 transcript, and a variety of D1 splice variants have been documented (www.ncbi.nlm.
nih.gov). Alternatively, the risk alleles of these 3’UTR polymorphisms might alter the binding 
sites of microRNA’s, and thereby inhibit translation initiation or promote degradation of D1 
mRNA (22, 23). However, both the C785T and the A1814G polymorphism did not interfere 
with predicted microRNA target sites in the 3’UTR of the DIO1 gene (www.microRNA.org). 
Therefore, the mechanism underlying the association between the 3’UTR polymorphisms 
and D1 function remains to be established. 
In conclusion, the D1-C785T polymorphism is consistently and significantly associated with 
serum thyroid hormone levels. However, the proportion of genetic influence explained by 
this particular polymorphism is small. No effect of the polymorphism on D1 mRNA levels, D1 
mRNA decay rate or D1 activity was observed. The underlying functional mechanism needs 
to be elucidated, but might be explained by linkage to another polymorphism elsewhere in 
the DIO1 gene. 
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abstract
introduction: Thyroid function and genetic variation in the hypothalamic-pituitary-thyroid 
axis have been implicated in blood pressure regulation and susceptibility to hypertension. 
However studies conducted thus far were small with controversial results. 
objective: To examine whether serum thyroid parameters and polymorphisms in the type 
2 deiodinase and the TSH receptor are associated with blood pressure and the presence of 
hypertension in two large cohorts of elderly subjects. 
Design and participants: We studied a random sample of 1444 subjects of the Rotterdam 
study, and 997 subjects of the Rotterdam Scan study, two population-based cohort studies 
among elderly individuals aged 55-90 years.
outcome measurements: Data on blood pressure and hypertension were obtained, and 
serum thyroid parameters, D2-Thr92Ala, D2-ORFa-Gly3Asp and TSHR-Asp727Glu polymor-
phisms were determined. 
results: In contrast to previous findings, no consistent and/or significant associations were 
found between serum TSH and FT4 and blood pressure in both cohorts. In addition, the D2-
Thr92Ala, D2-ORFa-Gly3Asp and TSHR-Asp727Glu polymorphisms were not associated with 
blood pressure or the risk of hypertension.  
conclusions: In two large populations of elderly subjects, neither serum thyroid parameters 
nor polymorphisms in the type 2 deiodinase and the TSH receptor, were associated with 
blood pressure or the presence of hypertension. Our data suggest that thyroid function is 
not an important determinant of hypertension in elderly Dutch subjects.
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introDuction
Adequate levels of thyroid hormone are essential for the regulation of many metabolic 
processes throughout life. Clinical manifestations of thyroid hormone excess, such as atrial 
fibrillation, illustrate the important role of thyroid hormone on the heart and vascular system 
(1). On the cellular level, triiodothyronine (T3) affects the heart via binding to nuclear T3 
receptors in cardiomyocytes, thereby altering the transcription rate of T3-responsive genes, 
such as myosin heavy chains α and β. Additionally, T3 decreases vascular resistance via dilata-
tion of arterioles of the peripheral circulation (1). This leads to a high cardiac output with 
enhanced systolic and diastolic function and low systemic vascular resistance in patients 
with hyperthyroidism. Hypothyroidism, on the contrary, is associated with decreased cardiac 
output, impaired systolic and diastolic function and increased systemic vascular resistance 
(1). In addition, vascular smooth muscle cells and endothelium play an important role in 
modulating vascular tone. Both are potential targets of thyroid hormone action and may be 
altered in the elderly (1).
Over the last years, several epidemiological studies have associated thyroid function with 
the occurrence of hypertension (2-4). In most cases, a positive association was found between 
thyroid stimulating hormone (TSH) and blood pressure in euthyroid subjects (2-4), although 
the relationship between subclinical thyroid disease and blood pressure is less clear-cut (5-8). 
More recently, genetic variation in the hypothalamic-pituitary-thyroid axis has been linked to 
susceptibility to hypertension (9, 10). The Thr92Ala polymorphism in the type 2 deiodinase 
(D2), which locally converts the pro-hormone T4 to the biological active T3, has been linked 
to blood pressure (10). This was, however, not confirmed in another study (11). Both studies 
were carried out in relatively small cohorts (n = 372, and n = 315 respectively) (10, 11). 
We analyzed in two large cohorts of elderly subjects (n=1444 in the Rotterdam Study and 
n=997 in the Rotterdam Scan Study) whether serum TSH and free T4 (FT4) are associated 
with blood pressure and hypertension. Since previous genetic studies were carried out in 
relatively small cohorts, we also studied whether genetic variation in D2 and the TSH receptor 
(TSHR) is a determinant of hypertension susceptibility in these large populations. 
subJects anD MetHoDs
Study populations
The Rotterdam Study is a population-based, prospective cohort study on chronic and dis-
abling diseases in the elderly. A total of 7983 men and women, aged 55 years and over living 
in a district of Rotterdam, agreed to participate (12). In a random sample of 1544 subjects, 
serum levels of TSH and FT4 were determined. Of these, 1444 were included in the present 
study. Exclusion criteria were the use of thyroid medication (n=34) or missing information on 
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blood pressure, body mass index (BMI) or the use of anti-hypertensive medication (n=17). In 
addition, 49 subjects were excluded based on serum FT4 levels indicating clinical hypo- or 
hyperthyroidism (FT4 < 11.0 or > 25.0 pmol/L). 
The Rotterdam Scan Study is an ongoing prospective population-based cohort study 
designed to investigate causes and consequences of age-related brain changes on MRI 
(13). In 1995 and 1996, subjects were randomly selected, in strata of sex and 10-years age 
groups, from the population-based Zoetermeer and Rotterdam studies (14, 15). Out of the 
1077 individuals who participated, 997 were eligible for analysis in this study. Subjects were 
excluded when they were on thyroid medication (n=23) or had serum levels indicating hypo- 
or hyperthyroidism (n=46). Furthermore, 11 subjects had missing data on blood pressure, the 
use of anti-hypertensive medication or BMI.
The Rotterdam Study and the Rotterdam Scan Study were approved by the Medical Ethics 
Committee of Erasmus University Medical School and written informed consent was obtained 
from all participants. 
Anthropometric and blood pressure measurements 
For both cohorts, anthropometric measurements were obtained at the research center. BMI 
was calculated as weight in kilograms divided by height in meters squared. Blood pressure 
was measured twice with a random-zero sphygmomanometer with appropriate adult cuff size 
and the participant in sitting position. The average of 2 measurements was used for analyses. 
Pulse pressure was calculated as systolic blood pressure minus diastolic blood pressure. 
Information on the use of blood pressure-lowering medication and thyroid medication was 
obtained during a home interview. In both cohorts, hypertension was defined as a systolic 
blood pressure of 160 mm Hg or higher, a diastolic blood pressure of 100 mm Hg or higher or 
the use of blood pressure-lowering medication (16). 
Thyroid hormone measurements
In the Rotterdam Study, TSH levels were measured with TSH Lumitest (Henning, Berlin, Ger-
many). In the Rotterdam Scan Study, serum TSH was measured by a chemoluminescence as-
say (Vitros, ECI Immunodiagnostic System, Ortho-Clinical Diagnostics, Amersham, UK). Serum 
FT4 and T3 was measured by a chemoluminescence assay (Vitros).  T3 was only determined 
in the Rotterdam Scan Study.
Genotyping
DNA was isolated from peripheral leukocytes according to standard procedures. Participants 
were genotyped for the D2-Thr92Ala (rs225014), the D2-ORFa-Gly3Asp (rs12885300) and 
the TSHR-Asp727Glu (rs1991517) polymorphisms. Genotypes were determined using the 
Taqman allelic discrimination assay (Assays-by-Design, www.appliedbiosystems.com). PCR 
cycling reactions were performed in 384 wells format in a 2 μl reaction volume on an ABI 
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9700 PCR system (Applied Biosystems Inc., Foster City, CA, USA). Results were analyzed by 
the ABI Taqman Prism 7900HT using the sequence detection system 2.22 software (Applied 
Biosystems). Five percent of samples were re-genotyped for assessment of genotyping ac-
curacy. No inconsistencies were observed. 
In the Rotterdam Study, DNA was available for genotyping in 1341 out of 1444 subjects. 
The genotyping success rate was 98.7% for D2-Thr92Ala, 99.1% for D2-ORFa-Gly3Asp and 
98.0% for TSHR-Asp727Glu. In the Rotterdam Scan Study, DNA was available in 974 out of 
997 subjects. Genotyping for D2-Thr92Ala failed in 4 subjects and for TSHR-Asp727Glu in 1 
subject.
Statistical analysis
Data were analyzed using SPSS 10.0.7 for Windows (SPSS, Inc., Chicago, IL).    P values are 
two-sided throughout and were considered significant if P < 0.05. For the polymorphisms, 
deviation from Hardy-Weinberg equilibrium proportions was analyzed using a Chi-square 
test. Linkage disequilibrium was assessed via the Haploview program (17). Haplotypes were 
constructed by the PHASE program (18).
Baseline characteristics between normotensive and hypertensive subjects were compared 
by χ2 test or by analysis of variance, adjusted for age, gender and BMI if necessary. Age, gender 
and BMI adjusted odds ratios with their 95% confidence intervals (CI), were calculated using 
logistic regression analysis with hypertension as the dependent variable and serum TSH, FT4 
or one of the polymorphisms as the independent variable.  For both cohorts, serum TSH and 
FT4 were categorized into quintiles. The highest quintile of serum TSH and the lowest quintile 
of serum FT4 were used as reference category.
All subjects on blood pressure-lowering therapy were excluded for the analyses of the 
association of serum thyroid parameters and polymorphisms with blood pressure (n=432 
in the Rotterdam Study and n=337 in the Rotterdam Scan Study). Serum TSH and FT4 were 
categorized into quintiles and linear regression analyses, adjusted for age, gender and BMI, 
were performed. For the polymorphisms, genotype-related differences were adjusted for 
age, gender and BMI and tested by analysis of covariance (ANCOVA). 
results
The characteristics of both populations are shown in Table 1. Participants of the Rotterdam 
Study were on average 4 years younger than the participants of the Rotterdam Scan Study. 
In the Rotterdam Study almost 60 % was female, while in the Rotterdam Scan Study there 
was a one-to-one sex ratio. The allele frequencies of the polymorphisms were similar be-
tween the two populations and similar to those reported in other Caucasian populations 
(19, 20). 
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Serum thyroid parameters and blood pressure
Table 2 shows the differences in characteristics between hypertensive and normotensive 
subjects. Subjects who are using antihypertensive drugs are included in the group of hy-
pertensive subjects. In both populations, subjects with hypertension were older and had a 
higher BMI than normotensive subjects. 
Since serum TSH was positively associated with BMI and serum FT4 was inversely associated 
with BMI in our and other cohorts (21-23), and obese subjects were more prevalent in the 
hypertensive group, we adjusted for age, gender and BMI in the analysis of thyroid param-
eters and hypertension. In the Rotterdam Study, subjects with hypertension had significantly 
higher serum FT4 levels than normotensive subjects (Table 2). In addition, the prevalence of 
hypertension was increased in subjects with the highest FT4 levels (Table 3). 
Several antihypertensive drugs (i.e. β-blockers and diuretics) are known to influence serum 
thyroid parameters (24, 25). For instance, diuretics are capable of binding to thyroid hormone-
binding proteins and may thus interfere in FT4 assays (25). Therefore, we also performed 
an analysis after exclusion of all subjects on anti-hypertensive treatment (432 subjects from 
the Rotterdam Study and 337 participants from the Rotterdam Scan Study were excluded). 
Then, the prevalence of hypertension was not increased in subjects with the highest FT4 
Table 1: Baseline characteristics of the Rotterdam Study and the Rotterdam Scan Study
Characteristic Rotterdam Study Rotterdam Scan Study
N 1444 997
Age (years) 68.84 ± 7.57 72.04 ± 7.33
Gender (female, %) 876 (60.7) 505 (50.7)
BMI (kg/m2) 26.36 ± 3.57 26.67 ± 3.57
SBP (mm Hg) 138 ± 21 147 ± 22
DBP (mm Hg) 73 ± 11 79 ± 12
FT4 (pmol/L) 16.31 ± 2.66 17.75 ± 2.75
T3 (nmol/L) - 2.02 ± 0.42
TSH (mU/L) 1.51 [0.99-2.30] 1.16 [0.73-1.76]
D2-Thr92Ala wild-type
 heterozygote
 homozygote
 Ala-allele frequency
 HWE p-value
521 (40.1)
634 (47.4)
169 (12.5)
36.7%
0.27
376 (38.8)
459 (47.3)
135 (13.9)
37.6%
0.79
D2-ORFa-Gly3Asp wild-type
 heterozygote
 homozygote
 Asp-allele frequency
 HWE p-value
533 (39.4)
630 (47.9)
166 (12.8)
36.2%
0.34
414 (42.5)
437 (44.9)
123 (12.6)
35.1%
0.65
TSHR-Asp727Glu wild-type
 heterozygote
 homozygote
 Glu-allele frequency
 HWE p-value 
1145 (87.1)
166 (12.6)
3 (0.2)
6.5%
0.24
820 (84.3)
149 (15.3)
4 (0.4)
8.1%
0.31
Data are shown as mean ± SD, or median [IQR] or as n, (%).
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levels (data not shown). In addition, no relation was observed between serum FT4 and blood 
pressure (Fig. 1A). Serum FT4 levels were, however, higher in participants on diuretic therapy 
compared to subjects with other anti-hypertensive treatment (subjects on diuretics vs. sub-
jects on other anti-hypertensive treatment: 17.04 ± 0.21 vs. 16.37 ± 0.18 pmol/L, P=0.015).
In the Rotterdam Scan Study, similar associations were found between serum FT4 and 
blood pressure, however these failed to reach significance (Table 2, 3, Fig. 1B). No associations 
were found between serum TSH and blood pressure in both cohorts (Table 2, 3, Fig. 1). In 
addition, no associations were found between serum TSH and FT4 and pulse pressure, which 
is recognized as an independent risk factor for cardiovascular disease (data not shown) (26). 
Triiodothyronine (T3), the active thyroid hormone, may have a more prominent role in the 
cardiovascular system than FT4 or TSH. However, serum T3 was not different between normo-
tensive and hypertensive subjects of the Rotterdam Scan Study. In addition, no associations 
were found between serum T3 and the risk of hypertension (data not shown). 
Table 2: Comparison between subjects with and without hypertension in the Rotterdam Study and the 
Rotterdam Scan Study
        rotterdam study
Hypertensive (575) Normotensive (869) P
Age (years) 70.75 ± 7.39 67.58 ± 7.44 <0.001
Gender (female, %) 363 (63.1) 513 (59.0) 0.12
BMI (kg/m2) 27.30 ± 3.57 25.74 ± 3.43 <0.001
SBP (mmHg) 150 ± 23 131 ± 16 <0.001
DBP (mmHg) 77 ± 11 71 ± 10 <0.001
FT4 (pmol/L) 16.59 ± 2.77 16.13 ± 2.57 0.001b
TSH (mU/L)a 1.62 [1.00-2.46] 1.46 [0.98-2.21] 0.19b
Use of anti-hypertensive 
medication (N)
432 0 <0.001
        rotterdam scan study
Hypertensive (502) Normotensive (495) P
Age (years) 73.66 ± 7.35 70.40 ± 6.95 <0.001
Gender (female, %) 265 (52.8) 240 (48.5) 0.17
BMI (kg/m2) 27.37 ± 3.63 26.10 ± 3.35 <0.001
SBP (mmHg) 159 ± 22 136 ± 14 <0.001
DBP (mmH) 82 ± 13 75 ± 9 <0.001
FT4 (pmol/L) 17.88 ± 2.78 17.62 ± 2.71 0.25b
T3 (nmol/L) 2.01 ± 0.28 2.03 ± 0.53 0.62b
TSH (mU/L)a 1.24 [0.73-1.78] 1.11 [0.74-1.74] 0.85b
Use of anti-hypertensive 
medication (N)
337 0 <0.001
Data are shown as mean ± SD, or median [IQR] or as n, (%).
a Due to non-normal distribution, TSH is transformed by the natural logarithm.
b Data are corrected for age, gender and BMI.
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D2-Thr92Ala, D2-ORFa-Gly3Asp, TSHR-Asp727Glu, serum thyroid parameters and blood pressure
In both cohorts, serum TSH and FT4 were not different between wild-type, heterozygous or 
homozygous subjects for the D2-Thr92Ala and D2-ORFa-Gly3Asp polymorphisms, in line with 
previous findings in populations of elderly Caucasians (10, 20, 27) (data not shown). No dif-
ferences in serum FT4 were observed between wild-type and carriers of the TSHR-Asp727Glu 
polymorphism. However, carriers of the TSHR-Glu727 allele had lower serum TSH levels than 
non-carriers (wild-type vs. carriers: 1.42 ± 0.04 vs. 1.36 ± 0.09 mU/L, P=0.06) (23). 
Although the presence of hypertension was increased in an allele-dose dependent man-
ner for the D2-ORFa-Gly3Asp polymorphism in the Rotterdam Scan Study, this same effect 
was not observed in the Rotterdam Study. In addition, risk of hypertension did not differ 
Chapter 9, eerste deel figuur 1A 
Tweede deel figuur 1A 
Figure 1A:  Mean systolic and diastolic blood pressure (with SE) by categories of TSH and FT4, adjusted for 
age, gender and BMI in the Rotterdam Study 
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by D2-Thr92Ala and TSHR-Asp727Glu genotype (Table 4). After exclusion of all subjects on 
blood pressure-lowering treatment, no associations between the polymorphisms and blood 
pressure were found (data not shown).
We analyzed the D2-Thr92Ala and D2-ORFa-Gly3Asp polymorphisms for linkage disequilib-
rium. In both cohorts, the D’ was ~0.8 and frequency estimates of the 4 different haplotype 
alleles were similar to those reported in other Caucasian populations (20) (Fig. 2A and 2B). For 
the haplotypes, results of the association analyses were similar to those of the D2-Thr92Ala 
and D2-ORFa-Gly3Asp polymorphisms separately as the variant alleles are most often 
assigned to separate haplotypes (e.g. the Asp3 allele to haplotype 2 and the Ala92 allele to 
haplotype 3).
Tweede deel Figuur 1B 
 
Figure 1B:  Mean systolic and diastolic blood pressure (with SE) by categories of TSH and FT4, adjusted for 
age, gender and BMI in the Rotterdam Scan Study
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Discussion
In this study we found no consistent associations between serum thyroid parameters and 
genetic variation in D2 and TSHR and blood pressure in two large populations of elderly 
Caucasians. 
The cardiovascular system is a target organ for thyroid hormone action, which is apparent 
by the marked changes in cardiac function in patients with hypo-or hyperthyroidism. Serum 
TSH is positively associated with blood pressure in several population-based cohort stud-
ies (3, 4), although the associations observed were modest, with a rise of about 6 mmHg in 
systolic blood pressure within the reference range of serum TSH (3, 4) and the populations 
studied were large: Asvold and colleagues studied almost 35,000 subjects, while Iqbal et al. 
analyzed approximately 6,000 subjects of the Trømso study (3). The relationship between 
subclinical thyroid disease and blood pressure is less straightforward. Several reports have 
found significant associations between subclinical hypo- and hyperthyroidism and blood 
Table 3: Odds ratio of hypertension by TSH and FT4 quintiles in the Rotterdam Study and the Rotterdam 
Scan Study
rotterdam study rotterdam scan study
tsH quintiles (mu/l) or (95% ci) tsH quintiles (mu/l) or (95% ci)
1 (0.01-0.90) 0.75 (0.53-1.07) 1 (0.01-0.65) 1.10 (0.73-1.66)
2 (0.90-1.30) 0.82 (0.58-1.16) 2 (0.65-0.98) 0.72 (0.47-1.09)
3 (1.30-1.78) 0.73 (0.51-1.03) 3 (0.98-1.37) 0.89 (0.59-1.35)
4 (1.78-2.56) 0.85 (0.60-1.21) 4 (1.37-1.96) 0.96 (0.63-1.45)
5 (2.56-12.48) Reference 5 (1.96-11.90) Reference
Ptr = 0.13 Ptr = 0.83
ft4 quintiles (pmol/l) or (95% ci) ft4 quintiles (pmol/l) or (95% ci)
1 (11.0-14.0) Reference 1 (11.0-15.3) Reference
2 (14.0-15.3) 0.78 (0.54-1.11) 2 (15.3-16.9) 1.01 (0.67-1.52)
3 (15.3-16.7) 0.94 (0.66-1.34) 3 (16.9-18.4) 1.18 (0.78-1.78)
4 (16.7-18.5) 1.19 (0.84-1.68) 4 (18.4-20.2) 1.17 (0.78-1.77)
5 (18.5-25.0) 1.52 (1.07-2.15) 5 (20.2-25.0) 1.15 (0.76-1.74)
Ptr = 0.002 Ptr = 0.36
no t3 data available t3 quintiles (nmol/l) or (95% ci)
1 (1.35-1.81) Reference
2 (1.81-1.94) 0.77 (0.51-1.16)
3 (1.94-2.05) 1.12 (0.74-1.70)
4 (2.05-2.18) 0.95 (0.62-1.44)
5 (2.18-12.68) 1.02 (0.67-1.55)
Ptr = 0.60
Data were adjusted for age, gender and BMI.
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pressure (n=3233) (28, 29), whereas others have not been able to confirm this (n=2000, 
n=883, n=1510) (6-8). 
In the Rotterdam Study, serum FT4 was significantly higher in hypertensive than normo-
tensive subjects. Similarly, subjects in the highest FT4 quintile had a two-fold increased 
prevalence of hypertension compared to those in the lowest quintile. However, this effect 
disappeared after exclusion of subjects on antihypertensive treatment. Moreover, we could 
not confirm our findings between serum FT4 and blood pressure in the Rotterdam Scan 
Study. In addition, no consistent associations were found between serum TSH or T3 and blood 
pressure. However, it should be noted that with regard to serum TSH there was a difference in 
median TSH between the two populations, due to the use of different assays, which makes it 
more difficult to interpret the data.   
Several factors might explain the discrepancy between our findings and previously 
published reports. First of all, the participants of the Rotterdam Study and the Rotterdam 
Scan Study had an average age of 68 and 72 years respectively. Since it is well known that 
blood pressure rises with increasing age (30, 31),  it could well be that age has a much more 
pronounced effect on blood pressure than serum thyroid parameters in our study. Secondly, 
serum thyroid hormone levels were associated with BMI. Since obese subjects had a higher 
risk of hypertension, we adjusted for BMI in our analysis of serum thyroid parameters. How-
ever, only in some of the studies, the results were adjusted for BMI (2-4). Finally, the associa-
tion between serum thyroid parameters and blood pressure appears to be quite modest (4). 
Table 4: Odds ratio of hypertension by D2-Thr92Ala and D2-ORFa-Gly3Asp genotype
Rotterdam Study Rotterdam Scan Study
cases/subjects or (95% ci) cases/subjects or (95% ci)
D2-Thr92Ala
Wild-type 211/521 Reference 193/376 Reference
Heterozygote 245/634 0.94 (0.73-1.20) 247/459 1.11 (0.83-1.48)
Homozygote 69/169 1.09 (0.75-1.57) 55/135 0.66 (0.44-1.01)
Ptrend = 0.90 Ptrend = 0.21
D2-ORFa-Gly3Asp
Wild-type 218/533 Reference 194/414 Reference
Heterozygote 239/630 0.79 (0.62-1.01) 233/437 1.29 (0.97-1.71)
Homozygote 70/166 0.94 (0.65-1.36) 68/123 1.44 (0.96-2.26)
Ptrend = 0.31 Ptrend = 0.04
TSHR-Asp727Glu
Wild-type 452/1145 Reference 417/820 Reference
Carrier 68/169 1.04 (0.74-1.47) 77/153 1.13 (1.09-1.18)
P = 0.83 P = 0.87
Data were adjusted for age, gender and BMI.
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Therefore, we cannot rule out that our populations were too small to observe such a relation-
ship. However, since we were not able to demonstrate an association between serum thyroid 
parameters and blood pressure in these two cohorts, we conclude that thyroid function 
does not seem to have a clinically relevant contribution to blood pressure in Dutch elderly. 
Moreover, if thyroid function would have an important influence on blood pressure, opposite 
associations between serum TSH and FT4 and blood pressure should be observed due to the 
tight regulation of TSH and FT4 in the hypothalamic-pituitary-thyroid axis. However, in our 
cohorts, the associations pointed in the same direction. Therefore, we believe that there is no 
thyroidal effect on blood pressure in these two populations. 
Based on the expression of D2 in the media of the aorta, human artery smooth muscle 
cells and vascular smooth muscle cells (32, 33), Gumieniak and colleagues proposed that 
polymorphisms in D2 might be associated with hypertension. Indeed, they showed that the 
Ala allele of the D2-Thr92Ala polymorphism was overrepresented in hypertensive versus 
normotensive subjects in a population of 372 subjects (10). In a study among type 2 diabetes 
mellitus patients, Canani and colleagues failed to show an association between the D2-
Thr92Ala polymorphism and hypertension in 315 participants (11). Based on these studies 
and on the expression pattern of these proteins, (10, 32, 33), we analyzed the relationship 
between polymorphisms in D2 and TSHR and blood pressure. It would have been of interest 
to study polymorphisms in D1 as well, since D1 is another important source of serum T3 in 
humans. However, D1 is not expressed in heart or aorta, nor has it previously been associated 
with blood pressure. For this reason, we focused on polymorphisms in D2 and TSHR.
In our study, no associations were found between the D2-Thr92Ala and D2-ORFa-Gly3Asp 
polymorphisms and blood pressure in two large populations of elderly Caucasians. In addi-
tion, in agreement with Gumieniak et al. we observed no significant associations between 
TSHR-Asp727Glu polymorphism and blood pressure. It should be noted that there are 
important differences between the populations we studied and the cohort of Gumieniak et 
al.  On average, the subjects in our populations were 30 years older than the participants in 
the cohort of Gumieniak et al. About 40-50% of the subjects of the Rotterdam Study and the 
Rotterdam Scan Study were hypertensive based on the World Health Organization (WHO) 
definition of hypertension (16). In the Gumieniak et al. report 82% of the participants were 
hypertensive based on criteria that were quite different from the WHO hypertension criteria 
we used. Unfortunately, we could not use the same definition for hypertension as Gumieniak 
et al. as no data on family members with hypertension were available in our cohorts.  In addi-
tion, we did not stop anti-hypertensive treatment 2 to 4 weeks before the start of the study. 
This might explain these conflicting findings. However, we could have detected a relative 
risk for hypertension for the D2-Thr92Ala polymorphism of at least 1.5 in the Rotterdam 
Study, whereas in the Gumieniak et al. report the odds ratio for hypertension in carriers of 
the D2-Ala92 allele was 2.11 compared with non-carriers (10).  Therefore, the inconsistency 
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between our data and the findings of Gumieniak et al. could be due to differences in popula-
tion characteristics, phenotype definition or chance.
In conclusion, the results of our study indicate that neither serum TSH and FT4, nor the D2-
Thr92Ala, D2-ORFa-Gly3Asp and TSHR-Asp727Glu polymorphisms are associated with blood 
pressure in euthyroid elderly Caucasians. Given the fact that there were no consistent and/or 
significant associations, our data do not support an important role for thyroid function and 
polymorphisms in thyroid hormone pathway genes in influencing blood pressure in elderly 
Dutch subjects. 
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abstract
introduction: In healthy subjects, variability in circulating concentrations of thyroid hormone 
between individuals is greater than variability in the same individual sampled repeatedly 
over time. It is estimated that approximately 65% of this variation is due to genetic factors. 
The causative genes are, however, not well established.
objective: To identify polymorphisms in known thyroid hormone pathway genes which 
influence serum TSH and FT4.
Design: We performed a pathway analysis of 67 genes involved in thyroid hormone synthesis, 
metabolism and transport using genome-wide association data of 1121 men and women of 
the Rotterdam Study. All subjects were euthyroid with negative thyroid peroxidase antibod-
ies. Association analysis was done using linear regression in PLINK, adjusted for age and 
gender.
results: For serum TSH, 2 polymorphisms located within the THRB gene showed significant 
association. In addition, 1 polymorphism in the LRP2 gene and 1 in the SCLO1B1 gene were 
also significantly associated with serum TSH. Four polymorphisms were significantly associ-
ated with serum FT4. Two were located within the DIO1 gene and 2 were located within the 
SLC7A8 gene. 
conclusions: This study has identified polymorphisms in the THRB, LRP2 and SLCO1B1 genes, 
which are associated with serum TSH levels. In addition, polymorphisms in the DIO1 and 
SLC7A8 genes are associated with serum FT4 levels. These findings provide insights into the 
molecular basis of population-based variation in serum TSH and FT4. 
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introDuction
Adequate levels of thyroid hormone are essential for normal development and growth, 
since thyroid hormone plays an important role in virtually all metabolic processes in the 
human body (1). This is clearly demonstrated in patients with thyroid hormone disorders. 
Hyperthyroidism, e.g., high serum levels of thyroid hormone, leads to symptoms such as 
palpitations, excessive sweating and weight loss (2-4). In contrast, decreased serum thyroid 
hormone levels due to hypothyroidism can result in weight gain, depression, atherosclerosis 
and hypertension (2, 5, 6). 
In healthy subjects, variability in circulating concentrations of thyroid hormone between 
individuals is greater than variation in the same individual sampled repeatedly over time. In 
addition to environmental factors such as dietary iodine intake, genetic variation plays an 
important role in the control of the hypothalamic-pituitary-thyroid axis. It is estimated that 
approximately 65% of this variation is due to genetic factors (7-9). The causative genes are, 
however, not well established. Polymorphisms in the deiodinases (10-12), TSH receptor (12, 
13), thyroid hormone transporters (14-16) have been associated with serum thyroid hormone 
levels, but their contribution to the overall variance is modest (17, 18). Recently, Panicker 
and colleagues performed a genome-wide linkage scan with 737 microsatellite markers in a 
large twin cohort (19). They identified eight chromosomal loci involved in the control of the 
pituitary-thyroid axis, but as expected from underpowered linkage scan in related subjects, 
they did not identify the actual genes explaining the variation in serum thyroid hormone 
levels. Arnaud-Lopez and colleagues recently performed a genome-wide association (GWA) 
study and demonstrated that polymorphisms in the Phosphodiesterase 8B gene are associ-
ated with serum TSH levels and thyroid function (20).
In this study we performed a focused analysis of thyroid hormone pathway genes in the 
context of a GWA study in elderly Caucasian men and women of the Rotterdam Study. We 
selected 67 genes based on their reported function in thyroid hormone synthesis, metabo-
lism and transport and associated them with serum TSH and FT4 levels. Four polymorphisms, 
of which 2 in the DIO1 gene and 2 in the SLC7A8 gene, were associated with serum FT4 
(P<0.001). For serum TSH, analyses revealed several polymorphisms in the THRB, LRP2 and 
SLCO1B1 genes with significant association. These data provide convincing evidence for 
an important role of these genes in thyroid hormone action and justify further clinical and 
biological investigation. 
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Materials anD MetHoDs
Study population
The cohort consisted of a sample of 1121 men and women from the Rotterdam Study, an 
ongoing prospective population-based cohort study, focused on chronic disabling condi-
tions of the elderly in the Netherlands. A total of 7983 men and women, aged 55 years and 
over living in a district of Rotterdam, agreed to participate (21). In a random sample of 1544 
subjects, serum levels of TSH and FT4 were determined. Of these, 1121 were included in the 
present study. Exclusion criteria were missing information on genome-wide genotype data 
and/or the use of thyroid medication (n=228). In addition, 195 subjects were excluded based 
on TPO-antibodies > 10 IU/L and/or serum FT4 levels indicating clinical hypo- or hyperthy-
roidism (FT4 < 11.0 or > 25.0 pmol/L). 
Anthropometric and thyroid hormone measurements
Anthropometric measurements were obtained at the research center. BMI was calculated as 
weight in kilograms divided by height in meters squared. Serum TSH levels were measured 
with TSH Lumitest (Henning, Berlin, Germany). Serum FT4 was measured by a chemolumines-
cence assay (Vitros). TPO-antibodies were assessed by ELISA (Milenia, DPC, Los Angeles, USA) 
and regarded as positive when greater than 10 IU/L.
Selection of candidate genes
Sixty-seven genes were selected on the basis of their reported function in thyroid hormone, 
synthesis and metabolism. This selection was made by searching NCBI Genbank for ‘thyro’ 
limited by ‘human’ and ‘current’. Via this method 520 genes were identified. Based on the 
current literature, a specialist in the field (Theo Visser) reviewed these genes and came to 
a final selection of 69 genes that were proven to be involved in thyroid hormone synthesis, 
metabolism and transport. Since our cohort consisted of both men and women, genes on the 
X-chromosome (i.e., MCT8 and TBG) were removed prior to analysis, resulting in a total of 67 
genes (Table 1).
Statistical methods
The Rotterdam Study was genotyped using the Illumina HumanHap 550K array, and qual-
ity control (QC) was performed using PLINK (22). After QC 561,466 polymorphisms (with a 
minimal sample call-rate of 97.5%) in 1121 men and women were available for analysis. After 
selecting polymorphisms with a minor allele frequency >=5%, HWE p > 1 x x10-6, a genotyp-
ing call-rate of at least 90%, and within a 10 Kb region of one of the 67 candidate genes 
(n=1297 polymorphisms), association analysis was done using linear regression in PLINK 
(22), adjusted for age and gender. Due to non-normal distribution, TSH was transformed by 
the natural logarithm. In GWA studies, analysing over 500,000 polymorphisms, a stringent 
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Table 1: Selection of candidate genes involved in thyroid hormone synthesis, metabolism and transport
Gene 
code
name iD chr start stop start - 
10kb
stop + 10kb
ALB Albumin 213 4 74488870 74505996 74478870 74515996
CD36 Fatty acid translocase 948 7 80069459 80144262 80059459 80154262
CGA Glycoprotein 
hormone alpha 
subunit
1081 6 87851941 87861543 87841941 87871543
CRYM Mu-crystallin 1428 16 21177343 21221918 21167343 21231918
DIO1 Type I deiodinase 1733 1 54132449 54149347 54122449 54159347
DIO2 Type II deiodinase 1734 14 79733622 79748278 79723622 79758278
DIO3 Type III deiodinase 1735 14 101097441 101099542 101087441 101109542
DIO3OS Opposite strand of 
type III deiodinase
64150 14 101088313 101091766 101078313 101101766
DUOX2 Dual oxidase 2 50506 15 43172144 43193651 43162144 43203651
DUOXA2 Dual oxidase 
maturation factor 2
405753 15 43193816 43197596 43183816 43207596
FOXE1 Forkhead box E1 2304 9 99655358 99658818 99645358 99668818
GPHA2 Glycoprotein 
hormone alpha 2
170589 11 64458519 64459936 64448519 64469936
GPHB5 Glycoprotein 
hormone beta 5
122876 14 62849395 62854316 62839395 62864316
IYD DEHAL1 389434 6 150731721 150767457 150721721 150777457
LRP2 Megalin 4036 2 169691865 169927368 169681865 169937368
NKX2-1 Thyroid transcription 
factor 1
7080 14 36055353 36059167 36045353 36069167
NKX2-5 NK2 transcription 
factor related, locus 5
1482 4 42436076 42438776 42426076 42448776
NR1D1 Rev-Erb alpha 9572 17 35502567 35510499 35492567 35520499
PAX8 Paired box 8 7849 2 113690045 113752968 113680045 113762968
RXRA Retinoid X receptor 
alpha
6256 9 136358231 136472252 136348231 136482252
RXRB Retinoid X receptor 
beta
6257 6 33269343 33276410 33259343 33286410
RXRG Retinoid X receptor 
gamma
6258 1 163636974 163681054 163626974 163691054
SECISBP2 SECIS binding protein 79048 9 91123232 91164381 91113232 91174381
SLC10A1 NTCP 6554 14 69312305 69333707 69302305 69343707
SLC16A10 MCT10 117247 6 111515502 111650907 111505502 111660907
SLC26A4 Pendrin 5172 7 107088316 107145490 107078316 107155490
SLC3A2 4F2hc 6520 11 62380094 62412929 62370094 62422929
SLC5A5 NIS 6528 19 17843782 17865897 17833782 17875897
SLC5A8 Apical iodide 
transporter
160728 12 100073402 100128120 100063402 100138120
SLC7A5 LAT1 282369 18 11470909 11499821 11460909 11509821
SLC7A8 LAT2 23428 14 22664344 22722689 22654344 22732689
SLCO1A2 OATP1A2 6579 12 21311651 21439638 21301651 21449638
SLCO1B1 OATP1B1 10599 12 21175404 21283997 21165404 21293997
SLCO1B3 OATP1B3 28234 12 20854905 20960925 20844905 20970925
SLCO1C1 OATP1C1 53919 12 20739666 20797587 20729666 20807587
table continued on next page
154 Chapter 10
Gene 
code
name iD chr start stop start - 
10kb
stop + 10kb
SLCO2A1 OATP2A1 6578 3 135134230 135231418 135124230 135241418
SLCO3A1 OATP3A1 28232 15 90197950 90507783 90187950 90517783
SLCO4A1 OATP4A1 28231 20 60744242 60774092 60734242 60784092
SLCO4C1 OATP4C1 353189 5 101597589 101660152 101587589 101670152
SLCO5A1 OATP5A1 81796 8 70747129 70909762 70737129 70919762
SLCO6A1 OATP6A1 133482 5 101735550 101862619 101725550 101872619
SULT1A1 Sulfotransferase 1A1 6817 16 28524414 28542367 28514414 28552367
SULT1A2 Sulfotransferase 1A2 6799 16 28510767 28515892 28500767 28525892
SULT1A3 Sulfotransferase 1A3 6818 16 30113244 30123151 30103244 30133151
SULT1B1 Sulfotransferase 1B1 27284 4 70627275 70661019 70617275 70671019
SULT1C2 Sulfotransferase 1C2 6819 2 108271527 108292803 108261527 108302803
SULT1C4 Sulfotranferase 1C4 27233 2 108360853 108370702 108350853 108380702
SULT1E1 Sulfotransferase 1E1 6783 4 70741519 70760459 70731519 70770459
SULT4A1 Sulfotransferase 4A1 25830 22 42551720 42589711 42541720 42599711
TG Thyroglobulin 7038 8 133948387 134216325 133938387 134226325
THRA Thyroid hormone 
receptor alpha
7067 17 35472589 35503646 35462589 35513646
THRB Thyroid hormone 
receptor beta
7068 3 24134709 24511317 24124709 24521317
THRSP Thyroid hormone 
responsive protein
7069 11 77452555 77457045 77442555 77467045
TPO Thyroid peroxidase 7173 2 1396242 1525502 1386242 1535502
TRH Thyrotropin-releasing 
hormone
7200 3 131176253 131179470 131166253 131189470
TRHDE Thyrotropin-releasing 
hormone degrading 
enzyme
29953 12 70952730 71345689 70942730 71355689
TRHR Thyrotropin-releasing 
hormone receptor
7201 8 110168900 110200989 110158900 110210989
TSHB Thyroid stimulating 
hormone beta
7252 3 27736279 27741514 27726279 27751514
TSHR Thyroid stimulating 
hormone receptor
7253 14 80491622 80682399 80481622 80692399
TTF1 Thyroid transcription 
factor 1
7270 9 134240756 134272042 134230756 134282042
TTR Transthyretin 7276 18 27425838 27432781 27415838 27442781
UGT1A1 Glucuronyltransferase 
1A1
54658 2 234333658 234346684 234323658 234356684
UGT1A10 Glucuronyltransferase 
1A10
54575 2 234333658 234346684 234323658 234356684
UGT1A3 Glucuronyltransferase 
1A3
54659 2 234302512 234346684 234292512 234356684
UGT1A7 Glucuronyltransferase 
1A7
54577 2 234255323 234346684 234245323 234356684
UGT1A8 Glucuronyltransferase 
1A8
54576 2 234191030 234346684 234181030 234356684
UGT1A9 Glucuronyltransferase 
1A9
54600 2 234245283 234346690 234235283 234356690
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p-value of <5 x10-7 is usually required to correct for multiple comparisons. In this study, we 
carried out a focused analysis of 67 genes (1297 SNPs), and therefore a P-value< 1,0•10-3 was 
found to be significant. 
results
Characteristics of the study population
The mean age ± SD of the 1121 subjects was 68.92 ± 7.56 years. Out of the 1121 subjects, 466 
(41.6%) was male. The mean FT4 concentration was 16.4 ± 2.7 pmol/liter, whereas the median 
TSH (with interquartile range) was 1.45 (0.97 –2.15) mU/liter. 
Association of polymorphisms in candidate genes with serum TSH and FT4
The analysis was carried out in 1121 elderly Caucasian men and women of the Rotterdam 
Study. For serum TSH, analyses revealed 4 polymorphisms with P-values <0.001. Two out of 
these 4 were located within the THRB gene (Table 2). In addition, one polymorphism in the 
LRP2 and one in the SCLO1B1 gene were also significantly associated with serum TSH. More-
over, several other polymorphisms throughout the THRB gene showed strong association 
with serum TSH; however, these did not reach the set threshold for significance. 
Four polymorphisms were significantly associated with serum FT4. Two were located 
within the DIO1 gene and 2 were located within the SLC7A8 gene. Interestingly, several other 
polymorphisms within the SLC7A8 gene were also strongly associated with serum FT4 levels 
(Table 3). 
Interestingly, four genes came up for both serum TSH and FT4. These were THRB, LRP2, 
FOXE1 and SLCO1B1.  
Discussion
In this study we used a pathway analysis of genes involved in thyroid hormone synthesis, 
metabolism and transport, to study the effects of common genetic variation in these genes 
on serum TSH and/or FT4. Polymorphisms in the THRB, LRP2 and SLCO1B1 genes were found 
to be associated with serum TSH levels with P-values <1,0•10-3. In addition, variants in the 
DIO1 and SLC7A8 genes were associated with serum FT4.
Studies performed over the recent years have established that many factors determine 
thyroid hormone action and can contribute to the inter-individual variation in serum thyroid 
hormone levels. In addition to environmental factors such as smoking and dietary iodine 
intake, genetic variation influences thyroid hormone action (7). For instance, the TSHR-
Asp727Glu polymorphism has been linked to lower serum TSH levels in up to 5 different 
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Table 2: Top polymorphisms associated with serum lnTSH from the pathway analysis based on GWA data 
from the Rotterdam Study (P<1,0•10-2)
Chr Polymorphism Position Minor allele Beta P-value Gene
2 rs12988804 169826057 A -0.1387 9,2•10-5 LRP2
2 rs10490130 169807357 C -0.1668 7,0•10-3 LRP2
3 rs6550858 24384219 G -0.1408 1,6•10-4 THRB
3 rs6792725 24495287 A 0.1146 9,9•10-4 THRB
3 rs13097208 24235063 A -0.1016 2,2•10-3 THRB
3 rs13066296 24149163 A -0.1355 3,4•10-3 THRB
3 rs12639293 24202179 A -0.09827 4,3•10-3 THRB
3 rs17014487 24319631 C -0.09215 4,5•10-3 THRB
3 rs9862985 24193883 A -0.09671 5,4•10-3 THRB
3 rs7636335 24255952 C 0.09705 6,4•10-3 THRB
3 rs7625035 135210556 G 0.1066 8,9•10-3 THRB
3 rs4858582 24194525 A -0.08545 9,4•10-3 THRB
12 rs964615 21220691 A 0.1838 4,0•10-4 SLCO1B1
12 rs16923154 20777198 G 0.1777 2,9•10-3 SLCO1C1
12 rs974453 20781209 A 0.1639 4,4•10-3 SLCO1C1
14 rs10131915 80550040 C 0.4501 3,1•10-3 TSHR
1 rs16844019 163632777 A -0.5656 4,6•10-3 RXRG
9 rs1443434 99657300 C 0.08805 5,8•10-3 FOXE1
12 rs4309196 71026529 C 0.1007 6,7•10-3 TRHDE
12 rs11568563 21348701 C 0.1784 8,9•10-3 SLCO1A2
20 rs6011628 60783951 G -0.1087 9,2•10-3 SLCO4A1
Table 3: Top polymorphisms associated with serum FT4 from the pathway analysis based on GWA data 
from the Rotterdam Study (P <1,0•10-2)
Chr Polymorphism Position Minor allele Beta P-value Gene
14 rs10145863 22706879 A 0.7075 9,3•10-5 SLC7A8
14 rs1884544 22727441 G 0.7781 4,5•10-4 SLC7A8
14 rs2268878 22689742 C 0.4512 2,1•10-3 SLC7A8
14 rs2331937 22683680 A 0.4057 3,0•10-3 SLC7A8
14 rs927041 22682426 A 0.3932 3,9•10-3 SLC7A8
1 rs2235544 54148158 C -0.4203 1,3•10-4 DIO1
1 rs11206244 54148289 A 0.4298 1,9•10-4 DIO1
6 rs17606253 111633138 G 0.4747 2,5•10-3 SLC16A10
6 rs9400467 111530708 G -0.349 5,3•10-3 SLC16A10
3 rs4563353 24465133 A -0.6288 2,6•10-3 THRB
3 rs9845983 24491068 A -0.6835 8,2•10-3 THRB
2 rs4667591 169711678 A 0.3978 3,3•10-3 LRP2
2 rs7568568 169843461 G 0.521 7,5•10-3 LRP2
2 rs10210408 169755096 G 0.3171 8,4•10-3 LRP2
12 rs964615 21220691 A -0.5045 5,3•10-3 SLCO1B1
9 rs1443434 99657300 C -0.2973 8,0•10-3 FOXE1
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cohorts of Caucasian subjects (12, 13, 17, 23, 24). Moreover, different studies have convinc-
ingly shown that polymorphisms in the DIO1 gene are associated with serum FT4 and rT3 
levels and alter the T3/rT3 ratio (11, 12, 18, 25). The D1-C785T (rs11206244) is associated with 
3.8% higher serum FT4, 14.3% higher rT3 levels and a lower T3/rT3 ratio, pointing towards a 
lower D1 activity in carriers of the T allele (18). Recently, Panicker and colleagues showed that 
the C-allele of the rs2235544 polymorphism in the DIO1 gene is associated with increased 
D1 function resulting in 8.3% lower FT4 levels and an 8.6% increased T3/T4 ratio with GWA-
wide levels of significance in 3976 individuals (25). In this study we demonstrate that these 
two polymorphisms are significantly associated with serum FT4, but not serum TSH in 1121 
elderly Caucasian men and women. Since these findings are consistent with not only the 
physiological role of D1, but also with the previous findings regarding these polymorphisms, 
this minimizes the risk of false positive findings. In addition, it convincingly demonstrates 
that D1 has an important role in thyroid hormone metabolism. 
Two polymorphisms within the SLC7A8 gene, encoding LAT2, were also significantly associ-
ated with serum FT4 levels. In addition, several other polymorphisms within the SLC7A8 gene 
were also strongly associated with serum FT4 levels, but these did not reach the set threshold 
for significance. Injection of Xenopus Laevis oocytes with cRNA for the LAT1 transporter stimu-
lated the Na+-independent uptake of several iodothyronines with Km values of 7.9 μM for T4, 
0.8 μM for T3, 12.5 μM for rT3, 7.9 μM for 3,3’-T2 (26). Smaller increments in iodothyronine 
uptake were noted after injection of LAT2 cRNA (26). Based on the findings in this study, it 
seems worthwhile to study the role of LAT2 in thyroid hormone transport in more detail. 
In addition, no studies have been conducted to link polymorphisms in the SLC7A8 gene to 
alterations in thyroid hormone transport that could as a consequence lead to altered serum 
thyroid hormone levels. Furthermore, it might be interesting to search for mutations in the 
SLC7A8 gene in patients who have elevated serum TSH and FT4 levels.
The role of genetic variation in the deiodinases (10, 27) the TSH receptor (12, 17) and 
thyroid hormone transporters (16) has been studied in depth over the recent years. Interest-
ingly, this does not hold true for polymorphisms in the thyroid hormone receptors. Many 
studies have shown that polymorphisms in other nuclear receptors, such as the estrogen and 
glucocorticoid receptors, play a role in age-related disorders, such as dementia and osteopo-
rosis (28-30). Thyroid hormone receptors are important in the negative feedback-loop of the 
hypothalamus-pituitary-thyroid axis. Therefore, polymorphisms in the THRB gene might be 
associated with serum thyroid parameters. Recently, we identified several polymorphisms in 
the THRB gene. To our surprise, only one of these polymorphisms, e.g., THRB-in9-G/A poly-
morphism, was associated with 8.9% higher serum TSH levels in 1116 healthy Danish twins 
(31). In this study, a number of polymorphisms within the THRB gene were associated with 
serum TSH levels. These findings suggest that genetic variation in thyroid hormone receptor 
β plays an important role in determining an individual’s set point of pituitary-thyroid axis. 
However, these findings are preliminary and need to be replicated in different large cohorts. 
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Our study has several strengths and limitations. We performed our analysis in a large co-
hort of both Caucasian men and women, which is representative for the general population. 
We excluded all subjects with thyroid disease or auto-immunity. Therefore, our data are not 
biased by gender or underlying disease. In addition, we have been able to replicate previous 
associations between polymorphisms in the DIO1 gene and serum FT4. However, we have 
not yet replicated these novel associations in an independent cohort cohort. Thus, the risk 
alleles we have identified in the THRB and SLC7A8 genes justify further clinical and biological 
investigations. 
In conclusion, we performed a focused analysis of thyroid hormone pathway genes in the 
context of a genome-wide association analysis in elderly Caucasian men and women of the 
Rotterdam Study. In this cohort, polymorphisms in the DIO1 and SLC7A8 gene were associ-
ated with serum FT4 levels. In addition, polymorphisms in the THRB gene were associated 
with serum TSH levels. These findings require replication, but they are beginning to provide 
insights into the molecular basis of population based variation These findings provide in-
sights into the molecular basis of population-based variation in serum TSH and FT4. 
acKnoWleDGeMents
The authors are very grateful to the participants of the Rotterdam Study.  Furthermore, we 
acknowledge all the participating general practitioners, pharmacies and the many field 
workers in the research center in Ommoord, Rotterdam, The Netherlands. In addition, we 
thank Mila Jhamai, Pascal Arp, Fernando Rivadeneira, Marijn Verkerk, Michael Moorhouse, 
Lisette Stolk and Joyce van Meurs for coordination of the genome-wide association genotyp-
ing of the Rotterdam cohort and their help with the statistical analysis. This study is sup-
ported by the Netherlands Organization of Scientific Research (NWO) Research Institute for 
Diseases in the Elderly (grant 014-93-015) for Wendy M. van der Deure and NWO Investments 
(175.010.2005.011). 
Pathway analysis 159
references
 1. yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-
1142
 2. Klein i, ojamaa K 2001 Thyroid hormone and the cardiovascular system. N Engl J Med 344:501-
509
 3. allain tJ, McGregor aM 1993 Thyroid hormones and bone. J Endocrinol 139:9-18
 4. sawin ct, Geller a, Wolf Pa, belanger aJ, baker e, bacharach P, Wilson PW, benjamin eJ, 
D’agostino rb 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in 
older persons. N Engl J Med 331:1249-1252
 5. asvold bo, bjoro t, nilsen ti, Vatten lJ 2007 Association between blood pressure and serum 
thyroid-stimulating hormone concentration within the reference range: a population-based 
study. J Clin Endocrinol Metab 92:841-845
 6. Dugbartey at 1998 Neurocognitive aspects of hypothyroidism. Arch Intern Med 158:1413-1418
 7. Hansen Ps, brix tH, bennedbaek fn, bonnema sJ, iachine i, Kyvik Ko, Hegedus l 2005 The 
relative importance of genetic and environmental factors in the aetiology of thyroid nodularity: 
a study of healthy Danish twins. Clin Endocrinol (Oxf ) 62:380-386
 8. Panicker V, Wilson sG, spector tD, brown sJ, Kato bs, reed PW, falchi M, richards Jb, sur-
dulescu Gl, lim eM, fletcher sJ, Walsh JP 2008 Genetic loci linked to pituitary-thyroid axis set 
points: a genome-wide scan of a large twin cohort. J Clin Endocrinol Metab 93:3519-3523
 9. samollow Pb, Perez G, Kammerer cM, finegold D, Zwartjes PW, Havill lM, comuzzie aG, 
Mahaney Mc, Goring HH, blangero J, foley tP, barmada MM 2004 Genetic and environmental 
influences on thyroid hormone variation in Mexican Americans. J Clin Endocrinol Metab 89:3276-
3284
 10. Peeters rP, van den beld aW, van toor H, uitterlinden aG, Janssen Ja, lamberts sW, Vis-
ser tJ 2005 A polymorphism in type I deiodinase is associated with circulating free insulin-like 
growth factor I levels and body composition in humans. J Clin Endocrinol Metab 90:256-263
 11. de Jong fJ, Peeters rP, den Heijer t, van der Deure WM, Hofman a, uitterlinden aG, Visser 
tJ, breteler MM 2007 The association of polymorphisms in the type 1 and 2 deiodinase genes 
with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin 
Endocrinol Metab 92:636-640
 12. Peeters rP, van toor H, Klootwijk W, de rijke yb, Kuiper GG, uitterlinden aG, Visser tJ 2003 
Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothy-
ronine levels in healthy subjects. J Clin Endocrinol Metab 88:2880-2888
 13. Peeters rP, van der Deure WM, van den beld aW, van toor H, lamberts sW, Janssen Ja, uit-
terlinden aG, Visser tJ 2007 The Asp727Glu polymorphism in the TSH receptor is associated 
with insulin resistance in healthy elderly men. Clin Endocrinol (Oxf ) 66:808-815
 14. van der Deure WM, Hansen Ps, Peeters rP, Kyvik Ko, friesema ec, Hegedus l, Visser tJ 2008 
Thyroid hormone transport and metabolism by organic anion transporter 1C1 and consequences 
of genetic variation. Endocrinology 149:5307-5314
 15. van der Deure WM, friesema ec, de Jong fJ, de rijke yb, de Jong fH, uitterlinden aG, 
breteler MM, Peeters rP, Visser tJ 2008 Organic anion transporter 1B1: an important factor 
in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 149:4695-
4701
 16. van der Deure WM, Peeters rP, Visser tJ 2007 Genetic variation in thyroid hormone transport-
ers. Best Pract Res Clin Endocrinol Metab 21:339-350
 17. Hansen Ps, van der Deure WM, Peeters rP, iachine i, fenger M, sorensen ti, Kyvik Ko, Vis-
ser tJ, Hegedus l 2007 The impact of a TSH receptor gene polymorphism on thyroid-related 
phenotypes in a healthy Danish twin population. Clin Endocrinol (Oxf ) 66:827-832
 18. van der Deure WM, Hansen Ps, Peeters rP, uitterlinden aG, fenger M, Kyvik Ko, Hegedus 
l, Visser tJ 2008 The effect of genetic variation in the type 1 deiodinase gene on the inter-
individual variation in serum thyroid hormone levels. An investigation in healthy Danish twins. 
Clin Endocrinol (Oxf )
160 Chapter 10
 19. Panicker V, Wilson sG, spector tD, brown sJ, Kato bs, reed PW, falchi M, richards Jb, 
surdulescu Gl, lim eM, fletcher sJ, Walsh JP 2008 Genetic loci linked to pituitary-thyroid axis 
setpoints: A genome-wide scan of a large twin cohort. J Clin Endocrinol Metab
 20. arnaud-lopez l, usala G, ceresini G, Mitchell bD, Pilia MG, Piras MG, sestu n, Maschio a, 
busonero f, albai G, Dei M, lai s, Mulas a, crisponi l, tanaka t, bandinelli s, Guralnik JM, 
loi a, balaci l, sole G, Prinzis a, Mariotti s, shuldiner ar, cao a, schlessinger D, uda M, 
abecasis Gr, nagaraja r, sanna s, naitza s 2008 Phosphodiesterase 8B gene variants are as-
sociated with serum TSH levels and thyroid function. Am J Hum Genet 82:1270-1280
 21. Hofman a, breteler MM, van Duijn cM, Krestin GP, Pols Ha, stricker bH, tiemeier H, uit-
terlinden aG, Vingerling Jr, Witteman Jc 2007 The Rotterdam Study: objectives and design 
update. Eur J Epidemiol 22:819-829
 22. stranger be, forrest Ms, clark aG, Minichiello MJ, Deutsch s, lyle r, Hunt s, Kahl b, an-
tonarakis se, tavare s, Deloukas P, Dermitzakis et 2005 Genome-wide associations of gene 
expression variation in humans. PLoS genetics 1:e78
 23. van der Deure WM, uitterlinden aG, Hofman a, rivadeneira f, Pols Ha, Peeters rP, Visser tJ 
2008 Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the 
Rotterdam Study. Clin Endocrinol (Oxf ) 68:175-181
 24. Peeters rP, van der Deure WM, Visser tJ 2006 Genetic variation in thyroid hormone pathway 
genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol 
155:655-662
 25. Panicker V, cluett c, shields b, Murray a, Parnell Ks, Perry Jr, Weedon Mn, singleton a, 
Hernandez D, evans J, Durant c, ferrucci l, Melzer D, saravanan P, Visser tJ, ceresini G, 
Hattersley at, Vaidya b, Dayan cM, frayling tM 2008 A Common Variation in Deiodinase 1 
Gene DIO1 Is Associated with the Relative Levels of Free Thyroxine and Triiodothyronine. J Clin 
Endocrinol Metab 93:3075-3081
 26. friesema ec, Docter r, Moerings eP, Verrey f, Krenning eP, Hennemann G, Visser tJ 2001 
Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endo-
crinology 142:4339-4348
 27. Peeters rP, van den beld aW, attalki H, toor H, de rijke yb, Kuiper GG, lamberts sW, Janssen 
Ja, uitterlinden aG, Visser tJ 2005 A new polymorphism in the type II deiodinase gene is associ-
ated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 289:E75-81
 28. schuit sc, oei HH, Witteman Jc, Geurts van Kessel cH, van Meurs Jb, nijhuis rl, van leeu-
wen JP, de Jong fH, Zillikens Mc, Hofman a, Pols Ha, uitterlinden aG 2004 Estrogen receptor 
alpha gene polymorphisms and risk of myocardial infarction. Jama 291:2969-2977
 29. schuit sc, van Meurs Jb, bergink aP, van der Klift M, fang y, leusink G, Hofman a, van leeu-
wen JP, uitterlinden aG, Pols Ha 2004 Height in pre- and postmenopausal women is influenced 
by estrogen receptor alpha gene polymorphisms. J Clin Endocrinol Metab 89:303-309
 30. van rossum ef, russcher H, lamberts sW 2005 Genetic polymorphisms and multifactorial dis-
eases: facts and fallacies revealed by the glucocorticoid receptor gene. Trends Endocrinol Metab 
16:445-450
 31. sorensen HG, van der Deure WM, Hansen Ps, Peeters rP, breteler MM, Kyvik Ko, sorensen 
ti, Hegedus l, Visser tJ 2008 Identification and consequences of polymorphisms in the thyroid 
hormone receptor alpha and beta genes. Thyroid 18:1087-1094
Chapter 11
General Discussion

General Discussion 163
Thyroid hormone is essential for many metabolic processes in the human body (1), which 
is clearly demonstrated in patients with hypo- or hyperthyroidism. Even small alterations in 
serum thyroid hormone levels result in an increased risk to develop osteoporosis and can 
cause changes in heart rate or mood (2-5). This thesis focuses on the effect of variation in 
thyroid hormone pathway genes on serum thyroid hormone levels and clinical endpoints. 
In addition, associations between serum thyroid parameters and clinical endpoints, such 
as osteoporosis and hypertension, were analyzed. In this chapter the main findings of the 
studies described in this thesis are brought together and placed in a broader perspective. 
Methodological considerations, strengths and limitations of the research described in this 
thesis are discussed. Finally, the relevance and potential clinical implications are considered 
and suggestions for future research are put forward.   
tHe role of tHe oatP1 subfaMily in tHyroiD HorMone transPort
Based on the lipophilic structure of thyroid hormone, it was long assumed that thyroid 
hormone enters the cell through simple passive diffusion (6). However, with the discovery 
of MCT8 as a specific and active thyroid hormone transporter and the fact that mutations in 
this transporter lead to the Allan-Herndon-Dudley syndrome (OMIM 300523), the interest in 
this area of research has greatly increased (7-9). In this thesis we focused on several members 
of the OATP1 subfamily as potential thyroid hormone transporters.  All four members of the 
OATP1 subfamily, OATP1A2, OATP1B1, OATP1B3 and OATP1C1, are located on the short arm 
of chromosome 12 and form a gene cluster together with a pseudogene. They are highly ho-
mologous and show a similar genomic organization, i.e., in all four transporter genes the open 
reading frame is composed of 14 exons. As demonstrated in this thesis, these transporters are 
capable of thyroid hormone transport, and exhibit overlapping substrate specificities.
Based on the different affinities for iodothyronines and the specific expression patterns, 
distinct physiological roles for these proteins are worthwhile considering. OATP1C1 shows 
narrow substrate specificity: Pizzagalli and colleagues demonstrated that it only transports 
T4 and rT3 (10). We extended these findings by showing that T4S uptake is also facilitated 
by OATP1C1. Together with the almost exclusive expression at the blood-brain barrier, this 
suggests that OATP1C1 is critical for T4 uptake into the brain. This important role is sub-
stantiated by Sugiyama and colleagues who showed that expression levels of OATP1C1 in 
isolated rat brain capillaries are regulated by thyroid hormone concentrations (11). OATP1C1 
is up-regulated in hypothyroid rats and down-regulated in hyperthyroid rats (11). Together 
with changes in D2 expression (12), OATP1C1 counteracts the effect of alterations in serum 
T4 to ensure stable thyroid hormone concentrations in the brain. Recently, OATP1C1 homo-
logues have been identified in chicken and mice (13, 14). Similar to its human ortholog, mice 
OATP1C1 transports T4 and rT3 with high affinity and is widely expressed in brain, suggesting 
164 Chapter 11
an important role in T4 transport across the blood-brain barrier (14).  Nakao and colleagues 
demonstrated that also in chicken OATP1C1 transports T4. 
Whether findings regarding the role of OATP1C1 in mice, rats and chicken can be extrapo-
lated to humans, remains up to debate. However, due to the high level of homology, expres-
sion pattern and substrate specificity between rodent and human OATP1C1, it seems plau-
sible that OATP1C1 is also important for T4 uptake in the human brain. This is supported by 
our data showing that polymorphisms in the OATP1C1 gene are associated with fatigue and 
depression in a cohort of hypothyroid patients (15). However, apart from T4 transport across 
the blood-brain barrier, no specific function of OATP1C1 in humans has yet been identified. 
In addition, no patients with a mutation in the OATP1C1 gene have thus far been identified. 
Loss of OATP1C1 function could possibly lead to a thyroid hormone related neuronal disorder 
characterized by resistance to thyroid hormone treatment (11). It seems worthwhile to study 
this in OATP1C1 knockout mice.
In contrast to OATP1C1, OATP1B1 and OATP1B3 are exclusively expressed in liver and share 
approximately 80% amino acid sequence identity with each other (16, 17). Both transporters 
have broad substrate specificities as they transport numerous compounds such as bilirubin, 
bile salts, drugs such as pravastatin and digoxin, but also steroid hormones (18). Many studies 
have been published on the role of these 2 proteins in drug absorption, distribution, and 
excretion (19, 20). They are involved in the cellular uptake of drugs into the liver, which is, 
besides the intestine and the kidneys, important for pharmacokinetics. In this thesis, we 
have demonstrated that OATP1B1 strongly induces uptake of iodothyronine sulfates T4S, T3S 
and rT3S, but has only little T4, T3 and rT3 transport activity (21).  Like OATP1B1, OATP1B3 
preferentially transports the sulfated iodothyronines and rT3. Under normal conditions, D1 in 
liver rapidly degradates rT3 and sulfated iodothyronines, keeping the serum concentrations 
of these substrates low (22-27).  However, serum iodothyronine sulfate and rT3 levels are 
high in preterm infants and during critical illness, possibly due to decreased degradation (23, 
25, 28).  It is therefore of interest that both OATP1B1 and OATP1B3 only facilitate transport 
of the iodothyronine sulfates and rT3. This reflects their role of transporters of endo- and 
xenobiotics that are metabolized in the liver and excreted in the bile. 
Finally, OATP1A2 is unique in transporting all (sulfated) iodothyronines. OATP1A2 facili-
tates transport T4, T3 and rT3. In addition, T4S, T3S and rT3S uptake is induced in OATP1A2 
transfected cells compared to mock transfected cells. OATP1A2 is expressed in multiple tis-
sues, among which liver, brain and kidney (29, 30). Based on its expression pattern, OATP1A2 
could play a role in delivery of thyroid hormone across the blood-brain barrier. Alternatively, 
it could play a role in the removal of thyroid hormone from different tissues for degradation 
and eventual elimination via bile or urine. However, the Km values of OATP1A2-mediated 
T4 and T3 transport are far above the physiological serum concentration. Therefore, it does 
not seem likely that there is an important role for OATP1A2 in thyroid hormone transport in 
a physiological situation. However, it may serve as a back-up transport system in case other 
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transporters malfunction or are saturized, or thyroid hormone concentrations are higher 
than under normal conditions. The function of OATP1A2 in thyroid hormone transport could 
be studied in a knock out mice model, although this might be complicated as OATP1A2 is 
capable to transport a wide range of substrates. Therefore, the phenotype of such a mouse 
might be the net result of impaired uptake of not only thyroid hormone, but also of other 
substrates, such as estrogen (30).
PolyMorPHisMs in tHyroiD HorMone PatHWay Genes anD seruM 
tHyroiD HorMone leVels
Virtually all studies described in thesis examine the effect of genes involved in thyroid hor-
mone metabolism and transport on serum thyroid hormone levels and clinical endpoints 
using a genetic approach. Therefore, it is worthwhile to make some more general comments 
regarding genetic association studies.
The unraveling of the sequence of the human genome has led to a big expansion of re-
search conducted in this area. Especially, studies on polymorphisms have expanded rapidly. 
This has lead to the publication of many genetic association studies with positive findings. 
However, only few of them have been replicated in other cohorts, usually with a much smaller 
effect size than the one described in the original paper (31, 32). This suggests that many 
of these initial studies were false positive. There are different ways to reduce false positive 
findings. First of all, it starts with reliable genotyping and phenotyping. Especially, in large-
scale population studies, problems can arise due to the large amount of data and the many 
researchers involved. In addition, if different definitions for the same phenotype are used, the 
chance of non-replication increases. Therefore, standardization and stringent criteria should 
be used, although certain diseases may show variable phenotypic expression. A second 
requirement is a strong a priori hypothesis. For instance, we tested whether the OATPs were 
capable of thyroid hormone transport, prior to analysis of potential associations between 
polymorphisms in these genes and serum thyroid hormone levels. Since all these proteins 
transported iodothyronines in a significant manner, associations between polymorphisms in 
the genes encoding these transporters seems plausible.
Another possibility to reduce false-positive findings is to validate findings from the initial 
‘training’ cohort in a second ‘validation’ cohort. Preferentially, both cohorts are large, thereby 
minimizing any power issues that might arise while studying polymorphisms with low 
minor-allele frequencies. In addition, the populations should be homogenous with regard 
to age, gender, ethnicity and environment. For instance, differences in age might cause 
non-replication. We can expect that the effect of a polymorphism is present at all ages, since 
a variant exists throughout life. However, genes can also be expressed and even function 
differently at different ages, e.g., genes that regulate puberty and/or menopause. In addition, 
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false-positive findings can also occur due to admixture. Frequencies of polymorphisms can 
differ between different ethnic groups. Except for the cohort of Danish twins, all populations 
studied in this thesis are of Dutch origin. Finally, it is important to realize that we do not 
completely understand interactions between environment and genetics in complex traits. 
Therefore, it is important to minimize differences between populations with regard to envi-
ronment. 
Genetic association studies are always faced with the issue of multiple testing. Performing 
a large number of tests will increase the number of false positive results. When should we cor-
rect for multiple testing? And if the answer to the former question is yes, how should we do 
this? By a simple, but conservative Bonferroni correction or by another method?  In the case 
of a strong a priori hypothesis and associations that all point in the same direction, the issue 
of multiple testing can probably be dealt with easily. However, often this is not the case. An-
other way to substantiate any observed association is to confirm the in vivo results in vitro. An 
example of a study in which many of the above mentioned requirements are met, is the study 
of the OATP1B1-Val174Ala polymorphism. This polymorphism has been studied extensively, 
as OATP1B1 facilitates uptake of many drugs from the bloodstream into the liver.  Previously, 
Niemi and colleagues have shown that this polymorphism leads to decreased function of 
OATP1B1 and thereby increases the systemic bioavailability of lipid lowering drugs (33). We 
have demonstrated that OATP1B1 preferentially transports sulfated hormones, i.e., T4S, T3S, 
rT3S and E1S (21). Therefore, we expected that the OATP1B1-Val174Ala polymorphism would 
be associated with serum levels of iodothyronine sulfates and E1S. Indeed, this polymorphism 
was associated with higher serum T4S levels in 155 blood donors, while in a larger cohort 
of elderly Caucasians this same polymorphism was associated with 40% higher E1S levels. 
Moreover, OATP1B1-Val174 showed a 40% higher induction of transport and metabolism of 
these substrates than OATP1B1-Ala174 in transfected COS1 cells (21) (Table 1).
However, regarding polymorphisms in other OATPs, the results were less clear-cut. OATP1C1 
is capable of T4, T4S and rT3 transport, but polymorphisms in the OATP1C1 gene were not 
consistently associated with serum thyroid hormone levels. In blood donors the OATP1C1-
C3035T was associated with higher FT4 and rT3 levels, but we failed to replicate this in a 
larger population of Danish twins (34). This inconsistency might be explained by many things 
including differences between the two populations. Iodine intake and conditions for serum 
sampling varied between these two groups. It is known that small differences in iodine intake 
are associated with altered thyroid function (35). According to the World Health Organization, 
Denmark is moderately iodine deficient, whereas The Netherlands has an adequate iodine 
intake (31). However, associations between variants in other thyroid hormone pathway genes 
and serum thyroid parameters, initially found in Dutch cohorts, have been replicated in the 
cohort of Danish twins (36). Moreover, no effect of the OATP1C1-C3035T polymorphism in 
vitro was observed either (Table 1). With regards to OATP1A2 and OATP1B3, no significant 
associations were observed between polymorphisms in these genes and serum thyroid hor-
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mone levels (Table 1). Whether this means that these transporters do not play a significant 
physiological role in thyroid hormone transport or that the selection of polymorphisms we 
studied was not adequate, remains up to debate. We preferentially chose non-synonymous 
polymorphisms and polymorphisms located in the 3’UTR. Although functional mechanisms 
are more easily comprehensible when studying this kind of polymorphisms, the risk of miss-
ing an effect is apparent as single polymorphisms usually have subtle effects. Therefore, a 
better strategy might be to capture the complete genetic variation of the gene of interest, 
using a tagging approach. However, this increases the number of genotypes and haplotypes, 
and thereby the number of tests performed. In addition, the definition of where a gene starts 
and stops is unclear, in particular for regulatory elements.
Due to disappointing results of studies that employ a candidate gene approach, more and 
more studies use a GWA strategy, which is made possible through rapid technical progress 
over the recent years. A GWA approach allows identification of genetic risk alleles without 
prior knowledge of function. In Chapter 10 we used this method to identify genetic variants 
associated with serum TSH and FT4. We performed a pathway analysis of 67 genes involved 
in thyroid hormone synthesis, metabolism and transport using GWA data of 1121 men and 
women of the Rotterdam Study and identified polymorphisms in the THRB, LRP2 and SLCO1B1 
genes which were associated with serum TSH levels. In addition, polymorphisms in the DIO1 
and SLC7A8 genes were associated with serum FT4 levels. Since loci associated with complex 
diseases are generally assumed to have a modest effect, GWA studies require large sample 
sizes and due to multiple testing require replication of the association signals in a different 
cohort.  This strategy has proven to be successful in the identification of genetic variants 
associated with different diseases, such as age-related macular degeneration (37), BMD and 
osteoporosis (38), type II diabetes (39) and cancer (40).  However, it is important to realize 
that GWA studies have similar problems as candidate-gene approach based studies, such as 
failure to replicate (32, 41, 42). In addition, even though these studies can pinpoint a region of 
interest, they cannot unambiguously identify the causal genes. Therefore, resequencing and 
fine-mapping of the area of interest, followed by functional studies is still required. However, 
it has been shown to be a very succesful approach to identify previously unknown biological 
pathways involved in complex genetic traits. 
effect siZe of PolyMorPHisMs on seruM tHyroiD HorMone leVels
Genetic variation in the TSHR and D1 affects normal thyroid hormone metabolism, as has been 
shown in different Caucasian populations. For instance, the Asp727Glu polymorphism in the 
TSHR is associated with lower TSH levels (36, 43, 44), whereas the D1-C785T polymorphism is 
associated with higher rT3 levels and a lower T3/rT3 ratio. Yet, the D1-A1814G polymorphism 
is associated with a higher T3/rT3 ratio (43, 45). In addition, Panicker and colleagues recently 
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demonstrated that another polymorphism in D1, rs2235544, is significantly associated with 
serum thyroid hormone levels in different populations (46). However, the effect size of these 
variants on serum thyroid hormone levels is not clear. In a large population of healthy Dan-
ish twins, we quantified the contribution of these polymorphisms to the genetic variance 
in serum thyroid hormone levels. Although the TSHR-Asp727Glu polymorphism was associ-
ated with decreasing serum TSH levels, this variant accounted for only 0.91% of the total 
phenotypic variance in serum TSH (36). In this same population, carriers of the D1-785T allele 
had 3.8% higher FT4 and 14.3 % higher rT3 levels, resulting in a lower T3/T4 and T3/rT3 ratio 
and a higher rT3/T4 ratio (47). However, the proportion of genetic variation of serum rT3 
and FT4 explained by the D1-C785T is small, in the order of 1 to 2%. Therefore, a substantial 
proportion of variation, accounted for by other common or rare genetic variants, still exists. 
In addition, part of this variation might be explained by gene-gene interactions or gene-
environment interactions. It suggests that multiple loci are involved in the control of serum 
thyroid variables, which is in agreement with the general notion that single polymorphisms 
usually have subtle effects. Such a multi-gene control may be regarded as an advantage for 
the overall control of thyroid hormone homeostasis, which is tightly regulated and under 
this scenario not as vulnerable to single gene mutations compared to when only a few genes 
were involved.
PolyMorPHisMs in tHyroiD HorMone PatHWay Genes anD clinical 
enDPoints
The question arises whether polymorphisms are relevant, when the effect size of individual 
variants on serum thyroid hormone levels is so small. Therefore, polymorphisms in thyroid 
hormone pathway genes have been studied for association with many different clinical 
endpoints (Table 2). For instance, the D1-C785T polymorphism has been related to increased 
muscle strength and muscle mass (48). Recently, this polymorphism has also been linked with 
enhanced potentiation of the antidepressant effect of sertraline by T3 as reflected by declining 
HRSD-21 scores over an 8-week period (Cooper-Kazaz et al., accepted for publication). Based 
on these findings, together with the consistent associations of the D1-C785T polymorphism 
with serum thyroid hormone levels, we feel that this genetic variant is clinically relevant, al-
beit with a modest effect. The mechanism underlying the association between the D1-C785T 
polymorphism and D1 function remains to be established. We tested the functionality of this 
polymorphism in transfected JEG3 cells, but no effect of the D1-C785T polymorphism on 
D1 mRNA decay rate or D1 activity was observed. This might mean that this polymorphism 
is linked to another functional polymorphism elsewhere in the DIO1 gene. For instance, it is 
linked to rs2235544, a polymorphism in intron 3 of the DIO1 gene, which has recently been 
associated with serum thyroid hormone levels in different populations (46).  Alternatively, the 
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D1-C785T polymorphism might cause an alteration in the binding sites of microRNA’s, and 
thereby inhibit translation initiation or promote degradation of D1 mRNA (49, 50). 
Many studies have been conducted to link the polymorphisms in the DIO2 gene to thyroid 
hormone related clinical endpoints. For instance, polymorphisms in the DIO2 gene have been 
associated with mental retardation in iodine-deficient areas (51). Guo and colleagues showed 
that the prevalence of genotypes of the DIO2 polymorphisms was different between children 
who were mentally retarded and children with a normal IQ in an iodine-deficient region 
of China. In addition, de Jong et al. published a study looking at the relationship between 
polymorphisms in the DIO1 and DIO2 genes and MRI features of Alzheimers disease. No as-
sociations were found between these polymorphisms and early MRI markers of Alzheimers 
dementia (45) (Table 2). 
Several studies have addressed the effect of DIO2 polymorphisms on response to thyroid 
hormone replacement. Appelhof et al. showed that there was no difference in preference 
for thyroxine monotherapy or combination therapy with T4 and T3 between carriers and 
non-carriers of the DIO2 polymorphisms (52) (Table 2). Recently, Torlontano demonstrated 
that in thyroidectomized patients carriers of the D2-Thr92Ala polymorphism require higher 
thyroxine dosages to acquire the same TSH levels than non-carriers (53). Based on these 
conflicting data, new studies are needed to confirm or to reject these findings.  
The D2-Thr92Ala polymorphism has also been associated with diabetes and hypertension 
in some studies (54-56), but these findings could not be replicated in our and in other studies 
(57, 58).  In two large cohorts, we tested whether this polymorphism was associated with hy-
pertension, but no association was observed (Table 2). In addition, no relationship between 
serum thyroid hormone levels and blood pressure was found either.  
There is a clear relationship between thyroid function and bone. In addition to direct ef-
fects of FT4 on the skeleton, TSH has been shown to have a direct effect on bone as well (59, 
Table 1: Effect of common variation in OATP1A2, OATP1B1, OATP1B3 and OATP1C1  
Gene Polymorphism Location Change Effect on serum thyroid 
hormone levels
In vitro effect
OATP1A2 rs57921276 Exon Ile13Thr No effect observed No effect observed
rs57550534 Exon Glu172Asp No effect observed Decreased 
transport capacity
OATP1B1 rs4149056 Val174Ala Higher bilirubin, T4S, E1S levels, 
lower T3/rT3 ratio
Decreased 
transport capacity
OATP1B3 rs4149117 Exon Ser112Ala No effect observed Not determined
rs7311358 Exon Met233Ile No effect observed Not determined
OATP1C1 rs10770704 Intron C/T No effect observed Not determined
rs36010656 Exon Pro143Thr Higher rT3 levels, however 
effect not consistent
No effect observed
rs10444412 3’-UTR C3035T Higher FT4 and rT3 levels, 
however effect not consistent
No effect observed
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60). TSHR knockout mice die by 10 weeks of age and display high-turnover osteoporosis, 
which supplementation with thyroid hormone fails to reverse. TSH inhibits through the TSHR 
both osteoclastic bone resorption and osteoblastic bone formation. In the Rotterdam Study, 
we first analyzed whether serum TSH and FT4 levels were associated with bone parameters. 
In line with the effect of TSH on bone in mice, serum TSH showed a positive trend with BMD in 
humans. This is strengthened by the association between the TSHR-Asp727Glu polymorphism 
and femoral neck BMD we observed in the same population (Table 2). However, serum FT4 had 
a much greater influence on bone than TSH (44). Recently, Heemstra et al. performed a cross-
sectional study with 148 patients, who had been thyroidectomized for differentiated thyroid 
carcinoma to study the relationship between serum TSH and indicators of bone turnover (61). 
They found a significant, inverse correlation between serum TSH levels and indicators of bone 
turnover, which was independent of serum FT4 and T3 levels as well as other parameters in-
fluencing bone metabolism. In addition, carriers of the TSHR-Asp727Glu polymorphism had 
an 8.1% higher femoral neck BMD, which was, however, no longer significant after adjusting 
for BMI (61) (Table 2). Besides a relationship between thyroid hormone and bone, Meulenbelt 
and colleagues have identified DIO2 as a susceptibility gene conferring risk to osteoarthritis 
(62). Osteoarthritis is a common late-onset articular joint disease for which no pharmaceuti-
cal intervention is available to attenuate the cartilage degeneration. Meulenbelt performed 
a genome-wide linkage scan and combined linkage association analysis. They demonstrated 
that female carriers of a common haplotype in the DIO2 gene, exclusively containing the 
minor allele of rs225014 and the common allele of rs12885300 polymorphism, had an odds 
ratio of 1.79 for developing advanced/symptomatic hip osteoarthritis (62) (Table 2).
Besides endpoints known to be directly related to thyroid hormone metabolism, it is also 
worthwhile to consider whether polymorphisms in thyroid hormone pathway genes are asso-
ciated with other clinical endpoints. For instance, polymorphisms in OATP1B3 are associated 
with impaired testosterone transport and improved survival in patients with prostate cancer 
(63). In addition, OATP1B3 polymorphisms have been studied in relationship with pharma-
cokinetics of paclitaxel, an anti-cancer agent (64, 65). Similar to OATP1B3, polymorphisms in 
OATP1A2, but especially in OATP1B1 are associated with pharmacokinetics of different drugs 
(19, 33, 66). Various studies have demonstrated that polymorphisms in the OATP1B1 gene 
can lead to altered transport characteristics or protein localization, which can contribute sig-
nificantly to inter-individual variations of drug effects. For instance, the OATP1B1-Val174Ala 
polymorphism shows decreased transport activity and leads to a higher area under the curve 
for different drugs such as statins or anti-cancer agents (67, 68). Recently, this same polymor-
phism has been associated with an increased risk of statin-induced myopathy. Genotyping 
this variant may help to achieve the benefits of statin therapy more safely and effectively (69). 
This points to the notion that, although we are still far from using genetic variants in daily 
clinical practice, probably genetic variants will be first used in individualized drug therapy as 
more and more evidence is accumulating that polymorphisms contribute significantly to dif-
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ferences in patients’ drugs responses.  For instance, Schwarz et al. showed that initial variability 
in the international normalized ratio (INR) response to warfarin was strongly associated with 
genetic variability in the pharmacologic target of warfarin, VKORC1 (70). In addition, genetic 
variants in thiopurine methyltransferase, uridine diphosphate glucuronosyltransferase and 
dihydropyrimidine dehydrogenase have been helpful in predicting the efficacy and toxic-
ity of anti-cancer treatment (71). Polymorphisms in immune response genes are known to 
influence individuals’ susceptibility to infectious diseases and the severity of those diseases. 
Likewise, genetic variation in bacteria or virusses can influence the severity of the disease 
or the likelihood of colonization. For instance, persistent carriage of S. aureus is influenced 
by genetic variation in host inflammatory response genes (72). The host genotype was also 
associatd with carriage of certain S. aureus genotypes. In addition, polymorphisms in the 
hepatitis C virus are used as predictive parameters to define the antiviral treatment strategy 
and the chance of therapeutic success (73). 
future stuDies
The role of OATPs in thyroid hormone transport has been analyzed in this thesis. It is worth-
while to discuss directions for further research regarding the OATPs. For instance, OATP1B1 
and OATP1B3 are important for the hepatic uptake of different drugs. Therefore, we wonder 
what would happen with serum T4S, T3S or rT3 levels in patients on statin therapy. In addition, 
besides transport of sulfated iodothyronines, we and others have demonstrated that OATP1B1 
transports E1S (17, 21, 74, 75). In this thesis, we show that carriers of the OATP1B1-Val174Ala 
polymorphism have almost 40% higher E1S levels than non-carriers (21). In contrast to the 
role of sulfation in thyroid hormone metabolism, the sulfation of estrogens is readily revers-
Table 2: Effect of common variation in thyroid hormone pathway genes on thyroid hormone related clinical 
endpoints 
Gene Effect on thyroid hormone related clinical endpoints Effect consistent?
DIO1 IGF-1, muscle strength and lean body mass (48)
Potentiation of the antidepressant effect of sertraline by T3
Alzheimers disease (45)
replication required
replication required
replication required
DIO2 Osteoarthritis (61)
Hypertension (54-58)
Diabetes (54-58)
Psychological well-being in patients on thyroxine 
Response to combination therapy in patients on thyroxine (52, 53)
Mental retardation (51)
Alzheimers disease (45)
replication required
No
No
replication required
No
replication required
replication required
OATP1C1 Psychological well-being in patients on thyroxine (15) replication required
TSHR Bone mineral density (44,61)
Insulin resistance / metabolic parameters (57)
Yes
replication required
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ible by estrogen sulfatase (76).  The formation of E1S is thought to serve as a reservoir for 
active estrogen, since serum concentrations of E1S are 10-20 times higher than those of the 
unconjugated estrogens (77). Estrogens play an important role in breast cancer, i.e., estrogen 
is the main hormone involved in the development and growth of breast tumors. Therefore, 
therapies aim to block interaction with the estrogen receptor by use of an anti-estrogen, or 
by inhibiting the conversion of androstenedione to estrone with an aromatase inhibitor (78, 
79). Local formation of estrogens in breast tumors might be more important than circulating 
estrogens for growth and survival of estrogen-dependent breast cancer in post-menopausal 
women (80). Serum E1S is a major source of estrogens for breast tissue through local sulfatase 
activity (81). The role of OATP1B1 in the risk of developing breast cancer should therefore be 
investigated, since carriers of the OATP1B1-Val174Ala polymorphism have life-long higher 
serum E1S levels (21). 
Another direction for future research worthwhile investigating, concerns the expression 
levels of OATP1C1 during fetal development. Sugiyama et al. already demonstrated that 
OATP1C1 expression in rats is regulated by thyroid hormone (11). Based on these and other 
findings, we speculated that OATP1C1 is important for T4 uptake across the blood-brain bar-
rier. If we would find significant expression levels of OATP1C1 in several brain regions from 
early fetal life onward, this would substantiate this hypothesis. 
Several polymorphisms in thyroid hormone pathway genes have been associated with varia-
tion in serum thyroid parameters and clinical endpoints. This holds true for the deiodinases 
(48, 82) the TSH receptor (36, 43) and thyroid hormone transporters (83). The role of genetic 
variants in the thyroid hormone receptors (TRs) is unknown, while many studies have been 
published on associations between clinical endpoints and polymorphisms in other nuclear 
receptors, such as the estrogen and glucocorticoid receptors. TRs are important in the nega-
tive feedback-loop of the hypothalamus-pituitary-thyroid axis. Patients with rare and severe 
mutations in TRβ display a phenotype of thyroid hormone resistance with elevated serum 
FT4 and non-suppressed TSH levels. Therefore, common and more subtle polymorphisms in 
the THRB gene might be associated with serum thyroid parameters. Recently, we identified 
several polymorphisms in the THRB gene. To our surprise, only one of these polymorphisms 
was associated with serum TSH levels (84). However, a candidate gene analysis of thyroid hor-
mone synthesis, metabolism and transport showed that many polymorphisms in the THRB 
gene were associated with serum TSH levels (Chapter 10). Therefore, the next step would 
be to study the THRB gene in relationship with thyroid hormone parameters and thyroid 
hormone-dependent endpoints. 
Although many patients with mutations in TRβ have been described, no patients with 
mutations in TRα have been identified yet. However, various mouse strains with mutations 
in TRα are viable (85-87). Depending on the location of the mutation, these mice exhibit 
extreme anxiety-like behavior, osteosclerosis, bradycardia, or signs of altered metabolism 
(e.g. obesity, increased fasting insulin levels). Intriguingly, in mice part of these symptoms 
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can be relieved by treatment with thyroid hormone (85). Although likely, it is currently not 
known whether genetic variation in TRα has similar effects in humans. Therefore, it is of inter-
est to study the consequences of genetic variation in the THRA gene, e.g., by searching for 
patients with mutations in the THRA gene and performing genetic association studies with 
THRA polymorphisms.
Besides the classical candidate gene approach, GWA analysis will be very useful to identify 
novel loci involved in the regulation of thyroid hormone levels.  Although a GWA study is 
complicated, as it requires large samples sizes, replication and reliable geno- and phenotyp-
ing, it will unravel previously unknown pathways involved in thyroid hormone metabolism. 
Panicker et al. identified several loci associated with serum FT4 and TSH by a genome-wide 
linkage scan with 737 microsatellite markers (88), but as expected from an underpowered 
linkage scan in related subjects, they did not identify the actual genes explaining the varia-
tion in serum thyroid hormone levels. Arnaud-Lopez and colleagues recently demonstrated 
that polymorphisms in the Phosphodiesterase 8B gene are associated with serum TSH levels 
and thyroid function (89). Probably, GWA studies will provide more candidate genes involved 
in thyroid function. 
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The thyroid gland, situated in front of the thyroid cartilage in the neck, consists of two lobes 
and only weighs a few grams in adults.  The thyroid produces mainly T4 (thyroxine), an inac-
tive form of thyroid hormone. T4 can be converted into T3, the active thyroid hormone, by 
enzymes called deiodinases, like the type 1 and 2 deiodinase (D1 and D2). The biological ac-
tivity of thyroid hormone is amongst others dependent on the presence of thyroid hormone 
in the blood stream, the binding of T3 to its nuclear T3 receptor, the activity of intracellular 
deiodinases, and the presence of thyroid hormone transporters. 
Thyroid hormone is essential for normal development and growth of virtually all tissues. 
Too much thyroid hormone, e.g., hyperthyroidism, leads to weight loss, restlessness, heat-
intolerance and osteoporosis. Hypothyroidism, decreased thyroid hormone levels, can lead 
to fatigue, weight gain, cold-intolerance or even depression. Even subtle changes in serum 
thyroid hormone levels can have important consequences on thyroid hormone related end-
points, such as atherosclerosis, heart rate, depression and osteoporosis. The studies described 
in this thesis show that small variations in genes involved in thyroid hormone synthesis, 
transport and metabolism influence serum thyroid hormone levels and thyroid hormone de-
pendent endpoints, such as normal bone development. The background of thyroid hormone 
production, metabolism and transport are introduced in chapter 1. In addition, the aims of 
this thesis are presented in this chapter. 
In chapter 2 the role of OATP1B1 as a thyroid hormone transporter was analyzed. In addition, 
the role of the OATP1B1-Val174Ala polymorphism was studied. Although OATP1B1 did not fa-
cilitate uptake of T4 and T3, it is an important factor in transport and metabolism of bilirubin, 
E1S and iodothyronine sulfates.  Moreover, carriers of the OATP1B1-Val174Ala polymorphism 
have higher bilirubin, E1S and T4S levels than non-carriers, since the OATP1B1-Ala174 displays 
40% decreased transport activity. chapter 3 reports on the function of OATP1C1, another 
member of the OATP1 subfamily, which is expressed almost exclusively at the blood-brain 
barrier. OATP1C1 transports T4, rT3 and to some extent also T4S. Taken together with a study 
from Sugiyama and co-workers, in which they show that OATP1c1 is up-regulated in hypothy-
roid rats and down-regulated in hyperthyroid rats, we feel OATP1C1 plays a significant role in 
thyroid hormone transport across the blood-brain barrier. Genetic variants in this transporter 
gene are not associated with serum thyroid hormone levels. However, in chapter 4 we dem-
onstrate that these OATP1C1 polymorphisms are associated with fatigue and depression in 
a population of hypothyroid patients on adequate thyroid hormone replacement therapy. 
Although carriers of the OATP1C1-intron3C>T and the OATP1C1-C3035T polymorphism had 
less complaints of fatigue and depression, they showed no differences in neurocognitive 
functioning, nor did they appreciate LT4/LT3 combination therapy over normal LT4 replace-
ment therapy. In chapter 5 we compared the four human members of the OATP1 subfamily. 
OATP1A2, OATP1B1, OATP1B3 and OATP1C1 transport (sulfated) iodothyronines and exhibit 
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overlapping substrate specificities. OATP1B1 and OATP1B3, both expressed exclusively in the 
liver, preferentially transport rT3 and iodothyronine sulfates, probably facilitating their deg-
radation by liver D1. This reflects their role in the removal of endo- and xenobiotics from the 
body. OATP1C1 transports T4, T4S and rT3 across the blood-brain barrier, whereas OATP1A2 
transports all (sulfated) iodothyronines. 
chapter 6 focused on the effect size of the TSHR-Asp727Glu polymorphism on serum 
thyroid parameters. Previously, this polymorphism has been associated with lower serum TSH 
levels. In a cohort of healthy Danish twins we determined the contribution of this polymor-
phism to overall variation in serum TSH levels. Although the TSHR-Asp727Glu polymorphism 
was significantly associated with serum TSH in this population as well, this polymorphism 
only explained 0.9% of the total variation in serum TSH levels. This suggests that multiple 
genes are involved in the control of hypothalamus-pituitary-thyroid axis. In chapter 7 this 
polymorphism was studied in relation to bone parameters, since TSH and thyroid hormone 
have independent effects on bone. In line with the effect of TSH on bone in mice, described by 
Abe and colleagues, serum TSH showed a positive trend with BMD in elderly Caucasians of the 
Rotterdam Study. Moreover, the TSHR-Asp727Glu polymorphism was associated with higher 
femoral neck BMD. However, serum FT4 had a much greater influence on bone than TSH.
chapter 8 described studies performed with polymorphisms in D1. Previously, the D1-
C785T and D1-A1814G polymorphisms, located in the 3’UTR of the DIO1 gene, have been 
associated with serum thyroid hormone levels in several Caucasian populations. In this 
chapter we studied both the in vivo and in vitro effects of these polymorphisms.  Although 
both polymorphisms were associated with rT3, and T3/rT3 ratio, no effect of both polymor-
phisms on D1 activity in transfected JEG3 cells was observed. In chapter 9 we focused on 
the relationship between thyroid function and blood pressure. Previously, TSH and FT4 have 
been associated with blood pressure. However, in two large cohorts of elderly Caucasians, no 
relationship between thyroid function and hypertension or blood pressure was observed. In 
addition, genetic variation in the hypothalamus-pituitary-thyroid axis has been implicated in 
blood pressure regulation and susceptibility to hypertension. However, in these two cohorts 
polymorphisms in D2 and the TSHR were not associated with blood pressure or the presence 
of hypertension. Therefore, we feel that thyroid function is not an important determinant of 
hypertension in elderly Dutch subjects.
chapter 10 shows the results of a pathway analysis of genes involved in thyroid hormone 
synthesis, metabolism and transport using GWA data of the Rotterdam Study. Several poly-
morphisms in the THRB, LRP2 and SLCO1B1 genes were associated with serum TSH levels. In 
addition, polymorphisms in the DIO1 and SLC7A8 genes were associated with serum FT4 levels. 
Although the majority of these findings require replication, they are beginning to provide 
intriguing insights into the molecular basis of of population-based variation in serum TSH and 
FT4. 
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In the general discussion, chapter 11, all results are discussed and put in a broader per-
spective. Methodological considerations, strengths and limitations of the research described 
in this thesis are discussed. Finally, the relevance and potential clinical implications are 
considered and suggestions for future research are made.
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saMenVattinG
De schildklier is een klein vlindervormig orgaan, dat zich bevindt zich voor het schildklier-
kraakbeen in de nek. Het belangrijkste product van de schildklier is schildklierhormoon. De 
schildklier produceert voornamelijk T4 (thyroxine), een inactieve vorm van schildklierhor-
moon. Door specifieke enzymen, de zogenaamde dejodases, kan T4 omgezet worden in het 
actieve schildklierhormoon T3. Het belangrijkste werkingsmechanisme van schildklierhor-
moon verloopt via binding van T3 aan de T3 receptor in de celkern. Zodra T3 bindt aan zijn 
receptor kunnen schildklierhormoon-gevoelige genen afgelezen worden. Hierdoor zullen 
bepaalde eiwitten aangemaakt worden of juist worden afgebroken. Aangezien de receptor 
zich in de celkern bevindt, hangt de biologische activiteit van schildklierhormoon af van de 
hoeveelheid hormoon in de bloedbaan en in de cel en van de aanwezigheid van dejodases 
en specifieke transporters, die schildklierhormoon vervoeren. 
Schildklierhormoon is noodzakelijk voor de normale ontwikkeling en groei van vrijwel alle 
andere weefsels in ons lichaam. Te veel schildklierhormoon, dat wil zeggen hyperthyreoϊdie, 
leidt tot gewichtsverlies, onrust, warmte-intolerantie en botontkalking. Hypothyreoϊdie, te 
weinig schildklierhormoon, kan leiden tot moeheid, gewichtstoename, koude-intolerantie of 
zelfs depressiviteit. Minimale veranderingen van de spiegels van schildklierhormoon in het 
bloed kunnen belangrijke consequenties hebben. Zo kan iemand meer of minder vaatverkal-
king hebben, een lagere of snellere hartslag krijgen en tevens een hoger risico op depressie 
of botontkalking lopen. De studies, die beschreven worden in dit proefschrift, laten zien dat 
kleine veranderingen in genen, die betrokken zijn bij de productie, transport en verwerking 
van schildklierhormoon, hun invloed hebben op de bloedwaarden van schildklierhormoon. 
Tevens kunnen deze kleine genetische veranderingen leiden tot een verhoogd of juist ver-
laagd risico op botontkalking of het krijgen van een depressie. Een inleiding over de manier 
waarop schildklierhormoon gemaakt, verwerkt en getransporteerd wordt door het menselijk 
lichaam vindt u in Hoofdstuk 1. Tevens worden in dit hoofdstuk de onderzoeksvragen van 
dit proefschrift geformuleerd. 
In Hoofdstuk 2 is de rol van het eiwit OATP1B1 als schildklierhormoon transporter bestu-
deerd. Tevens hebben we het effect van het Val174Ala polymorfisme in het OATP1B1 gen 
bekeken. OATP1B1 vervoert geen T4 en T3, maar het is wel belangrijk voor het transport 
en de verwerking van bilirubine, E1S en gesulfateerd schildklierhormoon. Aangezien de 
OATP1B1-Ala174 variant minder transportactiviteit heeft, hebben dragers van het OATP1B1-
Val174Ala polymorfisme tevens hogere bilirubine, E1S en T4S bloedwaarden dan niet-dra-
gers. Hoofdstuk 3 bespreekt de functie van OATP1C1, een eiwit dat ook onderdeel uitmaakt 
van de OATP1 familie. Het komt vrijwel alleen tot expressie op de bloed-hersen-barrière en 
vervoert T4, rT3 en in minder mate ook T4S. Sugiyama heeft aangetoond dat de expressie van 
OATP1c1 omhoog gaat in ratten met te weinig schildklierhormoon en omlaag gaat in ratten 
met hyperthyreoϊdie. Op basis van zijn en onze gegevens denken we dat OATP1C1 belangrijk 
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is voor schildklierhormoontransport over de bloed-hersen-barrière. Genetische variaties in 
het OATP1C1 gen hebben geen relatie met schildklierhormoon spiegels in het bloed. Echter, 
in Hoofdstuk 4 laten we zien dat deze polymorfismen wel een relatie hebben met vermoeid-
heid en depressie. In een groep patiënten met hypothyreoϊdie, die behandeld worden met 
schildklierhormoon, hebben dragers van het OATP1C1-intron3C>T en het OATP1C1-C3035T 
polymorfisme minder klachten van vermoeidheid en depressiviteit. Er was, echter, geen 
verschil in neurocognitief functioneren of voorkeur voor T4/T3 combinatie boven T4 mono-
therapie. In Hoofdstuk 5 hebben we de vier humane leden van de OATP1 familie vergeleken. 
OATP1A2, OATP1B1, OATP1B3 en OATP1C1 transporteren (gesulfateerd) schildklierhormoon 
en vertonen overlap wat betreft substraatspecificiteit. OATP1B1 en OATP1B3 komen beide 
alleen tot expressie in de lever. Ze transporteren alleen rT3 en gesulfateerd schildklierhor-
moon, waarna deze hormonen afgebroken worden door het type 1 dejodase in de lever. 
Dit weerspiegelt de rol van OATP1B1 en OATP1B3 in de verwijdering van afbraakproducten 
en lichaamsvreemde stoffen. OATP1C1 transporteert T4, T4S en rT3 over de bloed-hersen-
barrière, terwijl OATP1A2 alle (gesulfateerde) schildklierhormonen transporteert. 
In Hoofdstuk 6 is de impact van het TSHR-Asp727Glu polymorfisme op schildklierhor-
moonspiegels in het bloed geanalyseerd. In eerdere studies is aangetoond dat dit polymor-
fisme geassocieerd is met lagere TSH waarden. In een groep van gezonde Deense tweelingen 
hebben we de bijdrage van dit polymorfisme aan de gehele variatie in TSH waarden bepaald. 
Hoewel het TSHR-Asp727Glu polymorfisme ook in deze populatie significant geassocieerd 
was met TSH, verklaarde deze variant slechts 0.9% van de totale variatie die er bestaat in TSH 
waarden. Dit suggereert dat er vele genen betrokken zijn in de controle van hypothalamus-
hypofyse-schildklier as. In Hoofdstuk 7 hebben we hetzelfde polymorfisme bestudeerd in 
relatie tot bot. TSH en schildklierhormoon hebben onafhankelijke effecten op bot. TSH is 
positief geassocieerd aan botmineraaldichtheid in een groep oudere Nederlanders. Dit is in 
overeenstemming met het effect van TSH op bot in muizen, voor het eerst beschreven door 
Abe en collega’s. Ook het TSHR-Asp727Glu polymorfisme is geassocieerd met hogere bot 
mineraaldichtheid. Het effect van schildklierhormoon zelf op bot is echter veel groter dan 
dat van TSH. 
Hoofdstuk 8 gaat over studies met betrekking tot polymorfismen in het type 1 dejodase. De 
D1-C785T en D1-A1814G polymorfismen zijn geassocieerd met schildklierhormoon spiegels 
in verschillende Caucasische populaties. In dit hoofdstuk hebben we de effecten van deze 
variaties op schildklierhormoon waarden in bloed en op de activiteit van type 1 dejodase in 
cellen bekeken. Hoewel beide polymorfismen wederom geassocieerd waren met rT3 en de 
T3/rT3 verhouding, zagen we geen effect van beide varianten op de activiteit van het type 
1 dejodase in getransfecteerde JEG3 cellen. In Hoofdstuk 9 hebben we de relatie tussen 
schildklierfunctie en bloeddruk onderzocht. In eerdere studies bleken zowel TSH als FT4 
geassocieerd te zijn met bloeddruk. Echter, in twee grote populaties van oudere Nederlandse 
mannen en vrouwen konden wij geen associatie vinden tussen schildklierfunctie, bloeddruk 
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en/of verhoogde bloeddruk. Tevens hebben wij geen relatie gevonden tussen polymorfis-
men in het type 2 dejodase en de TSH receptor en bloeddruk, terwijl dit in een aantal andere 
studies wel naar voren kwam. Om deze reden concluderen wij dat in oudere Nederlanders de 
schildklierfunctie geen belangrijke rol speelt in het krijgen van een verhoogde bloeddruk
Hoofdstuk 10 beschrijft de resultaten van een analyse van genen die betrokken zijn bij de 
synthese, het metabolisme en het transport van schildklierhormoon. Met behulp van GWA 
data van het Rotterdam cohort hebben we polymofismen geïdentificeerd die geassocieerd 
zijn met TSH en FT4. Verschillende polymorfismen in het THRB, LRP2 en SLCO1B1 gen waren 
geassocieerd met serum TSH. Tevens waren polymorfismen in het DIO1 en SLC7A8 gen geas-
socieerd met serum FT4. De resultaten van deze studie moeten bevestigd worden in andere 
populaties. Echter, de rol van bepaalde genen, die betrokken zijn bij schildklierhormoon 
metabolisme, is wellicht toch anders dan in eerste instantie verondersteld. In de algemene 
discussie in Hoofdstuk 11, worden de resultaten besproken en in een breder perspectief 
geplaatst. Tevens worden de positieve en negatieve punten van het onderzoek besproken. 
Tenslotte worden de algemene klinische relevantie en toepasbaarheid van het onderzoek 
besproken en worden er aanbevelingen gedaan voor vervolgonderzoek.
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DanKWoorD
Zodra je begint aan het schrijven van het dankwoord, realiseer je je dat je proefschrift bijna 
klaar is. Een mooi moment om terug te kijken op de afgelopen jaren en om iedereen te 
bedanken. Ook al staat mijn naam dan op de voorkant van dit proefschrift, het was zeker niet 
gelukt zonder alle steun en hulp van vele anderen!
Als eerste: prof. dr. ir. Visser, dat zijn een hoop titels, maar vanaf het allereerste moment was 
het gewoon Theo.  Jij bent duidelijk niet het prototype saaie professor: wetenschappelijk ben 
je top, maar dat weet je ook nog te combineren met veel gezelligheid! Je deur staat altijd 
open en vele nieuwe ideeën ontstaan in een middag praten. Je bent niet alleen enthousiast 
en motiverend, maar bovenal geef je mensen veel vrijheid en wist je me het vertrouwen te 
geven dat het allemaal goed zou komen. 
Dr. Peeters, beste Robin. Drie jaar na je eigen promotie, zit je nu achter de tafel als mijn 
co-promotor! Ondanks je drukke baan in de kliniek was je altijd zeer betrokken bij het 
reilen en zeilen van mijn onderzoek, en had je zo door hoe het met me ging. Dank voor de 
wekelijkse vrijdagochtend, je enthousiasme en je terechte, maar soms o zo lastige vragen. 
Professor Hegedüs, dear Laszlo, it is an honour to have you in my committee. Thank you 
for the excellent collaboration we have had over the last years! You have always been very 
enthousiastic, to the point and in for new ideas. Besides science, you also take a great interest 
in the person behind the work, thank you for that. Professor Uitterlinden, beste André, tijdens 
mijn promotietijd had je altijd al veel nuttige suggesties en opmerkingen bij het doorlezen 
van mijn artikelen, dit bleek ook het geval te zijn met betrekking tot mijn proefschrift. Dank 
voor al het leeswerk! Professor van der Lelij, beste Aart-Jan, bedankt voor het plaatsnemen 
in de kleine commissie. Professor Fliers, beste Eric, hopelijk kunnen we de aankomende jaren 
de rol van OATP1C1 in de hersenen nog verder uitwerken, in ieder geval bedankt voor de 
geslaagde samenwerking en het plaatsnemen in mijn commissie. Professor Smit, beste Jan, 
de samenwerking met Karen en jou de afgelopen jaren was erg plezierig. Het is dan ook een 
eer dat je lid van mijn commissie wil zijn. Professor Pols, beste Huib, je staat hier als laatste 
genoemd van de commissieleden, maar eigenlijk sta je aan het begin van dit proefschrift. 
Iets meer dan vier jaar geleden maakten we kennis en voordat ik het wist, was ik aan mijn 
promotie-onderzoek bij Theo en aan mijn opleiding tot internist begonnen. Mijn grote dank 
hiervoor!
En dan de mensen van het schildklierlab: ontzettend bedankt voor de leuke en gezellige 
jaren bij jullie. Ik moest even loskomen in het begin, maar dat heeft niet aan jullie gelegen. 
Vanaf de eerste dag voelde het als een warm bad. Mede door de etentjes en de vrijdagmid-
dagborrels ben ik nog meer gaan genieten van de goede dingen in het leven. Jurgen, een 
paar maanden geleden stond ik naast jou en jij nu naast mij. Die jaren bij elkaar op de kamer 
in Ee500 zijn me erg waardevol: door jouw warmte, oprechtheid en enthousiasme voelde ik 
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me snel thuis. Dank voor alle gesprekken over een kop koffie/thee (soms met Koekela!). Lieve 
Edward, inmiddels is Ee500 ‘jouw’ kantoor. Het is prachtig om te zien met hoeveel talent en 
enthousiasme jij aan het werk bent. Veel succes de komende jaren! Lieve Edith, jij bent veruit 
de beste ‘lerares’ van het hele lab. Door jouw rustige uitleg kon ik binnen de kortste keren zelf 
de opname- en metabolismestudies doen. Dank voor al je hulp bij het labwerk, en ja, review-
ers willen altijd meer labwerk zien! Lieve Ellen, al was je vaak druk bezig met homogeniseren 
en dejodase-assays, je had en hebt altijd tijd voor een gezellig gesprek. Bovenal beheers jij 
de techniek van het bijhouden van werkelijk alle verjaardagen, trouwdagen en jubilea, dank 
voor je attentheid! Lieve Wim, zonder jouw labels en expertise van de wondere wereld van 
de HPLC was er van mijn proeven niet veel terechtgekomen. Dank voor je nuchtere kijk op 
het leven en al je hulp de afgelopen jaren. Jose, for you I will always be ‘de la Porte’! I am 
impressed by your lust for science, but also life in all its aspects, good luck in the future. Lieve 
Monique, na al die jaren op het lab heb je nu een nieuwe uitdaging gevonden op de HLO. 
Met jouw rustige aanwezigheid en prachtige onderzoek van D3 gaf je mooi tegengas aan 
al die ‘transport’ mensen! Marco, inmiddels ook al weer een paar maanden druk bezig met 
polymorfismen studies. Veel succes met al je plannen, ik weet zeker dat er mooie resultaten 
uit zullen gaan komen. 
Dit dankwoord is niet compleet zonder ook alle mensen van de 5e verdieping te bedanken. 
Bedankt voor alle ‘koffie met’-momenten, borrels en het lenen van 6-wells platen, kweekflessen 
etc. Een aantal mensen wilde ik graag nog even speciaal bedanken: Marieke, Michel, Nadia en 
Lisette. Vrijwel tegelijk begonnen wij aan ons promotie-traject als RIDE-aio’s. Het was heerlijk 
om af en toe even stoom af te blazen, succes met de afronding van jullie onderzoek. Marieke, 
bedankt voor de gezelligheid in San Francisco! De paper over Graves en GRsnps komt er zeker 
nog! Lisette, bedankt voor al je hulp bij de GWA analyses. Ook al had je het zelf hartstikke 
druk, je had altijd even tijd voor me. Dit geldt ook voor een hoop anderen op het genetisch 
lab: Fernando, Joyce, Pascal en Mila, en natuurlijk Michael, bedankt voor jullie hulp. Tevens 
waren de mensen van het diagnostisch lab van onschatbare waarde! Yolanda, bedankt voor 
het beschikbaar stellen van jouw lab voor al mijn bepalingen. Hans, Jonneke (zie je, ik ben 
je niet vergeten!), Jeanine, bedankt voor alle bepalingen, zonder jullie was mijn onderzoek 
nu nog niet af geweest! Beste Frank, ik vind het erg bijzonder dat ik heb mogen proeven van 
jouw expertise op gebied van de oestrogenen. En dan in de kamer ernaast, Carine, Lenie en 
Nel, bedankt voor het aanvragen van al die BB-nummers en de tijd voor een kletspraatje.
And then: the Danish connection! Pia, it has been a pleasure to work with you! Your kind-
ness and punctuality make you a very pleasant person to work with. Although we both know 
that is difficult to combine clinical work with research and family & friends, I hope we can 
continue our fruitfull collaboration. Helena, I have learned al lot from you! It was great to 
work with you, and I wish you, John and Johan all the best for the future. A big thank you 
also goes out to Thorkild, Mogens and Kirsten. It has been great to be able to work with the 
twin data. Ook de mensen uit Amsterdam en Leiden wil ik nog graag bedanken. Bente, Nadia 
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en Wilmar bedankt voor de zeer prettige samenwerking. Dit geldt ook voor Karen, hopelijk 
verdedig jij over een paar maanden jouw proefschrift! 
Een groot deel van mijn onderzoek is gebaseerd op ERGO data. Daarom wilde ik professor 
Hofman, professor Breteler en professor Witteman van harte bedanken voor de geboden 
kansen. Beste Monique, bedankt voor het gebruik van de SCAN data voor een aantal van mijn 
papers. Beste Jan, Charlotte en Frank-Jan, bedankt voor de samenwerking. Een aantal weken 
van mijn promotietijd heb ik doorgebracht op het ERGO-centrum in Ommoord: alle dames 
en enkele heer, bedankt voor de gezelligheid tijdens mijn ‘uitschrijfdiensten’! Graag wil ik ook 
al mijn ‘nieuwe’ collega’s bij de interne geneeskunde in het Maasstad ziekenhuis bedanken: 
jullie steun en betrokkenheid bij vooral die laatste loodjes waren super! 
Alhoewel ik voor mijn idee zeker de laatste maanden vrijwel alleen bezig ben geweest 
met mijn proefschrift of werk in het ziekenhuis, zijn er gelukkig een hoop mensen die voor 
de nodige afleiding hebben gezorgd. Lieve Monique, van secretaris tot ceremoniemeester! 
Ik had vooraf niet kunnen denken dat we zo’n goede band zouden krijgen! Dank voor de 
fietstochten (ik zal voortaan niet meer vallen) en alle gezellige etentjes en verantwoorde mu-
seabezoeken. Simone, na een jaar hard roeien, genieten we nu van de sauna of lekker eten. 
Hopelijk zullen er nog vele volgen. Natas, inmiddels getrouwd en moeder van een prachtige 
dochter! Begonnen als huisgenootje en nu een vertrouwde steun en toeverlaat. Dank voor 
al je lieve telefoontjes om te vragen of alles wel goed ging! Ik kan natuurlijk ook de dames 
van ‘de Blokker’ niet vergeten. Lieve Ingeborg, Leontine, Marcia, Marieke en Sonja: het is elke 
keer weer genieten van jullie verhalen en belevenissen. En tenslotte de meiden van ‘college’! 
Sinds de start van de studie in 1997 bij elkaar, en nu al aardig wat met elkaar beleefd: de 
maandelijkse etentjes, weekendjes weg, trouwerijen en ook de eerste telg is al geboren. 
Marije, Myrthe en Ruchi: bedankt voor alle gezellige jaren en die ‘speed-dial knop’, die komt 
er zeker. Maaike, ik vind het super dat je naast me wilt staan als mijn paranimf! Jouw nuchtere, 
maar o zo betrokken kijk op ons leven doet me veel. Dank voor je aandacht, warmte en hulp 
bij de voorbereidingen voor deze dag. 
Lieve Hans en Riet, lievere schoonouders dan jullie had ik me niet kunnen wensen: altijd 
warm, betrokken en geïnteresseerd! Lieve Maurice en Nicolien: lekker eten en drinken, Am-
stel Gold race en winkelen in Maastricht. Ook al wonen jullie tegenwoordig wat verder weg, 
die traditie houden we er zeker in. Lieve Son, grote zus! Vroeger kon ik je af en toe wel achter 
het behang plakken, maar waarschijnlijk komt dat omdat we toch meer op elkaar lijken dan 
we denken. Dank voor alle gezellige ontspannen dagen in Houten. Lieve Peet, jouw BBQ- en 
fotografiekunsten zijn onovertroffen! Nogmaals dank voor de prachtige uitnodiging voor ons 
huwelijk, maar bovenal voor al je spontaniteit en gezelligheid. Nakletsen bij het houtvuur 
na de BBQ hoort er inmiddels helemaal bij. Het is prachtig om te zien hoe jullie genieten 
van en met elkaar, helemaal sinds de komst van Luuk. Lieve Luuk: betoverende glimlachen, 
ondeugende blikken. Inmiddels heb je mijn hart veroverd, ondanks dat je me regelmatig 
ondersmeert met eten! 
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Lieve pap en mam, dank voor jullie steun de afgelopen jaren! Jullie kennen me zoals geen 
ander. Mam, net als vroeger heb je nog steeds de juiste woorden op het juiste moment. Pap, 
je bent de nuchterheid zelve en zeker het type ruwe bolster, blanke pit. Je stond en staat nog 
altijd voor me klaar, daarom hoop ik ook wat vaker te komen genieten van het goede leven 
bij jullie thuis. 
Lieve Jerry, jouw rustige en relativerende blik vormen een prachtig tegenwicht voor mijn 
soms iets te temperamentvolle karakter. Al mijn pieken en dalen heb je van dichtbij meege-
maakt, maar geen moment heb je eraan getwijfeld of het me zou lukken. Bedankt voor al je 
liefde en steun. Met jou ben ik overal thuis.
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abbreViations 
AN(C)OVA analysis of (co)variance
BMI  body mass index
BMD  bone mineral density
bp  base pairs  
BSA  bovine serum albumin
BSP  bromosulfophthalein
CI  confidence interval
CRYM  μ-crystallin
CVLT  California verbal learning test
D’  linkage disequilibrium coefficient
D1  type I deiodinase
D2  type II deiodinase
D3  type III deiodinase
df  degree of freedom 
DNA  deoxyribonucleic acid
DZ  dizygotic
e.g  for example
E1S  estrone-sulfate
FT3  free T3
FT4  free T4
GWA  genome-wide association
HAT  heterodimeric amino acid transporter
HEZ  heterozygote
HOM  homozygote
HPLC  high performance liquid chromatography
HPT  hypothalamus-pituitary-thyroid
HWE  Hardy-Weinberg equilibrium
i.e.  in other words
INR  international normalized ratio
IRD  Inner ring deiodination
IU  international units
Kb  kilo base pairs
LAT  L-type amino acid transporter
LD  linkage disequilibrium
ln  natural logarithm
LT3  liothyronine
LT4  levothyroxine
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MCT  monocarboxylate transporter
MCT  memory comparison test
MFI  multidimensional fatigue inventory
mRNA  messenger ribonucleic acid
MZ  monozygotic
NCBI  National Center for Biotechnology Information
NTCP  Na+/taurocholate cotransporting polypeptide
OATP  organic anion transporting polypeptide
ORD  outer ring deiodination
ORF  open reading frame
OS   opposite sex
PASAT  paced auditory serial attention task
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
POMS  Profile of Moods States
PTU  6-propyl-2-thiouracil
RIA  radio-immuno assay
RT  reverse transcriptase
rT3  reverse T3
rT3S  reverse T3 sulfate
SD  standard deviation
SDS  sodium dodecyl sylfate
SECIS  selenocysteine insertion sequence
SEM  standard error of the mean
SCL  symptom checklist
SNP  single nucleotide polymorphism
SULT  sulfotransferase
T4  thyroxin (3,3’,5,5’-tetraiodothyronine)
T4S  T4 sulfate 
T3  3,3’,5-triiodothyronine
T3S  T3 sulfate
TBG  T4-binding globulin
Tgabs  thyroglobulin antibodidies
TH  thyroid hormone
TPOabs  thyroid peroxidase antibodies
TRH  thyrotropin releasing hormone
TSH  thyroid-stimulating hormone (thyrotropin)
TSHR  thyroid-stimulating hormone receptor
TR  thyroid hormone receptor
Abbreviations 207
TTR  transthyretin
3’UTR  3’untranslated region
3,3’-T2  3,3’-diiodothyronine
WHO  world health organization
WT  wild-type
